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ABSTRACT
A homogeneous one step immunoassay for theophylline using the FCFD, a novel 
optical immunosensor has been described. The assay relies on the phenomenon of an 
evanescent wave which has the ability of distinguishing bound species from those in 
free solution without a prior separation step.
The FCFD based assay for theophylline involved competition between a fluorescent 
derivative of theophylline and theophylline in sample for a limited number of antibody 
binding sites. The theophylline assay, therefore, required fluorescent analogues of 
theophylline for use in the FCFD. Synthetic approaches to such analogues involved 
reaction of alkane-a,co-diamines with 6-chloro-l,3-dimethylpyrimidine-2,4-dione. 
Nitrosation of the corresponding 6-(o-Cbzaminoalkylamino)pyrimidines and 
subsequent thermal cyclisation afforded the 8-(Cbzaminonoralkyl)theophyllines in 
good yields. These were deprotected and the intermediate amines were coupled with 
fluorescein-5-isothiocyanate under conditions of controlled pH to give the required 
fluorescent derivatives.
Thus, in assessing the full performance of the assay, specific binding isotherms were 
constructed in both Tris buffer and serum albumin together with the kinetics of 
binding. A standard curve for theophylline was thus constructed using the analogue 
having the highest affinity for the anti-theophylline antibody and covered the clinically 
relevant region of theophylline (0-50 fig ml*1) without interference from theophylline 
metabolites and structurally related dietary xanthines. The potential for routine use of 
the FCFD device in clinical assay of theophylline has been demonstrated.
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THE BIOLOGY OF THEOPHYLLINE
1.1 Introduction
The detection of low molecular weight analytes, particularly drugs and biological 
peptides at concentrations found in blood is of great importance in drug therapy with 
clinical doses of such materials appearing at much lower concentrations than their 
large molecular counterparts (eg. DNA, proteins, bacteria and viruses). The use of 
analytical systems to measure such concentrations is of great importance to clinicians 
where rapid assay systems provide great diagnostic and therapeutic benefit to both 
patients and practitioners. One such drug of considerable clinical importance is 
theophylline, a low molecular weight analyte (Mr 180.1), which requires constant 
monitoring due to its narrow therapeutic window.
Theophylline is a naturally occurring alkaloid which is primarily found in tea, coffee, 
cola beverages and chocolate. It has a close structural relationship to caffeine and 






Figure I. Theophylline and related methylxanthines
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The methylxanthines share several pharmacological actions in common, including 
stimulation of the central nervous system (CNS) (Rail 1985), relaxation of smooth 
muscle (Karlsson and Persson 1981), inhibition of phosphodiesterase (Kuehl et al.,
1987), antagonism of adenosine activity (Sattin and Rail, 1970) and diuresis (Piafsky 
and Ogilvie, 1975). These effects are summarised in Table 1.








Caffeine -CH, CNS stimulant 0.2
Theophylline -H Broncholytic 1.0
Diprophylline -CH2(OH)CH2OH Broncholytic 0.1
Etophylline -c h 2c h 2o h Cardiotonic 0.14
Proxyphylline -CH2CH(OH)CH3 Cardiotonic/ 0.15
Broncholytic
The various stable derivatives of theophylline are formed by substitution of larger functional groups 
(R) on the 7-nitrogen of the 1,3-dimethylxanthine structure. In vitro potency was determined from 
the ability of these compounds to relax human tracheal strips (Svedmyr 1977). Table adapted from 
Hendeles and Weinberger (1983).
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Theophylline, however, is the principal drug of choice in the treatment of status 
asthmaticus. It has been recognised as a potent bronchodilator for the relief of acute 
asthmatic symptoms, chronic obstructive airways disease and related lung disorders 
(Hendeles and Weinberger, 1983, Rail, 1985). Subsequently, the use of theophylline 
has come to be regarded as the first-line therapy for acute asthmatic attacks and as a 
prophylactic agent in controlling the symptoms of chronic asthma (Weinberger et a l,
1981). Theophylline has also been indicated as a cardiac muscle stimulant and has 
been used to reduce the frequency of occurrence of neonatal apnoea (Rail, 1985) 
(Table 1).
The physiological effects of theophylline have been correlated with its circulating 
plasma concentration (Hendeles and Weinberger, 1982), which is not only dependent 
on its half life but varies considerably between individuals (Jenne et a l, 1977, 
Weinberger et al., 1981, Rowe et a l , 1988). Therefore, for adequate control of adult 
asthma, the therapeutic concentration range of theophylline has been optimised at 10- 
20 jig ml-1 (Weinberger et a l , 1981, Hendeles and Weinberger, 1983, Self and Abou- 
Dhala, 1994). For neonatal apnoea, therapeutically useful steady states are achieved at 
lower concentrations with the therapeutic range quoted at 5-10 |ig ml-1 (Weinberger 
etal., 1981).
The association between the peak serum concentration of theophylline and its toxicity 
has been established by numerous studies (Jacobs et a l , 1976, Helliwell and Berry, 
1979, Hendeles and Weinberger, 1982, Bertino and Walker, 1987). Theophylline 
toxicity is seen to occur in patients primarily receiving long-term therapy who develop 
toxic effects either acutely or chronically as a result of decreased drug clearance or 
inappropriate drug usage (Bertino and Walker, 1987).
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The most common side effects of theophylline administration are mild caffeine like 
symptoms including anorexia, nausea, vomiting and mild CNS stimulation (Rail, 
1985) and occur at concentrations above 20 pg ml*1. Fatal intoxication occurs at 
serum concentrations above 35 pg ml*1 and include seizures, brain damage and death 
in some instances (Hendeles and Weinberger, 1983), particularly with intravenous 
therapy.
Therefore, in view of the large inter-patient variability in the elimination of 
theophylline, effective therapy is best achieved by monitoring both the response of the 
patient and the concentration of theophylline in the plasma (Rowe et al., 1988). 
Measurement of theophylline concentration in serum is essential for optimal 
management of asthma, both chronic and acute, and provides a means of assessing 
dosage and diagnosing toxicity (Jacobs et a l , 1976).
Of the various analytical methods available, high pressure liquid chromatography 
(HPLC) and immunoassay techniques offer the greatest advantage. They are rapid, 
specific and require small sample volumes. The enzyme immunoassay technique 
(EMIT) has gained widespread popularity over time since it is more rapid than 
conventional techniques and is adaptable for large batches of samples.
Currently, the use of immunosensors for monitoring concentrations of theophylline in 
plasma has gained much momentum with the trend towards a one step assay system 
that is not only quick, easy to use and highly specific but conforms to patient 
compliance. The ultimate aim is, therefore, to develop a testing device that is feasible 
and accurate, and rapid to use.
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1.2 The physical chemistry of theophylline
Theophylline (1,3-dimethylxanthine) was first isolated from tea leaves by Kossel in 
1888 as a monohydrate salt with m.p. 272-274°C. A natural CNS stimulant and 
smooth muscle relaxant, theophylline has been prescribed as an effective 
bronchodilator since 1937 when Hermann and, subsequently, Greene showed the 
appreciable effect of intravenous theophylline in alleviating the symptoms of acute 
asthma (Greene et al., 1937).
Presently the use of theophylline has been restricted, not only by its dose limiting 
toxicity but by its poor solubility in water (Martindale, 1989). This lack of solubility is 
attributed to the relatively hydrophobic nature of theophylline which is related to its 
chemical structure and governed by two physiochemical factors. Firstly, theophylline 
forms only weak intermolecular hydrogen bridges with water, in part due to the 
presence of the two N-Me groups at positions 1 and 3, which cannot hydrogen bond, 
with one free acidic proton at position 9 (pKa 8.6 - refer to Table 1.1) which forms 








Figure 1. L The H-bonded dimerisation of theophylline
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The second effect is due to base stacking which is thought to contribute to the 
insolubility of most xanthines and, stabilises the structure of theophylline in the 
crystalline state (Bruns and Fergus, 1989) causing dimerisation (Figure 1.1). The 
solubility of theophylline is therefore 1 part in 120 at room temperature but it is freely 
soluble in hot water (British Pharmacopoeia, 1994).
Table 1.1. The pKas of theophylline and analogues




Subsequently, the aqueous solubility of theophylline has been enhanced by 
complexation with a variety of compounds, in particular with the metal salts of 
organic acids. These include such salts as calcium salicylate, sodium glycinate and 
sodium acetate. These are not only commercially available as salt complexes of 
theophylline but also have medical use as diuretics and cardiac stimulants. However, 
the derivatives of theophylline which have the greatest therapeutic importance are 
those containing one or two molecules of an alkylamine. The most important of these 
is aminophylline which is prepared from ethane-1,2-diamine (Figure 1.2) and contains 
the equivalent of 85% anhydrous theophylline (Hendeles and Weinberger, 1981).
[ H3NCH2CH2NH3 ]2+





The formation of such complexes is achieved at high pH and is the result of the 
tautomeric shift in the 9-NH proton (Scheme 1) of theophylline which, as an 




Scheme 1. The tautomeric structure of theophylline and its conjugate base
However, at physiological pH, these theophylline complexes dissociate rapidly and are 
no more than mixtures of the parent theophylline and the bases to which complexation 
occurred (Weinberger et a l, 1981, Rail, 1985).
1.3 Pharmacological actions of theophylline
The use of theophylline in the treatment of acute bronchial asthma and obstructive 
airways disease has been available to clinicians for almost a century. However, despite 
its widespread use as an effective bronchodilator and CNS stimulant, theophylline is 
far from ideal in that it suffers from a relatively low therapeutic index (Buckle et 
a l, 1994). Headache, nausea and vomiting are common dose-limiting side effects with 
excessive dosing leading to cardiac arrhythmias, convulsions, seizures and in some 
instances death.
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Controversy still exists concerning the molecular mechanisms by which theophylline 
exerts its therapeutic effect. However, inhibition of cyclic nucleotide 
phosphodiesterases, resulting in an increase of concentrations of intracellular cyclic 
adenosine monophosphate (cAMP) (Miech et al., 1979, Torphy and Undem, 1991) 
which leads to bronchodilation, is one of the mechanisms favoured. 
Phosphodiesterases (PDEs) act by hydrolysing cyclic AMP and cyclic GMP (cGMP), 
which are generated from ATP and GTP by the action of adenylate cyclase and 
guanylate cyclase, to their non-cyclic monophosphates. Therefore, inhibition of 
phophodiesterase activity increases the concentrations of cyclic nucleotides in the 
cytoplasm, resulting in relaxation of bronchial smooth muscle and subsequent 
bronchodilation (Figure 1.3).
A d e n o s i n e




A d e ny l a t e  c y c l a s e
A T P c A M P A M P
T h e o p h y l l i n e
br onc h i a l  s m o o t h  m u s c l e  r e l axat ion
Figure 1.3. The pharmacological action of theophylline
However, theophylline appears to cause smooth muscle contraction at 10- to 20-fold 
lower concentrations than required for PDE inhibition in vivo (Miles and Weinberger, 
1983, Svedmyr, 1988, Martindale, 1989), and, therefore appears to be a relatively 
weak inhibitor of PDE isoenzymes (Daly et al., 1981, Rail, 1982, Rail, 1985, Buckle 
eta l., 1994).
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In addition, it has been shown that PDE inhibitors such as dipyridamole, although 
possessing a greater potency, have no bronchodilatory activity. Findings by Heaslip 
(1994) suggest that the action of multiple PDE isoenzymes (PDE I-V) (Nicholson et 
al., 1991), which are not only differentially distributed in cells but possess a degree of 
selectivity for cAMP or for cGMP, are capable of hydrolysing both cyclic nucleotides 
(Torphy and Undem, 1993).
In respiratory smooth muscle, functionally relevant cAMP metabolism occurs 
principally by two distinct PDE isoenzymes (PDE-III and PDE-IV). Recent 
observations by Heaslip (1994) that PDE-IV is an important regulator of cAMP 
metabolism in both inflammatory cells and respiratory muscle have resulted in 
renewed interest in the therapeutic potential of PDE inhibitors as anti-asthmatic drugs.
Theophylline has also been shown to induce bronchodilation, via activation of 
adenylate cyclase, through blockade of adenosine receptors (Sattin and Rail, 1970, 
Hopwood et al., 1985) at concentrations within the range for therapy of asthma 
(Fredholm and Persson, 1982). Adenosine (Figure 1.4) is a naturally occurring purine 
nucleoside that is released in the airways after provocation by allergens (Svedmyr,
1988) and has been implicated in events related to both inflammation and immune 




Figure 1.4. The structures of adenosine and theophylline
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Although adenosine can affect a variety of physiological functions including the 
cardiovascular, gastrointestinal and nervous systems (Daly et al., 1981, Bruns and 
Fergus, 1989), particular attention has been directed over the years towards actions 
which might lead to clinical applications (Daly, 1982).
The antispasmodic and vasodilatory actions of adenosine appear to be linked to 
smooth muscle depressant effects which involve activation of two types of membrane 
receptor, Aj and A2 with inhibitory and stimulatory actions on the adenylate cyclase 
system. The A! receptor has been linked to an inhibitory G protein (Gj) that reduces 
the levels of adenylate cyclase, while the A^ receptor is associated with a stimulatory 
protein (GJ that increases activities of adenylate cyclase. Binding to both receptors is 
antagonised by theophylline, a weak non-selective adenosine antagonist, which has 
been shown to have a higher affinity for the Aj receptor (Kj = 8.5 |liM ), responsible 
for mediating smooth muscle contraction, than A^ receptor (Kj =25 jiM). Therefore, 
the bronchoconstrictor action of adenosine in asthmatic patients and its antagonism by 
theophylline, at concentrations lower than required for bronchodilation, represents an 
important area of research (Daly, 1982).
Other mechanisms which have gained much favour in establishing the bronchodilatory 
activity of theophylline include antagonism of the effect of protaglandins PGE2 and 
PGF2a on smooth muscle in vitro (Horrobin et al., 1977), stimulation of 
catecholamine release, the mobilization of intracellular calcium and supression of 
inflammatory activity through elevation of cAMP (Torphy and Undem, 1991, Teixeira 
etal., 1994).
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Subsequently, seven effects of theophylline have been proposed to be of therapeutic 
importance in asthma:
(1) Bronchial smooth muscle relaxation;
(2) Increase of mucociliary transport;
(3) Inhibition of the release of mediaters;
(4) Supression of permeability oedema;
(5) Decrease of pulmonary hypertension and increase in right ventricular ejection 
fraction;
(6) Improved contractility of fatigued diaphragmatic muscle;
(7) Central stimulation of ventilation.
The most important effect is bronchial smooth muscle relaxation, but the other effects 
may contribute to the antiasthmatic effect especially during maintenance therapy and 
as a prophylactic agent (Svedmyr, 1988).
1.4 Pharmacokinetics
1.4.1 Absorption and distribution
Theophylline is rapidly and completely absorbed in the gastrointestinal tract, 
particularly as a disintegrating tablet. However, theophylline is poorly absorbed slow 
release tablets and suppositories with rectal solutions having the best bioavailability. 
Following oral administration theophylline is rapidly and completely absorbed with 
peak plasma concentrations being attained within 2-3 h (Hendeles and Weinberger,
1982).
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At steady state plasma concentrations the drug is distributed rapidly into peripheral 
tissues with of a volume of distribution of 05 L kg'1. This volume is seen to be higher 
in neonates and diseased states, a phenomenon which is associated with a, low plasma 
albumin concentration (Piafsky et a l, 1976). In normal individuals theophylline is 
about 40% bound to serum albumin (Buss et a l, 1983) however, this figure has been 
quoted as high as 60% by some studies (Vallner et al., 1979, Hendeles and 
Weinberger, 1982). It was also apparent from studies performed by Shaw et al., 
(1982) that serum binding of theophylline was influenced by a number of factors 
including changes in pH (Vallner et al., 1979), temperature and the nature of the 
buffer solution.
1.4.2 Metabolism and Elimination
Theophylline is eliminated by hepatic biotransformation via two distinct and parallel 
pathways into mostly inactive metabolites that are rapidly excreted in the urine. 
Approximately 10% of the drug remains unchanged with 85-90% of the dose of 
theophylline being metabolised by the cytochrome P450 enzyme system (Campbell et 
al., 1987, Taburet and Schimdt, 1994).
This metabolism involves both first order and capacity limited pharmacokinetic 
processes, with the major metabolic routes involving both the 8-hydroxylation of 
theophylline to 1,3-dimethyluric acid, which represents 45-55% of the total clearance 
of the drug (Tang-Lui et a l, 1980, Jonkman and Upton, 1984) and 1-methyluric acid 
representing 20-25% of the dose (Figure 1.5).
The other metabolite through the demethylation pathway is 3-methylxanthine which 
represents 13-16% of the total dose of absorbed theophylline.
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Conversion of theophylline to caffeine is observed in neonates and children and also in 
adults with hepatic failure (Dan-Shya et a l , 1981).
It has been observed by Wilkinson and Shand (1975) that the hepatic clearance and 
terminal elimination half-life of theophylline are independent of changes in hepatic 
blood flow but are highly sensitive to the capacity of the liver to metabolise the drug. 
Therefore, factors that influence the microsomal oxidative enzymes, demethylation, 
hepatic uptake or the enzyme xanthine oxidase influence elimination of theophylline 
(Jonkman and Upton, 1984). Also, variability in clearance appears to be primarily due 
to physiological abnormalities and differential rates of heparic biotransformation 































Figure 1.5. The metabolism of theophylline
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Table 1.2. Non-genetic factors associated with theophylline clearance
Increased clearance Decreased clearance






Barbecued meat Antiviral vaccines
High protein, low carbohydrate diet Viral infections
Medical coal Liver cirrhosis
Youth Congestive heart failure 
Respiratory insufficiency 
Fever
However the single most important variable factor, is genetic, which accounts for a 
6-fold variation in clearance in the population (Svedmyr, 1988). Therefore, in order 




The bronchodilator effect of theophylline is proportional to the log of the plasma 
concentration over a range of 5-20 pg ml-1 with optimal plasma concentration being 
aimed at 10-20 pg ml'1 for adult asthma. For effective control of neonatal apnoea 
plasma theophylline concentrations are maintained at 5-10 pg ml-1 (Hendeles and 
Weinberger, 1981). However, although there is great inter-patient variability and 
complex pharmacokinetics, theophyline is not only an effective bronchodilator for 
acute asthmatic conditions but also a prophylactic agent in the management of 
asthma at optimal concentrations. Although theophylline is an effective 
bronchoplasmic agent at such concentrations, its therapeutic margin is very low and 
related to its dose limiting side effects including nausea, vomiting, cardiac 
arrhythmias, seizures and death. Therefore, in order to achieve the maximum benefit 
from theophylline for chronic asthma treatment, serum concentrations should be 
maintained within the therapeutic range around the clock.
Fluctuations in serum concentrations are a function of the rate of absorption of the 
product, the rate of elimination of the drug from the patient, and the dosing interval 
selected (Hendeles and Weinberger, 1983). When theophylline is used as an effective 
bronchodilator, the goal is to obtain a therapeutic serum concentration rapidly so 
that symptoms are relieved as quickly as possible.
This goal is best accomplished with an intravenous loading dose, although rapidly 
absorbed formulations such as oral solutions, plain uncoated tablets or rectal 
solutions may be adequate for patients at home or for those hospitalised with less 
severe symptoms.
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1.5.1 The toxic effects of theophylline
Theophylline has been the drug of choice for the treatment of asthma in the United 
States since 1937. However due its narrow therapeutic window (10-20 pg ml*1 in 
adults) and the resulting toxicity associated with plasma concentrations greater than 
20 pg ml*1, its use is severely limited (Table 1.3). Various drug toxicities have been 
described including nausea, cardiac arrhythmias and potentially lethal seizures. 
Generally symptoms of theophylline toxicity affect the cardiac, gastrointestinal or 
neurological systems, with the severity of the toxic reaction having been related to the 
patients peak serum concentration, as outlined in Table 1.3 (Hendeles and 
Weinberger, 1983).
Table 1.3. The efficacy and toxicity of theophylline dosage
Concentration mg l*1 Efficacy Toxicity
5 Minimal
10 ii




Jacobs et al. (1976), in assessing the relationship between dosage, serum 
concentration and toxicity, observed clear-cut toxic reactions relating to serum 
concentrations between the range 15.8-49.5 pg ml*1.
17
Mild toxic conditions were observed at serum concentrations below 25 pg ml*1, in 
particular relating to nausea and vomiting. Serious toxicity has been observed at 
serum levels greater than 35 pg ml*1 resulting in such conditions as tachycardia, 
cardiac arrhythmias, electrolyte abnormalities including hyperglycemia and 
hypercalcemia, seizures and death.
However, Hendeles and Weinberger (1982) have observed focal and generalised 
seizures at plasma concentrations as low as 25 pg ml*1 without prior signs of toxicity 
while Zwillich et al. (1975) reported serum concentrations of 54 pg ml*1 among 
patients with seizures, compared with 35 pg ml*1 for patients with minor adverse 
effects.
Cardiac toxicity has been most evident with adults, while tachycardia occurred in 
premature newborns at concentrations above 10 pg ml*1. Hypotension and sudden 
cardiac arrest has been associated with rapid intravenous dose of theophylline while 
among infants and children fatal toxicity has been as a result of therapeutic 
misadventure, particularly when multiple adult doses were administered (Hendeles and 
Weinberger, 1983). Further findings by Shannon (1994) reveal a greater risk of 
toxicity in elderly patients, which have been attributed to altered elimination rates as a 
result of concomitant heart and liver disease and through increase in drug reactions.
It must be stated that minor symptoms of toxicity such as nausea and vomiting cannot 
be relied upon as a dosing end-point (Hendeles and Weinberger, 1983). Only serum 
theophylline measurements provide a means of forewarning the clinician of impending 
life-threatning toxicity.
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1.6 Monitoring of theophylline serum concentration
The association between serum theophylline concentrations and efficacy, as well as 
toxicity, has been clearly defined by numerous studies (section 1.4) with a safe upper 
limit of 20 pg ml-1 and a much softer lower limit between 3-10 pg ml-1 (Hendeles and 
Weinberger, 1983). Adequate control is generally quoted between 10-20 pg mb1 but 
in cases of toxicity, levels as high as 60 pg mb1 may be encountered. Due to this 
narrow therapeutic range and a wide variation in inter-patient half life, related both to 
the drugs clearance and hepatic absorption, monitoring of serum theophylline levels is 
considered necessary for safe and effective use of the drug.
Various methods are available for the measurement of plasma theophylline 
concentrations including spectrophotometry, chromatography (GC and HPLC) and 
immunoassays involving radiolabels (RIA), enzymes (ELA) and fluorophores (FLA) as 
shown in scheme 1.1.
THEOPHYLLINE
IMMUNOLOGICAL ASSAYSCHROMATOGRAPHIC SPECTROPHOTOMETRIC
GC, HPLC UV RIA, EIA, FIA, IMMUNOSENSOR
Scheme 1.1. The analytical methods available for the measurement of serum 
theophylline levels.
The non-immunological methods, although useful, all have disadvantages primarily 
owing the requirement of large sample volumes, lack of selectivity and the use of 
technically complex and time-consuming sample preparations.
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Although being more labour-intensive HPLC does offer the advantage of measuring 
other metabolites including the closely related methylxanthine, caffeine (Rowe et al.,
1988).
On the other hand immunoassays are simple, permit direct analysis with small sample 
volumes (25 pi in EIAs), specific, have high sensitivity (particularly in the use of 
heterogeneous systems) and can be automated to deal with large batch of samples. 
The various published methods for monitoring theophylline serum levels are outlined 
in Table 1.4 and show a growing trend in the use of homogeneous immunoassay 
systems for the monitoring of clinically important drugs such as theophylline.
Table 1.4. Methods for monitoring theophylline concentrations
Assay Detection method Label used References
Fluorescence immunoassay Fluorescence Fluoresceinthiocarbamy Hodgkinson et al.,






Umbelliferone Li et al., 1981a
Enzyme multiplied 
immunoassay (EMIT©)
Spectrophometric glucose-6-phosphate Change/ al., 1982
Apoenzyme reactivation 
immunoassay (ARIS©)






Spectrophometric p-galactosidase Hinds et al., 1984
Immunosensor
(Flowinjection)
Electrochemical Alkaline phosphatase Palmer et a l , 1993
Immunosensor
(Amperometric)
Electrochemical NADH Athey et al., 1993
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The need for continuous monitoring without operator skill as well as rapid data 
collection has, therefore, led to the development of immunosensor technology. In the 
next chapter, the use of immunosensors as viable alternatives to conventional 
homogeneous assay systems is explored.
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CHAPTER 2
IMMUNOSENSOR ASSAY FOR THEOPHYLLINE
2.1 Introduction to Immunosensors
Immunoassays offer a highly sensitive and selective approach to the detection and 
quantification of trace metabolites arising from the interaction between antibody and 
antigen. The technique is highly specific and has found widespread use in diagnostic 
medicine in the detection of analytes such as hormones, clinical disease markers, 
drugs, bacteria and environmental pollutants (Robinson et al., 1987).
Following the pioneering work of Yalow and Berson in the early 1960s, immunoassay 
procedures have rapidly assumed a major role in the clinical investigation of disease, 
monitoring therapy and environmental analysis (Leech, 1994). The high specificity 
which typifies an antigen-antibody reaction has led to extensive research in the area of 
immunosensing. Subsequently, the demand for immunoassays and the remarkable 
progress in immunochemical technology (Aizawa, 1991) has led to the integration of 
current biosensor technology with both immunology and biotechnology.
Immunosensors take advantage of the high selectivity provided by the molecular 
recognition of antibodies, which, in principle, can be obtained against an unlimited 
number of determinants. An immunosensor is, therefore, described as a device 
incorporating a biological molecular recognition component {e.g. an antibody or 
antigen) connected to a transducer (the sensor) which can output an electronic signal 
that is proportional to the concentration being sensed (Byfield and Abushenka, 1994).
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A range of combinations of receptor-transducers have been proposed and listed in 
Table 2 with detailed reviews of such technological variation widespread in the 
literature (Cass, 1990, Turner ef a/., 1991).
Table 2. The variation in biosensor technology












The biological component of the biosensor element confers specificity and is divided 
into two distinct groups (a) catalytic, which includes enzymes, microorganisms and 
tissues and (b) non-catalytic, comprising of antibodies, receptors and tissues (Griffiths 
and Hall, 1993). The nature of the interaction of the biological element has a major 
impact on the current technologies available, in particular those utilising a wide range 
of optical and electrochemical systems in conjunction with biological sensing (Byfield 
and Abuknesha, 1994).
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Immunosensors, therefore, exploit the high specificity and sensitivity (Figure 2) which 
typifies an antigen-antibody reaction and can be applied to both sandwich (non­
competitive) and competitive assays
Laboled antigen
Tree a n t ig e n  
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Figure 2. Principle of an optical enzyme immunosensor (a) competitive and (b)
sandwich immunoassays
Both systems are based on the solid phase immobilisation of the biological component 
(antibody or antigen) on a planar or fibre optic guide and offer a means of detecting 
antibody binding reactions with sufficient sensitivity and specificity.
Immunosensors can also be utilised for both direct and indirect detection of antibody 
reactions in immunoassay procedures Indirect detection, which is by far the most 
predominant scheme, incorporates a tracer or label which is used to generate a signal 
(e.g. optical, electrochemical) which enables quantification of the amount of bound 
antigen relative to unbound. Examples of such tracers are shown in Table 2.1 which 
include enzymes, fluorescent molecules and electrochemical species.
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Table 2.1. Non isotopic immunoassay labels
Category Label




Enzyme Alkaline phosphatase 


















Subsequently, the incorporation of labels into the antibody-antigen immunocomplex 
provides a means of achieving highly sensitive immunosensors which can be 
determined by a variety of methods including amperometric, potentiometric and 
optical detection (Figure 2.1)
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Figure 2.1. Principle o f labelled immunosensors
Direct detection methods are not so widespread in immunosensing but offer a means 
of detecting the immunocomplex directly by measuring the physical changes induced 
by the formation of the complex (Aizawa, 1991).
The principle is based on the immobilisation of the antibody or antigen to a solid 
matrix which is sensitive to changes in its surface characteristics to detect 
immunocomplex formation Electrode, membrane, piezoelectric material or optically 
active material may be used to construct the non labelled immunosensor (Figure 2.2) 
with the immunocomplex formed altering the physical properties of the surface, such 
as electrode potential, intrinsic piezofrequency or optical properties including 
formation of evanescent wave and surface plasmon resonance (SPR) Table 2.2 lists 
the properties of the ideal immunosensor
Antibody
S o l id  Matrix
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[ ( ©  P o t e n t i a l  
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Figure 2.2. Principle of non-labelled immunosensors
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(iv) Stable - i.e., long shelf life
(v) Simple to use
(vi) Economical
(vii) Reusable or capable of continuous monitoring
(viii) Insensitive to environmental changes including temp, pH etc. 
(be) Able to sample a defined volume
(x) Homogeneous in use
2.1.1 Heterogeneous systems
The first heterogeneous immunoassays were performed by Yalow and Berson in 1959 
using a radioactive label, the radioimmunoassay (RIA). Since its development, the 
RIA has become one of the most important analytical tools in clinical chemistry and 
has been applied to monitor a whole host of analytes including hormones, therapeutic 
drugs (e.g. digoxin and theophylline which require close controls of serum 
concentration), drugs of abuse (e.g. cocaine, morphine) and agents of infectious 
diseases including AIDS and hepatitis.
The RIA procedure relies on the competition between labelled antigen (Ag*) and 
unlabelled analyte from serum sample for the Ab (antibody) raised against the analyte 
in question.
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After equilibration the bound fraction is separated from free and the radioactivity 
present is measured, giving a directly proportional indication of the amount of analyte 
in sample (Figure 2.3).
Ab + Ag* + Ag Ab-Ag* + Ab-Ag
from free sample separate and count
Figure 2.3. The principle of RIA
However, although RIA is the most common heterogeneous immunoassay procedure, 
the recent trend has been towards non-isotopic detection with radiolabels having 
various self-evident disadvantages, including handling of waste and toxicity, safety 
and the use of expensive bulky scintillation counters. There is, therefore, a need to 
design non-isotopic detection methods that are both sensitive and robust (McCapra,
1989).
The most common alternative labels for immunoassays include enzymes (e.g. alkaline 
phophatase, horseradish peroxidase and p-galactosidase), fluorophores (e.g. 
fluorescein and rhodamine) and chemiluminescent probes including luminol and 
phenanthridium ester.
Enzyme-labelling of antibodies or antigens for amplification of the signal and the 
detection of antigen levels is the most widely used in non-isotopic procedure. The 
schemes involved in the most common enzyme immunoassays are the sandwich and 
competitive type enzyme-linked immunosorbant assay system (ELISA).
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However, a number of enzymes have been applied to immunosensing technology, 
particularly in the assembling of oxygen-sensing electrodes by use of catalase enzyme 
catalyses the decomposition of hydrogen peroxide into oxygen and water (Ikariyama 
and Aizawa, 1985)
In heterogenous enzyme immunoassays (EIA), the labelling enzyme activity is 
measured by amperometry with the oxygen-sensing device and, because only a short 
time is required for measuring the enzyme label, a rapid and highly sensitive 
immunoassay can be achieved
Increased sensitivities may also be achieved using fluorescent labels, such as 
fluorescein or rhodamine These have been successfully used in both competitive and 
non-competitive assays Most of the commercially available fluorescence-based 
immunoassays utilise a solid phase antigen or antibody system and involves the 
separation of the label from endogenous interferences by attachment to a solid surface 




Figure 2.4. Heterogeneous (a) and homogeneous (b) immunoassays
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2.1.2. Homogeneous immunoassays
Since the establishment of the radioimmunoassay by Yalow and Berson in 1959 and 
the subsequent development in heterogeneous immunoassay procedures, several 
groups have attempted to devise assay systems where a separation step was not 
required. The first use of a non-separation immunoassay system was performed by 
Arquilla and Stavitsky in 1956, (Nakamura, 1992a) using erythrocyte-labelled insulin 
to detect insulin antibodies in diabetes. Subsequently, the first fluorescence-based 
homogenous immunoassay was developed by Dandliker and Feigen in 1961 
(Nakamura, 1992a) for penicillin, using fluorescence polarisation for fluorescein- 
labelled penicillin bound to antibody
The principle behind many homogeneous assay systems is the competition between 
the labelled and unlabelled drug for the specific antibody with the resulting antibody- 
antigen complex having different physical properties to the unlabelled drug. This, 
therefore, implies a negation for a separation or washing step when the complex is 
measured in the appropriate analytical system. A comparison between homogeneous 
and heterogeneous assay systems is outlined in Table 2.3.
Table 2.3. Comparison between Homogeneous and Heterogeneous assay systems
Homogeneous Heterogeneous
Simple to perform More complicated assay performance
Easy to automate Mechanisation difficult
Robust procedure Higher sensitivities
Limited sensitivity Wide dynamic range
Limited menu (small antigens) General applicability
Sensitive to interferences derived from Less prone to matrix differences
samples (e.g. background)
31
It is apparent from Table 2.3 that the requirement for an easy-to-use, robust and 
highly sensitive immunoassay system can be applied to both homogeneous and 
separation assays. However, a review of the literature indicates that, for most 
commercial assays an easy-to-use robust system requires a non-separation step. Such 
systems incorporate a variety of labels, of which enzymes (Table 2.4), fluorophores 
and luminescent compounds are the most common.
Table 2.4. Enzyme labels used in immunoassays
Enzyme pH
optimum
Sp act (U/mg) 
at 37°C
Mr x 103
Alkaline phosphatase 8-10 1,000 100
P-Galactosidase 6-8 600 540




Horseradish peroxidase 5-7 4,500 40
Urease 6.5-7.5 10,000 483
The application of enzyme, fluorescent and chemiluminescent labels had led to the 
development of many homogeneous immunoassays for a range of haptens and protein 
antigen. These are outlined in Table 2.5.
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Table 2.5. Homogeneous assay systems used in clinical chemistry
Basis Detection of Label Analyse Reference
Enzyme Inhibition (EMIT©) Spectrophotometer Drugs and proteins Blake and Gould 
1984








Polarisation Penicillin Dandliker et al, 
1973
Fluorescence enhancement Fluorescence emission T4 Smith 1977
(PGLIA) Prosthetic group 
label immunoassay
Spectrophometry Theophylline Rupchock et al, 
1985
(DELFIA) Delayed enhanced 
fluorescence immunoassay





Chemiluminescence cAMP, IgG Patel et al, 1983,
2.1.3 Fluorescence immunoassay (FIA)
The use of fluorescent labels to detect immunological reactions has rapidly become 
standard practice in the clinical investigation of drugs, proteins and hormones (Soini 
and Hemmila, 1979). The first reported use of a fluorophore as a specific label for 
biological material was performed by Coons and co-workers (1941) using anthracene 
isocyanate to label bacterial proteins. Subsequently, the use of fluorescent probes in 
immunoassay procedures have gained much popularity in clinical chemistry, in effect 
this is due to the decrease in use of radioisotopes as labels for immunoassay 
procedures and an increase in the use of non-isotopic labels of comparable sensitivity.
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The sensitivity of FIAs are generally quoted in the picomolar range although 
limitations due to high background fluorescence caused by bilirubin and other 
compounds in serum, combined with light-scattering and quenching effects, are 
prevalent in the literature (Byfield and Abuknesha, 1994: Mayer and Neuenhofer, 
1994) However, despite these limitations, fluorescent labels are seen as a viable 
alternative to radioimmunoassays particularly as fluorimetric labelling is relatively 
inexpensive and non radioactive, being therefore safer, rapid, simple and requiring 
relatively inexpensive instrumentation. Also, FIAs can be applied to both 
heterogeneous and homogenous systems particularly in the area of immunosensing via 
use of an evanescent wave (discussed in section 2.2.1). Increased sensitivity of 
immunochemical reactions is also achieved via use of fluorescence polarisation and 
time resolved fluorescence using lanthanide chelates.
The most commonly used fluorophores in immunoassay reactions are organic ring 
structures which fluoresce on absorption of light at the excitation wavelength. 
Fluorescein isothiocyanate (FITC) is the most common fluorescent probe used in 
labelling proteins. It has a strong fluorescence, a high quantum yield and a 
fluorescence spectrum with an excitation maximum at 490 nm and emission maximum 
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Figure 2.5. Absorption and fluorescence spectra of fluorescein at pH 7 1.
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Although FITC has become the fluorophore of choice in most applications (Jolley et 
a l, 1984) its use has been limited, due mainly to the small Stokes shift (20-30 nm) 
hence scattering causes considerable interference at low concentrations (Nakamura 
1992b). Similar properties are also exhibited by rhodamines which belong to the same 









Rhodamine isothiocyanate B Pyrene maleimide
Figure 2.6. Structures of common fluorescent labels.
Therefore, for optimisation of a fluorescence-based immunoassay, the probe in 
question must have;
(a) high fluorescence intensity with a quantum yield 
approaching unity.
(b) large Stokes shift, ideally >50 nm.
(c) emission wavelength between 500-700 nm so that it can be 
distinguished from background.
(d) binding to either antibody or antigen must not affect 
the fluorimetric properties of the probe.
The properties of the most common fluorophores are outlined in Table 2.6.










Fluorescein isothio- 0.85 4.5 520/420 7x  104
cyanate (FITC)
Rhodamine B isothio- 0.7 3.0 585/550 1.2 x 104
cyanate (R=Me)
Dansyl chloride 0.3 14.0 482-520/340 3.4 xlO3
Eu-(p-naphthoyl tri- 0.8 500,000 590, 613/340 3 x 104
fluoroacetone)3
Phycobiliprotein 0.5-0.98 580-660/550-620 7.0 xlO5
Lucifer yellow VS 540/340
N-(3-Pyrene)- 100 375, 392/340 3.8 x 104
maleimide
Fluorescent labels can be utilised in both heterogeneous and homogeneous 
immunoassay systems.
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The procedures involved are particularly useful in both competitive and sandwich type 
assays where antibody or antigen is immobilised on a solid phase. In heterogeneous 
assays, the bound fluorescent protein is separated from free fluorescent protein and 
the resulting fluorescence measured.
In homogenous systems, this washing/separation step is avoided. Examples of such 
immunoassay procedures include substrate-labelled FIA (SLFIA) (Li et al., 1981b), 
fluorescence polarisation assay (Li et al., 1981a), DELFIA (Hemmilia et al., 1993) 
and FIAs by internal reflection spectroscopy for use in optical immunosensing. The 
technique utilises total internal reflection to excite the fluorescence of FITC-labelled 
antibody which is bound to hapten-protein conjugate absorbed on a quartz plate in 
antibody solution (Kronick and Little, 1975). Other homogeneous systems include 
fibre optic fluorescence immunosensors which utilise the property of an evanescent 
wave to detect surface bound components (Aizawa, 1991) and the use of a 
fluorescence capillary fill device (FCFD), a planar optical waveguide (Badley et al., 
1987).
2.2 Optical immunosensors
Immunosensing is currently receiving much attention owing its promises of enhanced 
sensitivity and elimination of costly and tedious separation and incubation procedures 
(Ahluwalia et al., 1991). Transducing systems coupled to immunosensors for the 
direct detection of Antibody-Anitigen interactions include potentiometric, 
piezoelectric, acoustic and optical devices (Lowe, 1989). However, the most recent 
developments in immunosensing have all been directed towards optical sensing in both 
direct and indirect systems.
37
Optical immunosensing techniques have been applied to a wide range of analytes and 
have been incorporated into planar waveguides and fibre optic immunosensors. 
Indirect detection of the pregnancy hormone human chorionic gonadotrophin (HCG) 
was achieved by Christensen et al., (1994) using a planar waveguide utilising a 
fluorescence immunoassay. The technique has been applied to both competitive and 
sandwich assays with reported reaction times much shorter than traditional enzyme- 
based systems. Other optical sensing systems utilising fluorescence-based evanescent 
wave immunosensors have been reported with the most promising system 
incorporating a novel capillary fill device (Badley et al., 1987).
However, optical immunosensors for direct sensing have also been developed which 
also exploit the use of an evanescent wave to probe the interactions within a few 
nanometres of the sensor surface. These optical sensors are based on devices in which 
a thin layer (50 nm) of metal is deposited onto the glass surface which, on illumination 
with a light beam, cause the electrons within the metal surface to resonate. The 
technique is called surface plasmon resonance (SPR) and is sensitive to changes in the 
refractive index of the media at the surface.
The technology has already been commercially exploited by the development of the 
BLA. core SPR system by Pharmacia providing a means of attaining real time analysis 
of biological interactions (Buckle et a l, 1993).
2.2.1 Evanescent wave physics
The use of an evanescent wave to monitor antibody-antigen reactions at a quartz 
liquid interface has gained much popularity in the last ten years, particularly in the 
design of simple, rapid, homogeneous assay systems.
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Several groups (North, 1985, Badley et al., 1987 and Fletcher et a l, 1993) have 
incorporated the unique properties of an evanescent wave into immunosensor design 
in both direct and indirect systems. However the most sensitive immunosening 
techniques have been applied to the detection of fluorescent labels in an evanescent 
field in both planar optical waveguides (Badley et a l, 1987, Fletcher et a l, 1993, 
Christesen et a l, 1994) and fibre optics.
The generation of an evanescent wave relies on the unique optical characteristics 
found at the reflecting surface between two transparent media of different refractive 
indices (Harrick, 1967, Sutherland et a l, 1984). Therefore, on travelling within a 
transparent but optically dense medium (nx), a light beam is totally internally reflected 
provided that the incident angle (0) is greater than the critical angle (0C)
0C = arc sin OV^)-1
The internally reflected light beam generates an electromagnetic 'evanescent wave' 
close to the reflecting surface in the optically rarer medium (n2) which is part of the 
internally reflected light beam (Sutherland et a l, 1984). This evanescent wave 
penetrates a fraction of a wavelength beyond the reflecting surface into the rarer 
medium (n2) and decays exponentially with distance from the surface-solution 
interface.
Therefore, chemical or biological reactions occurring at, or very close, to this 
interface perturb the evanescent wave, giving rise to a change in signal, which for 
antibody-antigen reactions can be related to the amount of binding (Byfield and 
Abuknesha, 1994).
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For fluorescence-based systems, biosensing is achieved when there is a change in 
fluorescence excitation as a result of the interaction by the evanescent wave in this 
field upon binding of antigen to immobilised antibody (Sutherland et a l 1984) see 
expression below:
E = E0 exp (-2/dp)
where dP = the distance required for the electric field amplitude to fall to exp (-1) of 
its value at the surface (Figure 2.7).
777777
Figure 2.7. Generation of an evanescent wave at an interface between two optical 
media; (A) where n!>n2 and 0!>0C, the critical angle at which refraction occurs
Thus, the generation of an evanescent wave allows optical detection of a reaction or 
of reaction products at the interface between the two media without interference from 
the bulk solution (Sutherland et al., 1984). The evanescent wave phenomenon allows 
construction of an active immunosensing transducer which will measure 
immunochemical reactions on the surface of both optical fibres (Bluestein et al.,
1990) and planar waveguides (Parry et al., 1990). Subsequently, unbound molecules 
in solution beyond this evanescent region are not detected, thus eliminating the need 
for extensive washing prior to measurement is eliminated.
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2.2.2 Surface plasmon resonance
The phenomenon of surface plasmon resonance has been used in immunosensor 
technology by several groups, since the early part of the 1980s (Nylander et al., 1982, 
Liedberg et al., 1983, Flanagan and Pant ell, 1984), particularly in binding assays. The 
technique is both simple and direct and offers a means of measuring the antibody- 
antigen reaction without the need for a separation or wash-out step. Surface plasmon 
resonance (SPR) like total internal reflection spectroscopy is a technique based on 
direct sensing of immunological reactions by excitation of surface bound antibodies.
SPR is defined as a collective motion of electrons in the surface of a metal (usually 
gold) conductor which is excited by the impact of light of appropriate wavelength at a 
particular angle. Thus resonance only occurs if the momentum vector of the plasmon 
in the metal surface is equal to the longitudinal component of the momentum vector 
of the incident light. Therefore to achieve this plasmon excitation the grating surface 
is illuminated with white light at a fixed angle of incidence 0 with the signal generated 









The plasmon resonance, a direct result of the oscillation of electrons in the surface of 
a metal conductor, results in a high electric field strength close to the metal surface 
which decays exponentially away from the metal such that it penetrates a short 
distance into the solution.
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Therefore, only changes in refractive index occurring within this field affect the SPR 
signal and surface plasmons are thus unaffected by properties of the bulk solution and 
are modulated by changes in refractive index close to the metal surface such as the 
binding of analyte to antibody immobilised at the metal surface
In recent years the use of SPR has become an important feature in biosensing 
particularly for monitoring of real time biological interactions (Robinson et al, 1993). 
Presently the commercial exploitation of SPR has led to the development of the 
Pharmacia BIAcore™ system which represents a significant breakthrough in 
immunosensor technology (Byfield and Abuknesha, 1994) The BIAcore™ SPR 
system incorporates a gold surface which is linked to a carboxymethylated dextran 
matrix by a hydroxyalkyl thiol layer (Lofas and Johnsson, 1990), Figure 2.9.
:o
Figure 2.9.
The matrix reduces non-specific binding (NSB) by its hydrophilic nature and 
promotes biological binding reactions enabling the determination of important clinical 
samples such as theophylline (mM) and p2-micro globulin (1.7-83nM) to be detected 
in whole serum at reaction times of 5 min and 8 min respectively. The system is also 
finding much use as research tool in epitope mapping (Johne et a l , 1993).
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Other available uses of SPR technology include the detection of Human Chorionic 
Gonadotrophin (HGC) using a multilayer biotin-avidin-antibody system which has a 
detection limit of 0.1 nM (Leech, 1994) and an SPR-based immunosensor developed 
by Amersham pic. employing antibodies labelled with latex beads. These labelled 
antibodies serve to amplify the changes in refractive index properties of the sensor- 
surface and, in effect, reduce signal-to-noise ratio.
However although the use of SPR immunosensing technology offers exciting 
prospects for the direct detection of receptor-ligand binding interactions and is 
simpler to use than planar optical waveguides, SPR still suffers from a high degree of 
NSB to the metal surface by proteins in whole serum. It also has a lack of sensitivity 
comparable to ELISA technology (Leech, 1994) with theoretical analysis comparing 
the principles and sensitivities of both planar waveguide and SPR sensors predicting 
higher sensitivities for the waveguiding techniques (Buckle et al., 1993).
2.3 The fluorescence capillary fill device (TCFD)
The need for rapid, simple and easy to use homogenous immunosensors had led to an 
increase in sensors exploiting the evanescent field and is currently dominating optical 
biosensing (Narayanaswamy, 1991). Evanescent wave immunosensors have been 
incorporated into both direct and indirect format and allow surface bound components 
to be sensed without the need for a separation or washing step.
A number of research groups have incorporated evanescent wave immunosensors into 
fluorescent immunoassays in both planar optical waveguides and fibre optics, thereby 
achieving the required sensitivities in serum and whole blood (Sloper et al., 1990, 
Deacon e ta l, 1991).
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One such optical immunosensing device under commercial development is the 
fluorescence capillary fill device (FCFD), a fluorescence based evanescent 
immunosensor developed by Serono Diagnostics. This incorporates a novel capillary 
fill design (Badley et al., 1987). The system consists of two sheets of glass separated 
by a narrow gap (100 pm), with the base plate containing an immobilised layer of 
antibodies and acting as an optical waveguide (Figure 2.10).
immobilised
capture antibody opaque coating
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Figure 2.10. The fluorescence capillary fill device (FCFD
The device benefits from the capillary fill system and operates by drawing a fixed 
volume of sample into the space between the plates, regardless of bulk sample 
volume.
The Serono immunosensing system contains all, or some, of the reagents required for 
the assay which can be either covalently coupled or deposited in a soluble releasable 
form within the device (Parry et al., 1990, Fletcher et al., 1993).
The upper plate, therefore, contains on its surface a layer of fluorescently labelled 
analyte (antigen) which competes with any unlabelled analyte present in the sample for 
a limited number of antibody binding sites on the waveguide solid phase (Badley et 
al,, 1987, Parry et a l, 1990), Figure 2.11.
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Figure 2.11. Schematic diagram of a competitive binding assay within the FCFD.
The signal is generated by illuminating the device with light of wavelength necessary 
to excite the fluorophore, normally fluorescein at 415 nm, which results in labelled 
analytes fluorescing at longer wavelengths. Subsequently, reagent molecules that 
remain in solution can only fluoresce into relatively large angles relative to the plane 
of the waveguide in accordance with Snell's law of refraction. However, reagent 
molecules bound on, or close to, the surface of the lower plate will emit light into a 
broader range of angles than would be possible from solution and will emerge at 
angles less than 47° to the plane of the plate (Badley et a l, 1987), Figure 2.12.
This coupling into small angles is therefore known as evanescent-field coupling (El- 
Hang Lee et al., 1979) and allows the detection of surface bound fluorescence 
without negation of a separation or washing step.
Figure 2.12. Schematic diagram of ray paths of emitted fluorescent light in the FCFD.
detected light from fluorophore 
bound on base plate
light from solution fluorophore
light input at fluorophore 
excitation wavelength
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The FCFD competitive immunoassay system can be applied to sandwich assays, 
however the most promising results have been attained with competitive assays with 
sensitivities of 3.3 x 10' 12 M reported for the detection of prostate specific antigen 
(PSA) (Fletcher et al., 1993). This high sensitivity allied to the use of a whole blood 
samples, the ease of fabrication at low cost together with calibration of the system, 





The elucidation of the purine ring system by Fischer, 1898 in the early part of the 
nineteenth century led the way forward in establishing purine chemistry as one of most 
important subdivisions of modem bio-organic chemistry. Through his unambiguous
Subsequently, Fischer and co-workers demonstrated the conversion of uric acid to a 
number of naturally occurring purines (Figure 3.1.), including xanthine from 
gallstones, guanine from the excreta of sea birds and the N-methylated xanthines, 
including theophylline and caffeine from beverage plants. Therefore, following 
Fischer's groundbreaking work, purine chemistry flourished and, in 1953, resulted in 
the elucidation of the structure of DNA (Watson and Crick, 1953), in which the 
purines adenine and guanine were constituent bases of the double helix.
synthesis of uric acid (Figure 3), Fischer was able to elucidate its structure which had 
previously been predicted by Fittig, 1889 and Medicus, 1890 (Lister, 1971).
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Figure 3.1. The structure of some naturally occurring purines
Since nucleic acids are inherent to all living cells, purines have been detected in a 
diversity of living matter including the metabolic breakdown products of nucleotides 
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Scheme 3. The catabolism of purine nucleotides
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In recent years, understanding of purine chemistry has led to increasing amounts of 
research being focused on the design of anti-metabolites (e.g. methotrexate) which 
interfere with nucleic acid replication in malignant cells, and more recently, on 
antivirals in particular, drugs against HIV and herpes infection which include 
acyclovir, 6 -mercaptopurine and recently AZT (Figure 3.2).
NH
Acyclovir AZT (3 '-azido-2 ', 3 '-dideoxythymidin*
Figure 3.2. New drugs in anti-viral therapy
3.2 The chemistry of the purine ring
Many of the reactions undergone by purines can be explained by understanding the 
fundamental physicochemical nature of the heterocyclic system. The purine ring 
(Figure 3.3.) is basically composed of two heterocycle components, the pyrimidine 
and the imidazole systems. The pyrimidine component is an example of a 7u-electron 
deficient system due to the presence of the N-l and N-3 nitrogens which provide an 
electron localising effect within the ring. The imidazole ring structure, containing both 








Figure 3.3. The purine ring system
These contrasting electronic systems present within the unsubstituted purine ring 
result in a sharing of the imidazole n electrons by the pyrimidine moiety and provide a 
relatively stable bicyclic system. This balance, however, can be disturbed by insertion 
of the appropriate electron donating or withdrawing groups into either ring and 
therefore, allows the purine ring to undergo both electrophilic and nucleophilic 
reactions.
As a consequence of this localisation around the ring nitrogens, the adjacent carbon 
atom C- 8  also shows some degree of electrophilic and nucleophilic character which is 
not only dependent on the ionisation state of the molecule but also on the type of 
substituents at the ring carbons.
Subsequently, in the unionised molecule, the carbon at position 8  (C-8 ) appears to be 
the most electron-deficient. Substituents at carbon are displaced by nucleophiles in the 
order C-8>C-6>C-2. However, proton loss within the imidazole ring leads to 
formation of the anion and an increase in electronegativity, resulting in nucleophilic 
attack directed initially at C- 6  of the pyrimidine ring with subsequent displacement at 
C-2 and C- 8  positions. This anionic form is also readily attacked by electrophiles 







Scheme 3.1. Alkylation of purine in the anionic form
In neutral conditions electrophilic attack results in a mixture of products but the 
general trend is towards substitution at the 9 position of the molecule although 
reports of 7 substituted purines do appear in the literature (Shamim et al., 1989).
However, once a ring proton is replaced by an alkyl group, further alkylation is 
possible and can result in the formation of quaternary salts at either nitrogen in the 
pyrimidine or imidazole system. Furthermore the introduction of one or two strong 
electron-releasing groups (hydroxy or similar) into the pyrimidine ring activates the 8 - 
position which may achieve sufficient electronegativity to be attacked by electrophiles. 
Such electrophilic displacements result in direct alkylation, nitration and halogenation 
of the 8 -position of the purine moiety (Figure 3.4.)
O O
Me H Me H 
8 -chlorotheophylline
Figure 3.4. The direct chlorination of theophylline
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3.2.1 Reactions of the purine ring
As described in the earlier section, the reactions undergone by purines are not only 
governed by the presence of the appropriate electron donating or withdrawing groups 
but also the state of ionisation of the purine molecule at time of reaction. The majority 
of purine metatheses in the literature (Lister, 1971) are focused towards nucleophilic 
displacement reactions usually involving displacement of a halogen or thio group at 
the 2 -, 6 - and 8 -positions by a wide range of substituents.
Chloropurines are the most versatile derivatives with replacement of the chlorine 
atoms by nucleophilic reagents governed by the ionisation state of the purine. 
However, the presence of strong electron-releasing groups leads to electrophilic 
substitution at the 8 -position of the purine moiety and is particularly useful for 
reactions involving the methylxanthines. These methylated dioxopurines possess two 
strong electron-releasing groups and can undergo alkylation, halogenation and 
nitration at this 8 -position (Lister, 1971).
The next two sections concern both types of displacement particularly reactions 
involving halogenation and alkylation of both substituted and unsubstituted purines.
3.2.1.1 Alleviation
The purine ring system, as detailed in section 3.1, is the juxtaposition of a pyrimidine 
with an imidazole ring and, is capable of undergoing both electrophilic and 
nucleophilic reactions at its ring nitrogens. Thus one of the most important reactions 
involving the purine ring is the electrophilic substitution of the ring nitrogens by 
alkylating agents.
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The use of alkylating agents has attracted much attention in purine chemistry not only 
as a commercial route to the synthesis of the therapeutically important methylated 
xanthines (e.g. theophylline, theobromine) but also in the understanding of the 
mutagenic, carcinogenic and anti-tumour effects of such agents in biological systems 
(Lawley and Brookes, 1963). Therefore, as expected from such a ring system the 
alkylation of the ring nitrogens is complex and attributed to the ionic state of the 
purine derivative at the time of reaction. Thus the anionic form of purine (Figure 3.5) 
is readily attacked by such agents as dimethylsulphate/alkali, diazomethane to produce 
normally and exclusively N-9 substituted derivatives.
However, an excess of methyl iodide in DMF gives the 7,9-dimethylpurinium salt 
(Figure 3.6) whilst 6 -methylpurine gives 6,9-dimethylpurine as the main product.
Me
Figure 3.5. The anionic form of purine
Me
Figure 3.6. 7,9-dimethylpurinium salt
In neutral forms, the products of alkylation may vary although, once the ring proton 
♦
has been replaced, further alkylation can occur to produce quartenary salts at either 
the imidazole or pyrimidine ring nitrogens.
Thus, adenine gives mainly the 3-alkylated product under neutral conditions in the 
presence of alkyl bromide in dimethylacetamide while the anionic form gives a mixture 
of 3- and 9-alkyl derivatives, although in few cases the 9-isomer predominates (Lister, 
1971), Figure 3.7. In contrast, with adenosine and its, derivatives the 1-alkylated 
product is observed which is attributed to the hindrance to N-3 attack by the peri 9- 








Figure 3.7. The alkylation of the purine bases
Subsequently, in the case of the oxo, thio, thioxo and aminopurines, the availability of 
additional tautomeric forms enlarge the possibility of attack by electrophiles at the 
different ring nitrogens.
Thus, alkylation of guanine is a much more complex process which, under alkaline 
conditions, results in a mixture of 9-, 7- and 3-methyl derivatives. In contrast, the 7- 
position is readily alkylated when guanine is held in place in the Watson-Crick double 
helix in nucleic acids, by such alkylating agents as N-nitroso-N-ethylurea, dimethyl 
sulphate (DMS) and diazomethane (Strauss, 1976, Singer and Kusmierek, 1982).
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This preferential site of alkylation is attributed to the availability of the N-7 position 
for reaction with electrophilic reagents and being the most nucleophilic centre within 
this conjugated system (Lawley and Brookes, 1963). Further alkylation at this 
position gives rise to an unstable quaternary nitrogen which leads to separation of the 
purine ring from the deoxyribose, unit leading to interference in DNA replication 
(Hall, 1971).
Thus, extending this system to the alkylation of oxygenated purines, in particular to 
xanthine and its derivatives, it has been observed that alkylation under alkaline 
conditions proceeds in the order N-3, N-7, N-l (e.g. in the order of decreasing 
acidity) with methylation of xanthine giving first theobromine then caffeine, in the 
presence of methyl iodide and barium carbonate. Similarly 1-methylxanthine is 
methylated by dimethyl sulphate in alkaline solution to furnish 1,3-dimethylxanthine 
(theophylline) which is further alkylated to caffeine (Scheme 3.2)
Me.




However, blocking of oxygen function by trimethylsilylation leads to exclusive 
alkylation at N-7. In contrast, under neutral or acidic conditions, methylation of 
xanthine proceeds at the N-7 or N-9 position. Thus, in the presence of methyl iodide 
7,9-dimethylbetaine is formed via reaction with xanthine (Scheme 3.3) while 
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Scheme 3.3. The formation of 7,9-dimethylbetaine
3.2.1.2 Chlorination
Chlorination of the purine moiety is one of the most important reactions in purine 
chemistry and provides a route to both substituted and unsubstituted derivatives of 
purines. Subsequently, the exceptional reactivity of the chloropurines toward 
nucleophilic reagents makes them invaluable compounds for purine inter-conversion. 
Therefore, chlorine atoms located at the 2-, 6 -, or 8 -position are all replaceable but 
the ease or difficulty of displacement is modified in the presence of electron-releasing 
groups (Lister, 1971).
The synthesis of chloropurines has been achieved by a variety of methods of which the 
most successful has involved the inter conversion of appropriate oxo analogues to 
their corresponding 2-, 6 - and 8 -chloro derivatives. This transformation is normally 
carried out using a phosphorous halide, such as phosphorus oxychloride (POCI3 ) 
either alone or in a mixture with phosphorous pentachoride (PCI5 ) in an inert solvent 
such as toluene. This approach is extensively used in purine chemistry and has been 
adapted and modified from Fischer's initial synthesis of 2,6,8-trichloropurine from uric 
acid in the presence of phosphorus oxychloride (Lister, 1971), Scheme 3.4.
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) = 0  POCb t
\ Reflux
2 ,6 ,8 -trichloropurineUric acid
Scheme 3.4. The synthesis of 2 ,6 ,8 -trichloropurine
Adaptations of this method are extensive in the literature (Lister, 1971, Finar, 1981) 
and normally employ the combination of phosphorus oxychoride with phosphorous 
pentachloride used under reflux to synthesise the appropriate chloro derivatives from 
their corresponding di and trioxo counterparts.
However, a more efficacious procedure involves the use of tertiary aliphatic or 
aromatic amines (e.g. N,N-dimethyl or diethylanilines) as catalysts and/ or acid 
scavengers in the presence of phosphorus oxychloride for the chlorination of purines 
such as hypoxanthine to 6 -chloropurine which is not achieved by standard conditions. 
Interaction between the chlorine atom and the tertiary nitrogen atom is rare but some 
side reactions involving replacements of halides by amine fragments e.g. ( 1) to (2 ) or 





Even nucleosides may be chlorinated by this combination of reagents, providing that 
the sugar hydroxy groups are protected as acetoxy or benzyloxy groups. Other 
reagents which have been used include thionyl chloride in DMF (Vilsmeier-Haack 
reagent) which converts 2',3’,5'-tri-0-benzoylinosine into a 6 -chloropurine nucleoside, 
and chloromethylenedimethylammonium chloride in chloroform.
The presence of other groups is not, in general, deleterious to the purine molecule 
with alkyl groups (also N-alkyl), aryl, trifluoromethyl, amino and alkylthio substituted 
purines having all been successfully chlorinated. Direct chlorination of the purine 
nucleus has been achieved primarily through nucleophilic attack on the 8 -position and 
is only possible if the unoccupied 8 -position contains one or more electron releasing 
groups (e.g. hydroxy or oxo group), with the course of halogenation affected by the 
nature of the solvent used.
As a general rule chlorination of N-alkyl oxopurines is only possible in those cases 
where the oxo function is capable of existing in the enol form. Therefore alkylated 
oxopurines in which no enolisation is possible may also react but usually with 
elimination of one or more alkyl groups. Of the methylated forms theobromine (3) 
allows chlorination of both 2- and 6 -positions through loss of N-3 methyl group 
(Finar, 1981). In the presence of dimethylaniline purine (4) arises, whereas using a 
mixture of phosphorus oxychloride and phosphorus pentachloride results in the 















Similarly caffeine using the above mixture at elevated temperatures (180°C) gave the 
same trichloropurine (Lister, 1971) while 1,9-dimethylxanthine in phosphorus 
oxychloride at 140°C gave the corresponding 2,6-dichloro-9-methylpurine. Therefore 
direct chlorination of N-alkylated oxopurines is achieved by a number of reagents 
including thionyl chloride in chloroform, chlorine gas and in some cases N- 
chlorosuccinimide and sulphoryl chloride when 8 -methylpurine is used.
The high reactivity associated with halogenopurines as well as their ease of removal 
by a wide variety reagents infers that the chlorination of the purine moiety is one of 
the most important features of purine chemistry.
Replacement of chlorine by hydroxyl proceeds with ease under alkaline conditions 
only if other activating groups are present in the molecule with ring opening of the 
imidazole ring following hydroxyl attack at C-8 , especially when 7 or 9-alkyl groups 
are present. However the most widely used reactions of chloropurines has been with 
amines, leading to a wide variety of purines of synthetic and biological importance 














3.3 Synthetic routes to purines
The purine ring is the fusion of two aromatic heterocycles, the pyrimidine and the 
imidazole. A logical starting point for ring synthesis is an appropriately substituted 
pyrimidine or imidazole molecule from which a second ring can be constructed by a 
cyclisation process, this is illustrated in Scheme 3.8
H
Scheme 3.8. Synthetic routes to purines via two pathways
Two methods of synthesis are present in Scheme 3.8 and both have been successful 
for the synthesis of the purine moiety. The first method (i) is the most common and is 
known as the Traube route and is by far the most versatile method for the synthesis of 
purines.
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The 5,6-diaminopyrimidine starting compound reacts with a wide range of 
electrophiles particularly acids, acid chlorides, formamides, ethyl orthoformate and 
other similar electrophilic reagents to become the intermediate 5-acylamino 
substituent of the pyrimidine component, which via cyclisation with base or 
phosphorus oxychloride provides the ring-closed 8 -substituted purine.
The synthesis via route (ii) is a useful alternative to that based on diaminopyrimidines 
and involves the use of 5-aminoimidazole-4-carboxamide and related compounds as a 
starting precursors for the purine moiety. The route utilises a variety of reagents 
commonly used in the cyclisation process of the Traube route and include formic acid, 
alkyl and trialkyl esters, amides and urea. Intermediates isolated are normality the 
formylated or acylated amino compounds of the starting carboxamides which are 
subsequently ring closed by heating directly or by base catalysis. This method is 
closely related to the biological route to purines, with the starting 5-aminoimidazole-
4-carboxamide occurring naturally as a ribonucleotide and being the precursor of 
purine nucleotides. Imidazoles are, therefore, useful in the synthesis of both purine 
nucleosides from imidazole nucleoside precursors and in the synthesis of 2 ,6 ,8 - 
substituted purines reflecting the type of carboxylic acid used in the building of the 
purine ring.
3.3.1 The T raube route
The Traube route to purines is the most widely used and versatile synthetic route to 
purines. Modifications have led to the synthesis of a wide range of substituted and 
unsubstituted purines, including the pharmacologically important methylxanthines 
(Traube, 1900), adenosine antagonists (Jacobson et al., 1988, Peet et a l , 1993) and 
derivatives of theophylline (Pfleiderer and Niibel, 1959, Fuschs et al., 1978, 
Miyamoto et a l, 1993).
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In recent years the route has been modified and generalised to two main synthetic 
procedures both incorporating a pyrimidine precursor.
The first and most commonly utilised starting precursor is 5,6-diaminopyrimidine 
(Papesch and Schroeder, 1951, Speer and Raymond, 1953) which reacts with 
carboxylic acids or their corresponding acid chlorides to produce the 5-acyl 
intermediate with ring closure in aqueous alkali provides a route to purines 
unsubstituted at the 8 -position. The earliest example of the use of such precursors was 
in the synthesis of uric acid via the acylation of the starting diaminouracil (Traube, 
1900). Cyclisation of the imidazole moiety was effected by boiling in base, Scheme 
3.9.
H
0  O H
k X , nhco2b  h . J l  n
CICQzEt ¥  |J 18CTC  ̂ J  \ _ 0




Scheme 3.9-The synthesis of uric acid via the Traube route
The intermediates during this reaction are usually the N-formyl or N-acyl derivatives 
of the 5-position, with acylation/formylation through reaction with formic acid-acetic 
anhydride mixture or with formamide alone (Traube, 1900). Cyclisation of these 
intermediates is through fusion or heating in alkali with ease of ring closure associated 
with the acidity of the 5-formamido intermediate as outlined by the spontaneous 









Scheme 3.10. The cyclisation of intermediate 5-formamido derivative to caffeine
Subsequent extension of this route to 8 -substituted purines has close parallels with 
methods for unsubstituted derivatives with the starting diaminopyrimidine precursor 
being acylated with the corresponding substituted acids or their acid chlorides. Ring 
closure, although more difficult with such intermediates, can alternatively be effected 
either through treatment with alkali or refluxing with phosphorus oxychloride 
(Traube, 1900, Shimada, 1992), Scheme 3.11. Further, condensation of the 
diaminopyrimidine with an aldehyde, followed by oxidative cyclisation, also gives the 
corresponding 8 -substituted product, particularly 8 -alkyl and 8 -aryl derivatives 
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Scheme 3.11. Routes to 8 -substituted purines
Adaptations to Scheme 3.11 include, the synthesis of 8 -amino derivatives of 
theophylline following the reaction of 5,6-diaminopyrimidine with a mixture of DMF 
in phosphorus oxychloride (Vilsmeier-Haack reagents). Recent modification of this 
procedure by Yoneda and co-workers utilising the 5-nitroso-4-amino precursor 






Scheme 3.12. Synthesis of 8 -aminopurines using Vilsmeier-Haack reagents
Routes to 8 -substituted purines although successful through utilisation of the starting 
diaminopyrimidine precursor have been superseded by cyclisation of the 5-nitroso-4- 
alkylaminopyrimidines. Nitrosation of the 5-position affords derivatives which can 







Scheme 3.13 Routes to 8 -and 9-substituted purines
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Cyclisation under refluxing conditions in butanol or xylene has been developed 
through the work of Bredereck et al., (1962), Pfleiderer and Walter, 1964, and 
Goldner et al., (1966). This cyclodehydration reaction utilises the reaction between 
the C4-alkylamino and the 5-nitroso group with the loss of water.
Alternatively, reduction of this nitroso derivative in a mixture of formamide/formic 
acid results in concurrent cyclisation to the 9-substituted derivative (Pfleiderer and 
Nubel, 1960). Similarly addition of sodium nitrite followed by heating in sodium 
dithionite at low temperatures also gave the 9-substituted derivative, Scheme 3.13.
3.3.2 Synthesis of purines from imidazoles
Although the most common route of synthesis for purine analogues has been via the 
use of a pyrimidine precursor, the use of other alternative intermediates has been 
investigated with the use of imidazole derivatives being popularised by many 
researchers in the purine field as appropriate starting products for synthesis of a wide 
variety of purines.
The first synthetic approach to purines via an imidazole intermediate was due to 
Sarasin and Wegmann in 1924, (Lister, 1971). However, the lack of suitable 
intermediates together with the lability and oxidation of these derivatives under 
normal conditions made them difficult to work with. In recent years, however, these 
disadvantages have been overcome with imidazole derivatives providing not only a 
suitable means by which substituted and unsubstituted derivatives of purines could be 
synthesised but also offering a route to purine nucleosides and nucleotides under 
milder reaction conditions.
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Nowadays purine syntheses from imidazoles involve the use of the starting 
intermediate 5(4)-amino-4(5)-carboxamide and its related compounds including the 
thiocarboxamide (8 ), carboxamidine (9), nitrile (10) and the corresponding ester (11) 
(Figure 3.8).
S O  o
(8) (9) (10) (11)
Figure 3.8. Imidazole derivatives for use in purine synthesis
The intermediates used for the completion of the purine ring are much the same as for 
the cyclisation of diaminopyrimidines involving the use of formic and carbonic acids 
but requiring much milder conditions. Therefore, the use of imidazole precursors has 
provided a useful route to purines not possible by other conventional methods.
In the next two sections the use of 4-amidoimidazole-5-carboxamide and 5(4)- 
aminoimidazole-4(5)-carboxamide as precursors to purines particularly substituted 
purines, including xanthine and its derivatives, will be reviewed.
3.3.2.1 The use of 5-aminoimidazole-4-carboxamide as a precursor
The use of 5-aminoimidazole-4-carboxamide for the preparation of xanthine and its 
derivatives was first observed by Baxter and Spring 1944 (Lister, 1971) using 
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The following year Baxter and Spring, 1945 (Lister, 1971) expanded this route to the 
synthesis of 9-alkylxanthines (13) by use of the appropriate N-alkylimidazole 
precursor (12, R=alkyl) via the Lossen rearrangement of the 4-carboxamide group 




As a result of this early work this procedure has found use not only in the preparation 
of xanthine derivatives, but also as a possible route to nucleosides by use of the 
appropriate starting 5-glycosylimidazole-4-carboxamide.
3.3.3.2 The use of 5f4)-aminoimidazole-4f5)-carboximide as precursors
Almost all recorded purine syntheses from imidazoles involve the starting precursors 
of 5(4)-aminoimidazole-4(5)-carboximides which under appropriate conditions are 
cyclised to the purines in question.
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Thus the synthesis of hypoxanthine is achieved through the formylation of the starting
5-aminoimidazole-4-carboxamide in the presence of formic acid-acetic acid mixture. 
The C-2 substituted product is subsequently obtained by treatment of the N-formyl 
derivative with a mild base, Scheme 3.15.
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Scheme 3.15. Route to hypoxanthine
Contrasting this to the Traube route, formamide has little application as a one carbon 
cyclisation reagent with amino imidazoles however, 7-methylxanthine was obtained on 
heating 4-amino-1 -methylimidazole-5-carboxamide with formamide.
In an analogous reaction adenine was obtained from the aminoimidazonitrile in the 
presence of formamide although yields were improved on heating with formamide 
acetate.
heat Xanthine
Scheme 3.16 Routes to xanthine
The xanthines are prepared by reaction of 5-aminoimidazole-4-carboximide with 
diethylcarbonate in refluxing sodium ethoxide, scheme 3.16.
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This route has been readily expanded to accommodate the preparation of nucleoside 
derivatives including the synthesis of xanthosine via use of 5-aminoimidazole-4- 






The development of a novel one-step homogeneous immunoassay for theophylline is 
an important goal in both clinical chemistry and diagnostics. Current methods for the 
measurement of theophylline serum concentrations rely on heterogeneous systems and 
include such techniques as ELISA (Danilova and Vasilov, 1991), radioimmunoassay 
(Neese and Soyka, 1977), enzyme immunoassay (Eppel et al, 1978, Rupchock et al., 
1985) and fluoroimmunoassay (Meola et a l, 1979). These methods although both 
specific and sensitive do not fulfil the criteria for a rapid, easy-to-use and cost 
effective assay. Recently focus has moved towards immunosensors which not only 
offer speed and convenience to the user but require no separation step.
One such technology which has shown great promise is the FCFD a homogeneous 
assay system (Badley et al., 1987), based on optical immunosensing, which provides 
an easy-to-use assay with a rapid reaction time. In view of the advantages of such a 
detection system particularly in the assay of small molecules, the FCFD was used to 
develop an immunoassay for theophylline with the potential of monitoring serum 
plasma concentrations with the ability of discriminating between toxic and normal 
levels. However, in the course of constructing a homogeneous assay for theophylline 
utilising the FCFD, it became necessary to prepare fluorescent analogues of 
theophylline which were not only immunoreactive against the anti-theophylline 
antibody, immobilised within the device, but also soluble in the required assay system.
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Further, the photoproperties of the chosen fluorophore together with the length and 
lipophilicity of the link between theophylline and the fluorophore must be optimised 
prior to use in the competitive theophylline assay. Thus the synthetic approaches 
utilised in the preparation of such congeners is outlined in section 4.2.
4.2 Synthetic Approaches
The main aim of the synthetic procedure was to synthesise 8 -substituted derivatives of 
theophylline containing a hydrophilic linker. These linkers would incorporate either an 
alkylamino or an alkylethoxy chain and possess a terminal functional group (e.g. 
amino or carboxy) which could be used as an attachment point in linking the 
fluorescent group to the theophylline moiety. However prior to synthesis of such 
derivatives a number of approaches were considered and are subsequently outlined:
(i) the first and most important concern was the attachment point of the fluorescent 
group to theophylline moiety. As is apparent in Figure 4, theophylline can be 





Figure 4. The structure of theophylline
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Subsequently, in view of these available positions, several groups (Neese and Soyka, 
1979, Danilova, 1991) have utilised the 8 -position of theophylline in the production of 
monoclonal antibodies by synthesising conjugates attached to the 8 -position of 
theophylline. While others have seen highly immunogenic derivatives by utilising the 3 
and 9-positions (Cook et al., 1976, Hu et al., 1980). However since the attachment 
point corresponding to the supplied monoclonal antibody was unknown, the 8 - 
position was chosen as the most useful option for the synthesis of the required 
compounds.
(ii) Once the position of attachment of the fluorescent probe to theophylline was 
established, the route of synthesis to such derivatives was discussed. There were two 
possible options available:
(a) involving the synthesis of the theophylline moiety from the starting pyrimidine via 
modification of the Traube route
(b) by use of an appropriate imidazole precursor.
The utilisation of these two routes has been outlined in section 3.3 with both 
procedures being prevalent in literature (Lister, 1971). The route chosen for the 
synthesis of 8 -substituted theophyllines was therefore, via the starting pyrimidine 
which provided both scope and versatility in the final synthetic approach.
Initially two routes were investigated: through ring closure of the starting 5,6- 
diaminopyrimidine (A) and the cyclodehydration of the appropriate 5-nitroso-4- 









Figure 4.1. Pyrimidine precursors to 8 -substituted theophyllines
The use of the starting diaminopyrimidine involved a one-step procedure to the ring 
closed theophylline derivative. The route followed initial acylation of the 5-amino 
group followed by ring closure in the appropriate solvent. Conditions generally 
favoured were refluxing of the acyl intermediate in formic acid, formamide, or 
through base catalysed cyclisation (Bredereck and Fohlisch, 1962, Lister, 1971).
Subsequently, the versatility of 5,6-diamino-1,3-dialkylpyrimidines has been utilised as 
starting precursors for the synthesis of a wide variety of 8 -substituted purines 
including derivatives of theophylline (Speer and Raymond, 1953, Bredereck and 
Fohlisch, 1962, Goldner et al., 1966), adenosine antagonists (Daly et al., 1982, 
Jacobson et al., 1988, Katsushima et al., 1990, Suziki et al., 1992, Peet et a l, 1993) 
and PDE inhibitors (Kramer et al., 1977, Buckle et a l, 1993).
The second route employed involved the use of 5-nitroso-l,3-dimethyl-4- 
alkylaminopyrimidine which through heating in butanol or xylene provides a route to 
the desired 8 -substituted theophylline product. Subsequently, cyclisation through this 
procedure has been associated with a number of research groups including Bredereck 
and co-workers (1962) and Goldner et al, (1966).
(iii) Once the route of synthesis was established the choice of linker was then sought. 
The synthesis of 8 -substituted theophyllines were required to possess a functional 
terminal amino or carboxy group.
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Such groups were chosen due to their ease of formation and versatility for inter group 
conversion particularly in their reaction with electrophiles including isocyanates and 
isothiocyanates. These groups are present in the most common fluorescent labels (e.g. 
fluorescein, rhodamine) and are particularly useful in the linkage of the theophylline 
moiety to the fluorescent moiety.
Thus the initial synthetic strategy involved the synthesis of 8 -carboxytheophylline via 
the oxidation of 8 -hydroxymethyltheophylline with possible extension to 8-(3- 
carboxypropyl)theophyllines.
(iv) The choice of the fluorescent congener was determined prior to synthesis of the 
8 -substituted theophyllines. The FCFD had already been used in a rubella assay (Parry 
et a l, 1990) in which the label employed was fluorescein which was attached as its 
isothiocyanate (FITC). Other probes considered for attached to the theophylline 
moiety were DTAF (dichlorotriazinylfluorescein) and dansyl chloride.
The aim of the synthetic procedure was to synthesise fluorescent probes of 
theophylline possessing a hydrophilic spacer between the 8 -position of theophylline 
and the fluorescent label. The spacer would incorporate a 5-10 carbon unit between 
the two functional groups and would contain either a polymethylene or a polyether 
group as the linker (Figure 4.2).
THEOPHYLLINE------------ LINKER----------- FITC
Figure 4.2. The required analogue of theophylline in the FCFD assay
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Ultimately the strategy was to synthesise fluorescent probes of theophylline which 
were not only soluble in alkaline buffer solutions as well as biological samples but be 
immunoreactive towards the anti-theophylline antibody. This was the most important 
requirement, since the basis of the immunoassay is competition between the labelled 
theophylline moiety and unlabelled theophylline.
4.3 The synthesis of 8 -carboxvtheophvlline
As outlined in the previous section the requirement for a suitable theophylline 
derivative for the attachment of a fluorescent probe was the main priority of the 
synthetic work. Subsequently, initial work focused on the synthesis of 8 - 
carboxytheophylline (2 0 ) from the oxidation of 8 -hydroxymethyltheophylline 
precursor (15). Direct routes to 8 -carboxytheophylline have not been reported 
therefore, fiinctionalisation of the hydroxy precursor to the carboxy moiety was 
considered to be the most suitable approach for obtaining (2 0 ).
However, investigation into the synthesis of 8 -hydroxymethyltheophylline led to two 
routes being considered. Initial work focused on the one step procedure of Bredereck 
and Fohlisch (1962) through the acylation and cyclisation of the starting 5,6-diamino- 
1,3-dimethylpyrimidine precursor (14), Scheme 4.
Me Me H
(14) (15)
Scheme 4. A. Hydroxyacetic acid, NaOH.
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Acylation of the starting 5,6 -diamino-1,3-dimethylpyrimidine (14) was primarily 
through reaction with hydroxyacetic acid following insitu formation of the 5-acyl 
intermediate which following cyclisation in base afforded the hydroxy derivative (15) 
in very low yields (2 .6 %).
Isolation of this cyclised (15) product was through recrystallisation in water, with 
analysis of proton spectrum confirming the presence of the two N-Me groups of the 
theophylline moiety which resonate as singlets at 6  3.25 and 5 3.40 together with a 
signal at 8  4.75 which was assigned to the purine-CH2 group.
Disappointment in obtaining such low yields of the hydroxy precursor (15) through 
this one-step procedure led to the preparation of (15) via an alternative route. Thus 
the synthesis of 8 -hydroxymethyltheophylline followed the multi-step procedure of 
Goldner et al, (1966) involving the initial preparation of 1,3-dimethylbarbituric (16) 
through condensation of N^-dimethyl urea with propane dioic acid in the presence 
of a mixture of acetic anhydride/acetic acid, scheme 4.1.
MeNH
M (CH3CO) 2
c h 3c o o h
c o 2h (16)
Scheme 4.1 . The synthesis of l,3-dimethyl-2,4,6-trione
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Treatment of this pyrimidinetrione (16) with phosphorus oxychloride (POCl3) and a 
small catalytic amount of water afforded 6-chloro-l,3-dimethylpyrimidine (17) 
through Scheme 4.2. Removal of excess POCl3 from the final reaction mixture led to 






Scheme 4.2. A. POCI3, reflux, 40 min.
However although the 6 -chloro derivative (17) was obtained in high yields there were 
problems involved in the reproducibility of this derivative in a pure form. The removal 
of POCl3 from the reaction mixture was problematic as was the possibility of further 
chlorination of the carbonyls at positions 2 and 4 of the pyrimidine moiety. 
Subsequently, 6 -chloro-1,3-dimethylpyrimidine (17) was obtained commercially and 
used in the proceeding steps without difficulty.
Displacement of the 6 -chloropyrimidine (17) by ethanolamine under reflux afforded 6 - 
(2-hydroxyethylamino)pyrimidine (18) through Scheme 4.3 (Condition A). However 
isolation of this product by recrystallisation in water proved to be troublesome with 














Scheme 4.3. A. H2NRi / heat R1=CH2CH2 0 H , Ri=CH2CH2CH2OH 
B. H2NRi, Na2C0 3 , heat
Alternatively modification of this procedure, Scheme 4.3 (Condition B), through 
refluxing of the chloro derivative (17) with ethanolamine in the presence of NajCOj in 
ethanol led to the isolation of (18) in 75% yield.
The synthesis of (19) followed nitrosation of the 5-position using isoamyl nitrite in the 
presence of aqueous acid, Scheme 4.4. The reaction proceeded swiftly and afforded 
the nitroso derivative (19) as a purple crystalline product in 63% yield. However, it 
was apparent that prolonging the reaction time of the nitrosation step resulted in the 
formation of side products, this was confirmed by TLC. Subsequently reaction times 








Scheme 4.4. C. isoamyl nitrite, HC1, EtOH, RT. Rj=CH2CH2OH
Ri=CH2CH2CH2OH
Mechanistically the reaction proceeds through the insitu formation of the nitrosonium 
ion by acid hydrolysis of isoamyl nitrite moiety.
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This subsequently leads to the attack of this weak electrophile by the C-5 carbon atom 
which following resonance stabilisation of the pyrimidine moiety by the electron 
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Scheme 4.5 The mechanism of nitrosation
Cyclisation to 8 -hydroxymethyltheophylline (15) was subsequently achieved through 
the cyclodehydration of the C-5 nitroso group and the C-4 alkylamino group via the 
loss of water in refluxing butanol, Scheme 4.6. The reaction occurs with ease 
following the decolourisation of the initial nitroso product to afford the ring closed 
moiety in 54% yield.
(19) (15>
Scheme 4.6 D. BuOH/reflux
Following cyclisation of the nitroso to the ring closed 8 -hydroxy compound (15), the 
required 8 -carboxytheophylline (2 0 ) was attained through the oxidation of the 
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Analysis of carboxy product via proton NMR proved to be troublesome with a 
spectrum only achieved in the presence of deuterated trifluoroacetic acid. The loss of 
the methylenic hydroxy group at 5 4.69 was indicative of the oxidation of the hydroxy 
moiety. This was further confirmed by analysis of the mass spectra of the carboxy 
product and the starting hydroxy compound, which on comparison yielded molecular 
ions (M+) at 210 and 224 respectively.
However, although this carboxy (20) compound was attained in good yield as a final 
target compound through the oxidation step, problems were encountered with the 
solubility of this derivative in organic solvents. Subsequently, the lack of solubility of 
this carboxy moiety inferred that utilisation of this precursor in the preparation of 
fluorescent theophylline derivatives was not possible. Subsequently 8 -hydroxy 
derivatives possessing longer alkyl substituents were sought which could be oxidised 
to a carboxy functionality providing not only a suitable linkage group but also 
improve the solubility of the carboxy derivative.
4.3.1. The synthesis of 8-(2-hvdroxvethvDtheophvlline
As described in the previous section (4.3) the utilisation of the carboxy group for the 
linkage of amino groups in proteins and peptides in an important process in synthetic 
and protein chemistry.
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Several groups have reported the synthesis of 8 -alkylcarboxy derivatives of 
theophylline in the synthesis of protein conjugates for utilisation as immunogens in the 
preparation of monoclonal antibodies. Li et al., (1981a) prepared 8-(3-carboxypropyl) 
theophylline while Oh etal., (1991) prepared the butyl derivative, 8-(4-carboxybutyl) 
theophylline for utilisation as a possible immunogen. Thus with a view to preparing 
carboxy derivatives of theophylline possessing such an increase in alkyl chain length, 
the derivative 8 -hydroxyethytheophylline (23) was synthesised.
Preparation of 8-(2-hydroxyethyl)theophylline followed the multi-step procedure of 
Goldner et al., (1966) from the starting precursor 6 -chloropyrimidine (17). Initial 
preparation of 6 -hydroxypropylaminopyrimidine (21) was through reaction of 3- 
aminopropanol with 6 -chloro- 1,3-dimethylpyrimidine (17) in 80% yield, Scheme 4.3. 
Reaction conditions were similar to the synthesis of 6 -hydroxypropylaminopyrimidine 
with the exception of using butanol as the refluxing solvent.
After purification to remove any remaining traces of butanol, the derivative (21) was 
nitrosated in the presence of isoamyl nitrite to afford (2 2 ) in 60% yield with 
subsequent refluxing in butanol affording the cyclised 8 -(2 -hydroxyethyl) derivative 
(23) in 50% yield, Scheme 4.8.
Me..NOMe.
MeMe
Scheme 4.8. D. Butanol, reflux Ri= CH2OH
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Attempts to oxidise the hydroxy derivative (23) were not pursued due to a change in 
approach of the synthetic procedure pursued and the need for hydrophilic linkers for 
attachment to such derivatives, see section 4.4.
4.3.2 8 -methoxyethvl and 9-methoxvethvl derivatives of theophylline
As discussed in section 4.2 and 4.3 synthesis of 8 -substituted derivatives of 
theophylline is possible in good yields particularly in the formation of 8 -hydroxyalkyl 
derivatives of theophylline. Although synthesis of these derivatives was an important 
goal in the preparation of theophylline targets particularly derivatives possessing 
functional moieties, it was also important to demonstrate the versatility of this route 
by directing the synthesis towards 9-substituted derivatives.
Through the work of Bredereck and Fohlisch, (1962) 9-substituted derivatives of 
theophylline were reported via the reduction and subsequent formylation/cyclisation 
of the starting 5-nitroso precursor. Conditions employed for reduction usually 
favoured use of electron-transfer reagents such as sodium dithionite or use of zinc in 
formic acid (Kramer et a l , 1977).
The importance of these nitrosated derivatives lie in their versatility, with ring closure 
to 8 -substituted derivatives through refluxing in butanol while reduction of the nitroso 
moiety leads to the preparation of useful amine intermediaries. Ring closure is 
normally effected in refluxing base to afford the 9-substituted derivative.
Initial approaches to the synthesis of the model nitroso derivative (25) was through 
reaction of 6-(2-methoxyethylamino)pyrimidine (24) with isoamyl nitrite (Scheme 
4.9).
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Prior to synthesis of nitroso intermediate (25), 6 -chloro-1,3-dimethylpyrimidine (17) 
was substituted with 2-methoxyethylamine to afford (24), as a model derivative, in 
80% yield with NajCOg in refluxing ethanol, Scheme 4.9.
Isolation of this pure compound (24) was by recrystallisation with tetrahydrofuran 
with characterisation of product by proton NMR confirming the presence of the 
methoxy singlet at 5 3.08.
This model compound (24) was subsequently nitrosated by dropwise addition of a 
solution of sodium nitrite in acetic acid following the method of Kramer et al., (1977). 
Nitrosation proceeded swiftly with reaction reaching completion within 3 h and 
resulting in a colour change of the solution from clear to purple. Isolation of the 
nitroso product (25) was by evaporation of the reaction mixture with recrystallisation 








Following this nitrosation, the nitroso compound (25) was used in the synthesis of 
both 8 -methoxymethyl-1,3-dimethylpyrimidine (26) and 9-(2-methoxyethyl)-1,3- 
dimethylpyrimidine (27).
Thus, thermal cyclisation of nitroso product (25) in butanol afforded (26) as a creamy 
solid in 50% yield following recrystallisation in ethanol (Scheme 4.10).
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Cyclisation proceeded with ease and was followed by the decolourisation of the 
purple nitroso product in solution.
The synthesis of the 9-substituted product involved the reduction of the nitroso to an 
amino group in a mixture of zinc/formic acid which was followed by acylation in 
formic acid. The formamido intermediate formed insitu was not isolated but 
immediately ring closed through base catalysed cyclisation in aqueous NaOH to afford 





A. Butanol, reflux; B. zinc/formic acid; C. NaOH (aq)
Scheme 4.10. The synthesis of 8  and 9-derivatives of theophylline using the 5-nitroso 
precursor
Alternatively, the reduction of (25) was also attempted with aqueous sodium 
dithionite in ammonia to afford the 5-amino compound (27a) in 50% yield, although 
this was not confirmed by NMR. Due to the instability of (27a), the amino product
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was formylated and cyclised without further purification. Formylation was achieved 
through reaction with formic acid which following cyclisation of this intermediate 
with aqueous base yielded (26) as a crude solid. Analysis of the crude product (26) by 
TLC ( 1 0  CH2C12 : 1 MeOH) inferred the presence of a mixture of products.
Further analysis by NMR confirmed this observation and the belief that the reaction 
had not reached completion due to presence of CHO singlet peak at 6  10.13. Isolation 
of this intermediate was not pursued with attempts to obtain the ring closed 9- 
methoxyethyl derivative in refluxing base proving to be unsuccessful. Alternative 
routes were pursued.
4.3.3. 8 -nitrotheophvlline
Subsequent extension of the modified Traube route led to the synthesis of 8 - 
nitrotheophylline with the possibility of attack by electrophiles (Mosselhi and 
Pfleiderer, 1993) leading to substitution at the 8 -position. The composite electronic 
system together with the insertion of N-Me groups, electron-releasing groups within 
the theophylline ring system leads to activation of the 8 -carbon leading to attack by 
electrophiles.
Attempts to synthesise 8 -nitrotheophylline by direct nitration of theophyllline proved 
to be highly successful, through the method of Duesel et a l , 1954, Scheme 4.11 
Initial conditions involved the reaction of theophylline with nitric acid in the presence 
of glacial acetic.
The temperature during the nitration step was carefully controlled and did not exceed 
90°C, with isolation of the nitrated product as a yellow solid (28) in 60% yield 





Scheme 4.11. A. HN03, CH3COOH, 87°C, lh.
Analysis of the proton spectrum in (CD3)2SO revealed the presence of the two N-Me 
groups of the theophylline moiety which were found to resonate as singlets at 8  3.25 
and 5 3.43. This was in no way indicative that formation of 8 -nitrotheophylline (28) 
had been achieved and thus further analysis through melting point determination 
confirmed formation of (28). Thus melting points agreed with literature values of 281 
°C c f  with 274°C for theophylline.
Following nitration attempts were made to substitute the 8 -nitro group with sulphur 
by reaction with mercaptoethanol. Direct reaction of 8 -nitrotheophylline (28) was 
attempted with mercaptoethanol, initially at 40°C, then at temperatures above 90°C. 
However electrophilic displacement of the nitro moiety at this position was not 
successful and alternative routes were sought.
A possible utilisation of the nitro moiety may involve its reduction to the amino group 
via the use of sodium dithionite (Jones and Robins, 1960) with subsequent attachment 
of the fluorescent moiety via a thiourea linkage. Thus, a useful comparison between 
the analogue described and the fluorescent theophylline congeners possessing linker 
chains, section 4.4, could have been achieved.
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4.4 Linker Studies
The use of linkers or spacers is an important requirement of both protein chemistry 
and organic synthesis. Haptens as well as protein particles require linkage to a large 
globular protein in order to achieve an immunological reaction. Spacers or linkers are 
molecules that provide not only an attachment for the hapten but also for the protein 
complex. In protein chemistry most linkers are based on:
(i) a,©-alkanediamines (e.g. hexane-1 ,6 -diamine, ethane-1 ,2 -diamine)
(ii) amino acids (e.g. glycine, lysine)
(iii) monomers or polymers of ethylene glycol (e.g. PEG)
(iv) 6 -aminohexanoic acid
(v) diaminodipropylamine (DADPA)
These are linkers usually built from individual molecules no more than 10 atoms in 
length. The best choices have appropriate coupling functionalities on either end and 
overall hydrophilic character which is enhanced in the presence of polar constituents 
such as secondary amines, amide linkages, ether groups or hydroxyls. The most 
common spacers are represented in Figure 4.3, see below.
H2N -(C H 2)6-N H 2 H2N —(CH2)5—c o 2h
Hexane-1,6-diamine 6 -aminohexanoic acid
H






Thus, with a view to incorporating a hydrophilic linker between the theophylline 
moiety and the fluorophore, a set of linkers were proposed, incorporating either:
(i) an alkylethoxy group based on the starting precursor 2 -aminoethoxyethanoI with 
proposed chain elongation at the hydroxy terminus
1 ,8 -diamine
(iii) a,co-alkanediamines directly in the reaction with 6-chloro-l,3-dimethypyrimidine
Linkers incorporating ethers were chosen for their increased hydrophilic 
characteristics.
4.4.1 Linkers based on alkvlethoxvdiamines
4.4.1.1 The use of 2-aminoethoxvethanol as starting precursor
The synthesis of alkylethoxydiamines and their selective protection were important 
targets in linker production. Initial work was focused on the use of the starting 
precursor 2 -aminoethoxyethanol as a route to the final a,o-diaminopolyether chain 
(Figure 4.4). Elongation was proposed at the hydroxy functionality via a Michael 
addition reaction with acrylonitrile, while protection of the terminal amino group was 
achieved through use of di-tert-butyl dicarbonate (t-boc) and phenylmethyl 
chloroformate (Cbz).
(ii) mono-protected polyetherdiamines via selective protection of 3,6-dioxaoctane-
(17).
2 -(2 -aminoethoxy)ethanc 
Figure 4.4.
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Thus protection of 2-(2-aminoethoxy)ethanol precursor was initially through use of t- 
boc under standard conditions in the presence of base.
Coupling to the amino functionality was quantitative and resulted in the formation of 
the carbamate (29) as a clear oil in 99% yield, Scheme 4.12. Analysis of this oil (28) 




(H3C )3^ 0 ^ S c H 3)3 --------— *■ B o c - Y  0 H
H
(Boc) (29)
Scheme 4.12 A. H2NCH2CH2OCH2CH2OH, (Et3)N, RT
Elongation of this ethoxy precursor (29) was achieved by cyanoethylation of the 
terminal hydroxy group with use of acrylonitrile under basic conditions. Reaction was 
a standard Michael addition and resulted in the formation of the cyano product (30) in 
60% yield following Scheme 4.13. Analysis of the reaction product by I.R. indicated 
the presence of the sharp nitrile peak at 2200cm-1 while analysis of the proton NMR 








The nitrile was initially synthesised for its versatility and anticipated ease of intergroup 
conversion in particular the reduction of the cyano group to an amino functionality 
through route (i) or its subsequent hydrolysis to a carboxylic acid through route (ii), 
Figure 4.5.
(  Linker ^  Polyether chain
Figure 4.5. Proposed utilisation of 2-aminoethoxy ethanol in linker studies
However attempts to reduce this cyano group (30) met with little success. Catalytic 
hydrogenation in the presence of palladium on carbon at ambient temperature resulted 
in the isolation of the starting nitrile. Subsequent hydrogenation under more vigorous 
conditions, under increasing pressure ( 1 0 0  psi), failed to the reduce this nitrile 
functionality; thus alternative reducing agents were sought.
One such reducing agent was borane-THF (BH3-THF complex) which due to its 
Lewis acidic characteristics cannot be used in the presence of the acid-labile Boc 
groups. Thus an alternative amino protecting group was sought and 
benzyloxycarbonyl (Cbz), was chosen not only for its superior acid stability but its 
resistance to cleavage by reducing agents such as the boron complex.
Q — (  linker )  1
^ P ^ — (  Linker ) — <
^  Linker ) — <
=  Protecting group for terminal amine 
(e.g. t-boc,Cbz or phthalimide)
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Thus under similar conditions to the formation of the Boc-protected amine, 2-(2- 
aminoethoxy)ethanol was protected through the nucleophilic substitution reaction of 
the amino group with the labile chloro via Scheme 4.14.
(31)
A. ItNCH2CH20CH2CH20H, (C2H5)3, c h 2ci2, r t  
Scheme 4.14.
The carbamate (31) was obtained in 60% yield after isolation of the reaction mixture 
by washing the organic solution several times with water ensuring removal of both 
excess starting amino-alcohol and resulting triethylamine hydrochloride from the 
reaction mixture.
Again, treating this protected carbamate (31) with acrylonitrile gave the Michael 
addition product (32) as a brown oil in 98% yield, Scheme 4.15. Analysis by I.R. 
indicated the presence of the sharp nitrile peak at 2250 cm-1 while the proton 













Reduction of this derivative with BH3-THF under anhydrous conditions again proved 
to be difficult with analysis of reaction solution by TLC (silica gel 20 CH2C12 : 1 
MeOH) indicating the presence of a number of products. This was further 
complicated by the proton NMR spectrum obtained, with assignment of protons 
proving to be troublesome. Subsequently the isolation of the amino product from this 
complicated mixture was not attempted as it was believed that partial reduction of the 
nitrile had occurred leading to difficulties in isolation of target amino compound.
An alternative approach to the reduction of this cyano group was its subsequent 
hydrolysis to a carboxylic acid which could be fimctionalised through further 
modification. Conditions generally favoured were hydrolysis under basic conditions or 
formation of the methyl ester using a mixture of HC1 in methanol with subsequent 
hydrolysis to the carboxylic acid.
Initial attempts to hydrolyse the cyano moiety (32) in the presence of the Cbz group 
was met with partial success. The first method adopted was the procedure of Hartley 
(1962), who oxidised dinitriles of dioxolan to their corresponding amides using 
hydrogen peroxide which following hydrolysis in base afforded the di-acid.
Subsequently, adaptation of this route involved the use of 30% aqueous potassium 
hydroxide in hydrogen peroxide under gentle reflux, Scheme 4.16.




Scheme 4.16 A. H20 2 in 30% KOH, N2, reflux, 7 h.
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Refluxing of the cyano compound (32) in this mixture was lengthy with reaction
hydrochloric acid, the resulting carboxamide was extracted portionwise with 
diethylether. However, evaporation of the organic portion led to the isolation of a 
brown gum (33) which could not be triturated even with the most polar of solvents 
including water and methanol. Subsequent analysis of this gum by proton NMR 
showed a mixture of products to be present within this reaction mixture. Thus, it was 
concluded that partial hydrolysis of the cyano moiety to the carboxamide may have 
occurred together with loss of the protecting Cbz moiety, see Figure 4.6 below. 
Although this is only a hypothesis the difficulty in re-isolation of the starting nitrile 
suggested hydrolysis to this carboxy moiety.
Further attempts to hydrolyse this nitrile moiety (32) in refluxing base were also met 
with disappointment with the nitrile moiety proving to be particularly stubborn to base 
hydrolysis. Refluxing in dry HCl/MeOH also proved to be disappointing as 
methylester production was not seen with recovery of starting nitrile (32). The lack of 
success in utilisation of the nitrile moiety proved frustrating with a mixture of 
products seen during reduction or recovery of starting material upon hydrolysis.
Thus it was concluded that the presence of the two ether functions may somehow be 
causing deactivation of the nitrile group leading to resistance to intergroup 
conversion. Although this may be somewhat surprising particularly in view of the 
work of Newkombe et al., (1991) who were able to hydrolyse alkyethoxy nitriles to 
their corresponding methylesters by refluxing in dry HCl/MeOH, in the Pinner 
reaction, with hydrolysis affording the carboxylic acid.
completion after 7 h. Following quenching of this hot solution with concentrated
Figure 4.6
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However, in their approach the starting cyano precursors possessed only one ethoxy 
moiety which may have less of a deactivating effect than in the case of cyano 
compound (32) where two are present. Thus further work on the utilisation of ethoxy 
nitriles needs to be pursued.
4.4.1.2 The use of 3.6 -dioxaoctane-1.8-diamine as starting precursor
As outlined in the previous section (4.4.1.1) attempts to functionalise amino protected 
diethoxy derivatives of nitriles (30) and (32) proved to be difficult and met with little 
success. Therefore, attempts were made to selectively mono-protect the commercially 
available 3,6 -dioxaoctane-1,8 -diamine (Figure 4.7) starting precursor in the presence 
of phenylmethyl chloroformate (Cbz).
The selective protection of a,co-alkanediamines has been associated with Atwell and 
Denny (1984) who synthesised mono-protected intermediates of poly diamines in the 
presence of the Cbz group. □ Attempts to locate procedures to selectively protect 
diamino polyethers proved to be difficult, therefore the use of Cbz was an attractive 
option in this synthetic approach.
In the initial reaction, it was critical that an excess of the starting 3,6-dioxaoctane-l,8- 
diamine (34) was in solution prior to addition of the amino protecting group. The 
rationale was that the large excess of the starting precursor would discourage the 




Thus a two molar excess of the precursor (34) was allowed to react by dropwise 











Cbz ^  O Cbz
(36)
Scheme 4.17.
To achieve complete reaction between the diamine and the Cbz protecting group, the 
reaction mixture was stirred overnight at room temperature. After completion, the 
solution was washed with a small quantity of water ensuring removal of excess 
starting diamine without loss of the highly soluble mono-Cbz protected product (35).
Analysis of the reaction mixture by TLC proved to be disappointing as two spots 
were located, of which the lower Rf was attributed to the mono-Cbz derivative (35), 
which was also ninhydrin active, while the one with higher Rf was assigned to the bis- 
Cbz protected compound (35). Further analysis by proton NMR indicated that the 
major product of the synthesis was the bis protected derivative, therefore, attempts 
were made to isolate these products by extraction of the final reaction mixture.
Isolation of the mono-Cbz protected compound (35) was achieved by washing the 
organic layer with 2M HC1, extracting the aqueous portion then washing with 2M 
NaOH with subsequent extraction of this basic layer with ethyl acetate. Evaporation 
of solvent afforded the mono-protected amine (35) in 20% yield as an oil.
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While the bis-protected by-product (36) was isolated by evaporation of the organic 
portion to afford an oil which crystallised on standing in 40% yield.
Repeating this procedure with larger molar excesses of the polyether diamine in the 
reaction mixture had little or no improvement in the yields obtained for the mono 
protected product. This approach was thus abandoned due to the difficulty in 
obtaining high yields of the mono-protected derivative.
4.4.1.3 The use of 2-r2-(2-chloroethoxv)ethoxv]ethanol
The final approach in the use of ethoxy moieties led to use of 2-(2-(2- 
chloroethoxy)ethoxy)ethanol by reaction with potassium phthalimide, Scheme 4.18. 
The reaction is based on the Gabriel procedure which has been modified by Maeda et 
al, (1982) and Botros and co-workers (1986) in the preparation of amino-protected 
diether derivatives.
The procedure followed reaction of 2-(2-(2-chloroethoxy)ethoxy)ethanol starting 
precursor with potassium phthalimide (37) in DMF (Scheme 4.18). Isolation of the 
phthalimido product (38) was by flash column chromatography in 20-35% yield 
maximum. Increasing reaction temperatures had little or no effect on the yield of the 
final product and subsequently, this derivative was used without further purification in 
the proceeding step.
Thus before removal of the phthalimide group to afford the amino compound, the 
hydroxy terminus was oxidised to the carboxy derivative in the presence of potassium 









. 0 c o 2h
o (39)
(i).Cl(CH2)20 (C H 2)20 (C H 2)2OH, DMF,1 IOC;
(ii) K2C1O3/H2SO4, acetone, RT, 4 h.
Scheme 4.18.
The carboxy derivative (39) was obtained in 60% yield with no isolation of the 
aldehyde intermediate, as confirmed by the mass spectrum of the carboxy moiety with 
a molecular ion of 294. Subsequently an attempt was made to utilise this carboxy 
derivative, prior to removal of the phthalimide group, through reaction with 5,6- 
diamino-l,3-dimethylpyrimidine (14) in the presence of dicyclocarbodiimide in 
(Shimada e ta l, 1991), Scheme 4.19.
This route was primarily adopted as a means of obtaining the 5-amido intermediate
(40) through condensation of the acid (39) with 5,6-diaminopyrimidine (14).
(39)
Scheme 4.19 A. (1), DCC, DMF
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In section 4.3 attempts were made to obtain 8 -hydroxymethyltheophylline (15) via the 
use of the diaminopyrimidine precursor (14). Yields were low with isolation of the 
final cyclised product (15) proving to be difficult. Thus, since polyether chains were 
required as hydrophilic linkers and with attempts at obtaining mono-protected 
aminoethoxycarboxy derivatives (see section 4.4.1) proving to be difficult, it was 
decided that the phthalimido derivative (39) was a useful starting precursor.
Through Scheme 4.20 the formamido product (40) was obtained as a crude solid. 
Analysis by TLC indicated the presence of a number side products present within the 
reaction mixture. Of these the phthalimido product (40), possibly the cyclised product 
and theophylline were assigned. Subsequent purification of the reaction mixture by 
column chromatography led to the isolation of the phthalimido product as a yellow 
solid in 1 2 % yield.
Through analysis of the !H proton spectrum the phthalimide ring system was found to 
resonate at 8  7.86 while mass spectrum confirmed the isolation of the amido 
intermediate (40) with (M+) 445. Attempts to cyclise this amido intermediate (40) in 
aqueous base were not pursued due in effect to the low yield of this procedure and the 
formation of undesirable side products.
However, utilisation of this method requires a change in reaction solvent since 
dimethylformamide has been reported as a cyclisation agent for 5,6-diaminoprecursors 
in the Traube route (Speer and Raymond, 1953). Also, the starting diaminopyrimidine 
is highly unstable and requires purification prior to use. Thus in view of these 
problems, an improvement in the yield of the final product could be achieved by prior 
purification of the diamino compound.
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4.5. Utilisation of a.q)-alkanediamines
4.5.1 The use of N'-Bochexane- 1.6-diamine as starting precursor
Commercially available N’-bochexane-1,6-diamine (41) was protected with 
phenylmethyl chloroformate (Cbz) under basic conditions using standard procedures. 
The reaction proceeded over a 24 h period and resulted in a product protected at both 
terminal amino ends, with a Boc group at one end and Cbz at the other, scheme 4.20.
H
I
Boc n h 3 cr
(41)
O (C2H5)3N
x  ------------- "
O Cl
Scheme 4.20
The bis-protected compound (42) was isolated in 8 6 % yield following successive 
washing of the product in water and then acid.
Removal of the Boc amino protecting group from the bis-protected product (42) was 
achieved using HC1 gas in dichloromethane. Deprotection was achieved without loss 
of the Cbz moiety in yields of 95% and above to afford the mono-Cbz protected 
hydrochloride (43) as a solid, Scheme 4.21.














This method is a standard procedure for the removal Boc groups from amino
protecting group in the presence of another. Since the Cbz moiety is acid stable, Boc 
groups can be selectively removed from the terminal amino group of the 
hexanediamine while still protected at the other. The resulting hydrochloride salt (43) 
is thus used without further purification in the reaction with 6 -chloropyrimidine (17).
Subsequent reaction of the mono-Cbz hydrochloride (43) with 6 -chloropyrimidine 
derivative (17), in refluxing 1,4-dioxan (Scheme 4.22) afforded the 6 -substituted-Cbz 
protected amino compound (44) in 60% yield following recrystallisation in ethanol.
Nitrosation of the 6 -substituted Cbz-protected product (44) was achieved in the 
presence of isoamyl nitrite in aqueous HC1 via the reaction outlined in Scheme 4.23. 
Isolation of this nitroso derivative (45) was in 73% yield with subsequent cyclisation 
in butanol affording the cyclised derivative (46) in 97% yield. Scheme 4.25. 
Purification by recrystallisation in butanol afforded (46) in analytically pure form for 
use in the deprotection step.
functionality and is particularly useful method for the selective removal of one amino
O
c r  N NH(CH2)6NHCBz 
Me
(44)
Scheme 4.22 A. (42), NajCC^, 1,4-dioxan, reflux
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Scheme 4.23 B. isoamyl nitrite, HC1, R.T., C. butanol, reflux
Deprotection of the amino protecting group was achieved using hydrogen bromide in 
acetic acid (Ben-Ishai, 1953). Isolation of the hydrobromide salt (46) was attained in 
99% yield after trituration with diethyl ether. Analysis of the proton NMR spectrum 
confirming the presence of the broad singlet NH+3Br peak at 6  9.00 with the 
disappearance of the Cbz phenyl peak at 5 7.01.
Thus the successful synthesis of 8-(5-Aminopropyl)-2,4-dimethylpurine-l,3-dione 
(46) as the hydrobromide salt, through this multi-step procedure has led to the 
utilisation of alkanediamines as linkers in the final fluorescent theophylline moiety.
4.5.2 The synthesis of 8 -fco-aminoalkvDtheophvllines
The initial attempts to synthesise appropriate theophylline derivatives for attachment 
of a fluorescent electrophiles were met with partial success. The synthesis of 8 - 
hydroxymethyl and 8 -hydroxyethyltheophylline were attained in high yields, 54% and 
82% respectively, from the starting 6 -chloropyrimidine (17). However, subsequent 
oxidation of 8 -hydroxymethyltheophylline to the 8 -carboxy derivative resulted in a 
product which was insoluble in most polar solvents (e.g. methanol, DMF) apart from 
trifluoroacetic acid.
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Therefore, due to the insolubility of such carboxy derivatives other synthetic targets 
were sought containing appropriate linkers and a terminal fuctionality for the 
attachment of the fluorescent probe.
Subsequent investigation has therefore led to the development of a series of 8 -(co- 
aminoalkyl)theophyllines as possible targets for the attachment of fluorescent 
electrophiles. Optimisation of chain length was achieved by use of appropriate starting 
a,co-alkyldiamines through the procedure of Fuschs et al., (1978) utilising the 6 - 
chloropyrimidine derivative (4) as a starting precursor, Scheme 4.24.
Me.
'N ( C H 2)nNH2 
Me HMe
O 7) (47) n = 6
(48) n = 9
(49) n =10
(50) n = ethoxy
A. alkane-a,co-diamine, dioxane, Na2C0 3, reflux, 4 h.
Scheme 4.24
The initial conditions of the substitution reaction involved refluxing starting a,co- 
alkyldiamines (n = 6 , 9, 10, alkylethoxy) in ethanol in the presence of sodium 
carbonate.
However analysis of the reaction mixture by TLC was indicative of the formation of 
three products with the formation of an ethoxy derivative as a side product at Rf 056 
compared with required mono product at Rf 0.45. Therefore, in order to eliminate the 
possibility of such side reactions with ethanol, an inert solvent was desired and thus 
our solvent of choice was 1,4-dioxan.
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The substitution reaction for all spacers was subsequently carried out in boiling 1,4-
were carefully controlled and an a 2.5 molar excess of the diamine was used as an 
optimal quantity to achieve the maximum possible yield of the mono-product.
Isolation of the substituted 6 -aminoalkylaminopyrimidine derivatives was through 
removal of excess starting diamine via an aqueous wash and removal of solvent, thus 
ensuring ensured possible interferences in the proceeding benzylation step. Thus 
analysis of crude amine products by TLC confirmed the presence of two components, 
the major 6 -amino product being ninhydrin active and located at an of Rf 0.15 while 
the bis product is seen at Rf 0.63., Figure 4.8.
dioxan containing an excess of the starting diamine and base. The reaction conditions
O
O N  'N ( C H 2)nNH2 
Me H
n = 6 , 9, 10, ethoxy
O O
(CH2) n \
Me H H  Me
bis-pyrimidine 
Figure 4.8.
Attempts to isolate this major product, the 6 -aminoalkylamino derivative, through 
recrystallisation and column chromatography proved troublesome. Subsequently, the 
product was used in the next step without further purification.
However, through our earlier work, isolation of the 6 -aminononyl (51) and 6 - 
aminodecyl (52) derivatives was possible through recystallisation in aqueous ethanol 
in yields of 65% and 64% respectively. However for ease of synthesis and isolation of 
the Cbz protected product, the 6 -amino derivatives were not purified and 
subsequently were used in the benzylation step fairly swiftly.
Nitrosation as previously recorded for the 6 -hydroxyalkylpyrimidines (section 4.2) 
was achieved directly by use of isoamyl nitrite under mild acid conditions. However, 
the presence of free amino groups presented possible side reactions occurring, in 
particular the formation of unwanted nitrosoamines. Subsequently, prior to nitrosation 
these 6 -minoakylamino derivatives were protected as their Cbz counterparts.
A number of amino protection groups were considered, however only phenylmethyl 
chloroformate (Cbz) matched the criteria required including being stable in acid 
environments as well as ease of removal without disruption of the theophylline 
moiety. Thus, the 6 -substituted derivatives of the alkylamines (n=6 , 8 , 9) and 
alkylethoxyamine (CHjCHjOCHjCK^OCI^CHj) were protected through reaction of 
phenylmethyl chloroformate (Cbz) in the presence of triethylamine, Scheme 4.25.
Reaction times were 24 h stirring at room temperature with isolation of crude Cbz 
product via concentration of solvent in vacuo. Purification of these protected amino 
6 -alkylamino derivatives was through column chromatograpy with isolation of these 
alkyl linkers (n = 6 , 9, 10) using the system 4 chloroform : 1 EtOAc. While isolation 
of the alkylethoxy linker required a more polar system and was achieved in 5 EtOAc : 
1 MeOH in 44 % yield. Table 4 represents the yields obtained
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O ^ N '  'N H (C H 2)nNHCbz
Me
n compound number % Yield
6 53 54
9 54 43
1 0 55 54
ethoxy 56 44
Table 4.
Nitrosation of these Cbz-protected amines followed with ease via reaction with 
isoamyl nitrite and resulted in a number nitroso derivatives which were all isolated as 





O ^ N  N H (C H 2)nNHCbz 
Me
[n = 6 , 9, 10, ethoxy]
(53), (54), (55), (56)
O
O ^ N  N H (C H 2)nN H C bz 
Me
(57), (58). (59), (60)
Scheme 4.25
The instability of these nitroso derivatives enabled the cyclisation step to proceed 
swiftly with the cyclised products attained in good yields, Table 4.1 .
o
Me- NX ^ N
I f  y — (CH2)riNHCbz
o '  n '  ^
Me H




ethoxy 64 6 8
Table 4.1
Deprotection of the terminal amino group was achieved through reaction with
hydrogen bromide in acetic acid, with trituration in diethyl ether affording the penta
(65), octa (6 6 ) and nonamethylene (67) derivatives as the hydrobromide salts in high
yields. However, isolation of the ethoxy derivative (6 8 ) required trituration with ethyl
acetate to afford the hydrobromide as a crystalline solid. Yields obtained for the







n compound number %Yield
5 65 1 0 0
8 6 6 1 0 0
9 67 87
ethoxy 6 8 1 0 0
Table 4.2
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Analysis of the proton NMR spectrum reveals the presence of the broad 3-H proton 
peak at 8  7.71 (as indicated for the nonamethylene derivative, see experimental) 
indicative of the NH3+ group of the hydrobromide salt with no protons at the aryl 
region indicating the loss of the Cbz protecting group. Subsequent conjugation to the 
FITC congener is outlined in the next section (4.6) via reaction with the 
hydrobromide salts synthesised.
4.6 Synthesis of fluorescent congeners
Fluorescent probes have been utilised in biochemistry either for analysing 
quantitatively functional groups in proteins or probing the environment around 
functional groups (Okamato et al, 1982). The most common probes are based on 
fluorescein {e.g. FITC, DTAF, rhodamine) and sulphonyl chlorides, in particular 
dansyl chloride (5-dimethylamino-l-naphthalenesulphonyl chloride). Utilisation of 
these probes as fluorescent labels is through reaction with free amino groups in 
aqueous solutions under alkaline conditions. Yields for coupling are almost 
quantitative with isolation of products as highly fluorescent derivatives.
To advance the utilisation of these fluorescent probes more widely, theophylline 
derivatives were coupled to FITC, dansyl chloride and DTAF under controlled basic 
conditions, Figure 4.9.
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Theophylline — Y— NH2.HBr
alkaline pH
®
Theophylline - y - Q
Fluorescent electrophile Y -  (CH2)5, (CH2 )8 > (CH2)9, 
j nTC CH2 OCH2 CH2 OCH2 CH2
2. Dansyl chloride
3. DTAF
Figure 4.9 A diagram depicting the general synthetic strategy in the development 
of fluorescent congeners for theophylline
Investigations led to the synthesis of a series of highly fluorescent theophylline 
congeners, possessing both an alkyl and alkylethoxy linker, which were subsequently 
used to assess the FCFD assay for theophylline.
Therefore, functionalisation of the fluorescent chromophore onto the theophylline 
moiety involved reacting the hydrobromide salts of the 8 -alkylamino and 8 - 
alkylethoxy derivatives of theophylline with fluorescein isothiocyanate (FITC), 
dichlotiazinylaminofluorescein (DTAF) and dansyl chloride under controlled basic 
conditions.
4.6.1 FITC conjugation to primary amines
Fluorescein isothiocyanate (FITC) is an electrophile used primarily in the labelling of 
proteins and peptides through reaction with free amino groups. Final products are 
highly fluorescent derivatives which are coupled to the FITC moiety through a 




e.g. RN=C=S + R'NH2
S
Scheme 4.26
The aim of the synthetic procedure, as discussed in Section 4.2, was to synthesise 8 - 
substituted fluorescent derivatives of theophylline possessing an alkylamino or 
alkylethoxy linker between theophylline and the fluorophore.
The hydrobromide salts of the 8 -alkylaminotheophyllines containing a penta, octa, 
nona methylene and an ethoxy linker were functionalised onto the fluorescein moiety 
by careful choice of reaction conditions.
Reactions were performed under controlled basic conditions by reacting the salts of 
these derivatives with fluoresceinisothiocyanate (isomer I) in a mixture of 1:1 
dioxan/lM KjCC^ and stabilising the pH at 9.0 ±0.1 by further addition of base. The 






(65) A. I F  ) — (CH2)n 
r " N  y
HO O OH
(69)-(72)
A. n=5, 8 , 9, pH 9.0± 0.1, 1M K2C03, dioxan, RT.
Scheme 4.27
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After 3 h stirring at room temperature, the reaction mixture was acidified to pH 6.0. 
This mixture was then taken up in water, and subsequently freeze-dried for 24 h to 
afford the crude product as an orange yellow solid.
Analysis of the crude thiourea products by TLC inferred the presence of a number of 
impurities. Purification through flash column chromatography on silica led to isolation 
of the desired 8 -conjugated products as orange solids in high yields, Table 4.3.
o
y - (ch2)„—n  f
n compound number % Yield
5 69 50
8 70 72
9 71 6 8
ethoxy 72 77
Table 4.3
Analysis of these products were through proton NMR and COSY.
Figures 4.10 and 4.11 show the NMR and COSY spectra respectively, of the 
(CH^NHCSNH-linked fluorescein-theophylline in (CD3)2SO. The spectra clearly 







 jL _________ __/V ■ '  . L   A .
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The two N-CH3 groups of the theophylline moiety resonate as singlets at 8  3.22 and 5 
3.41, identical to the chemical shifts for the precursor 8-(9-aminononyl)theophylline 
hydrobromide. The purine 9-NH also resonates at similar chemical shifts in the 
conjugate and the precursor ( 8  13.1 and 5 13.18, respectively).
The COSY spectrum allows assignment of the resonance of the nonamethylene unit of 
the linker. The central (C H ^ unit appears as a broad peak centred around 5 1.29 
whereas the other four methylenes appear as discrete signals. Interestingly, the broad 
quintet at 5 1.56 couples with the broad peak at 5 3.48 and the broad quintet at 5 1.68 
couples with the triplet at 5 2.67.
Since the signal at 8  2.67 can be assigned to the purine-CH2 on the basis of chemical 
shift (cf. 8  2 .6 8  in the precursor) and mutilpicity, then the signal at 8  1 .6 8  can be 
assigned to the purine-CH2CH2. Similarly, the signal at 8  3.48 corresponds to CH2N, 
on the basis of chemical shift. Thus the signal at 8  1.56 must arise from CHjCHjN. 
The order of the chemical shifts of purine-CH2CH2 and CH2CH2N is unexpected, 
considering simple inductive effects. The thiourea NH signals appear at 8  8.06 
(CH^NH) and 8  9.86 (Ar-NH).
In the fluorescein moiety, the signals from the benzene ring and from the xanthene 
appear in separate clusters. The protons of the fewer form a typical trisubstituted 
benzene spin system. H-3 resonates as a doublet at 8  7.17 ortho-coupled to H-4 ( 8  






The signals for the xanthene show the symmetry of this group. Again, the C-H signals 
indicate a trisubstituted benzene. H-l' and H-8 ' form a doublet at 8  6.58 which is 
ortho coupled to H-2' and H-7' at 8  6.56. H-4' and H-5' appear as a narrow doublet at 
8  6.67, which is meta coupled to H-2* and H-7'. The phenolic OH resonate together as 
a singlet at 8  10.13.
4.6.2 The use of dansvl chloride
Through the successful coupling of the hydrobromide salts to the FITC congener, the 
pentamethylene analogue was used as a model compound in the reaction with other 
fluorescent electrophiles.
The conjugation of 8 -aminoalkyl and 8 -aminoethoxyalkyl derivatives of theophylline 
to FITC (section 4.6.1) was an important goal in the preparation of fluorescent labels 
of theophylline. The ease of synthesis as well as isolation of the required congeners in 
high yields provided a route to the synthesis of other fluorescent derivatives. Thus, 
subsequent utilisation of the synthetic procedure enabled conjugation of the 
pentamethylene derivative to dansyl chloride (5-dimethylamino-l-napthalenesulphonyl 
chloride).
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Dansyl chloride was chosen as alternative label due to its successful use as a 
fluorescent handle for the study of proteins (Gray, 1967). Reactions with primary and 
secondary amino groups as well as phenolic hydroxyl and imidazole groups of amino 
acids occur under mildly alkaline solutions to yield sulphonyl derivatives which 
fluorescence strongly in organic solvents (Airhart et al., 1973).
Conjugation of dansyl chloride to the pentamethylene derivative (65) was achieved 
through Scheme 4.29. The pH of the reaction was carefully maintained at 9.5, with 
isolation of the dansyl product (73) in 54% yield as a green solid. A pH of 9.5 was 
chosen as the optimal pH of coupling as outlined by the work of Gray (1967) who 
optimised the coupling of amino acids to dansyl chloride between pH 9.5-10.5.
Me.





Subsequent analysis of the proton NMR spectrum (Figure 4.13) inferred successful 
conjugation of dansyl chloride to the theophylline moiety.
Figure 4.13 clearly shows the protons attached to the purine moiety, linker and the 
dansyl portion. The methylene protons within the linker moiety appear as multiplet 
signals resonating at 6  1.14, 1.29 and 1.49.
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The NHCH2 group appears to be downfield at 8  2.76 while the purine N-CH3 groups 
attached to the theophylline moiety appear as singlets at 6  3.22 and 8  3.39 together 
with the purine-CHj protons.
iO
T rT TliC 0
Figure 4.13.
The naphthalene portion is identified by the singlet N(CH3) 2 peak at 8  2.81 while the 
aromatic signals clustered in the region 8  7.2-8.4 are allocated to the naphthalene ring 
system of the fluorescent portion, Figure 4.14.
R = pentamethylene derivative of theophylline
Figure 4.14
The protons were assigned without the aid of a COSY spectrum therefore all protons 
available in the naphthalene aromatic region were allocated as Aryl-H and appeared as 
doublets.
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4.6.3 The use of DTAF (Dichlorotriazinylaminofluorescein)
The successful conjugation of both FITC and dansyl chloride to the hydrobromide 
salts of theophylline precursors led to the extension of this procedure towards 
coupling with other fluorescent congeners. Thus DTAF, an important derivative of 
fluorescein, was chosen as a suitable probe for the labelling of theophylline.
DTAF has found extensive use in the labelling of proteins reacting with free amino 
groups through substitution at the triazine ring resulting in the formation of highly 
fluorescent cholrotriazinylaminoflurescein (CTAF) derivatives. Thus through the 
method of Mahoney and Azzi (1987), DTAF was successfully conjugated to the 
pentamethylene derivative (63) via Scheme 4.30 under controlled basic conditions, pH
8 .0 .
Isolation of the fluorescent CTAF derivative (74) was through column 
chromatography in 6 8 % yield as an orange solid. In comparison to the conjugation of 
both FITC and dansyl chloride to the theophylline derivative possessing a 
pentamethylene linker, DTAF required less alkaline conditions, pH 8.0 c f  pH 9.0 for 
FITC and pH 9.5 for dansyl chloride. Also pH control was not as stringent as for 











Subsequent analysis of the proton NMR spectrum implied successful coupling of 
DTAF to the theophylline moiety (Figure 4.15). The spectra clearly shows the three 
parts of the structure-theophylline, linker and the fluorescein moiety
JUUyv
i 4 12 10 0
Figure 4.15.
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As can be seen from Figure 4.15, the two N-CH3 are found to resonate as singlets at 8  
3.25 and 3.29 and appear slightly upheld cf. the N-CH3 of the (CH2)5NHCSNH- 
linked fluorescein theophylline which appear at 8  3.24 and 3.4 respectively. The 
central (CH2) 5 unit of the linker, again, appears as a broad peak centred at 8  1.29 
while the other methylenes appear as discrete signals centred between the region 8  
1.40-3.10.
In the fluorescein moiety the signal from the benzene ring and from the xanthene 
appear in separate clusters although only the Ar-3H of the benzene ring could be 
allocated with ease resonating as a doublet at 8  7.14. Further, the signals of the 
xanthene show symmetry of this group with the C-H signals indicative of a 
trisubstituted benzene. Thus, H-l' and H-8 ' appear as a doublet at 8  6.48 while the 
ortho coupled H-2' and H-7' appear as a dd at 8  6.41 with the C-H signal for H-4' and 
H-5' appear as a doublet at 8  6.56. The final assignment of the xanthene portion was 
attributed to resonance of two phenolic OH which appear as a singlet at 10.02.
It must be stated that the protons allocated for the xanthene portion are through 
comparison of both the fluoresceinthiourea derivatives synthesised (as for FITC 
derivative) and analysis of uncoupled DTAF in (CD3)2SO.
For further analysis a COSY spectrum is required although as is apparent in Figure 
4.15, coupling of DTAF to the pentamethylene derivative has been both successful 
with isolation of final product (77) in good yield.
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4.7 Conclusions
Initial approaches towards the synthesis of theophylline derivatives possessing a 
hydrophilic linker which could be coupled to a fluorescent congener were outlined in 
section 4.2. The first approach afforded 8 -hydromethyltheophylline via two routes 
with the initial one-step procedure using the starting 5,6-diamino-l,3- 
dimethylpyrimidine precursor (14) proving to be of little use. The lack of success was 
attributed to a number of factors including the stability of the starting diamine and its 
lack of solubility in organic solutions.
Although successful utilisation of 5,6-diamino-l,3-dipropyl derivatives have been 
reported in the literature via use of the Traube route, their success has been attributed 
to their enhanced solubility due to the presence of the propyl group within the 
pyrimidine moiety.
Successful synthesis via use of the starting 6-chloro-l,3-dimethylpyrimidine was 
subsequently utilised in the final synthesis of the 8 -alkylaminotheophyllines by reaction 
with a,o-alkanediamines and, 8 -alkylethoxyamine using 3,6 -dioxaoctane-l,8 -diamine 
(section 4.4.3).
Approaches to the synthesis of mono-protected polyether diamines proved to be 
disappointing although isolation of mono-protected Cbz-amino derivative of 3,6- 
dioxaoctane-1,8-diamine (35) was achieved in low yield. The lack of utilisation of 
polyether chains as hydrophilic linkers were attributed to the presence of the two 
ethoxy groups with possible deactivation effects causing lack of reaction.
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Thus, from the initial synthetic strategies adopted a series of 8 - 
alkylaminotheophyllines possessing an alkyl and an alkylethoxy linker, conjugated to 
FITC have been synthesised. Isolation of final target compounds (Figure 4.16) was 
achieved in good yields with coupling conditions stringently controlled at pH 9.0.
Through the successful coupling of FITC congener to the 8 -alkylaminotheophylline 
precursor alternative fluorescent electrophiles were considered for conjugation. 
DTAF was a useful option in the respect that its quantum yield is comparable to 
fluorescein (approaching unity) with a larger Stokes shift as well as superior stability.
Coupling again was achieved under controlled basic conditions (pH 8.0) using the 
pentamethylene derivative as a model derivative, with isolation of target derivative 
(74) as an orange solid which was highly fluorescent in both organic and aqueous 
solutions.
Dansyl chloride was also coupled to the model pentamethylene derivative under basic 
controlled conditions (pH 9.5). The final product was isolated as a green solid which 
gave a green-blue fluorescence in both aqueous and organic solutions.
In summary the synthesis of 8 -alkylamino derivatives of theophylline have been 
synthesised by careful choice of reaction conditions through adoption of the method 
of Fuschs et al., 1977. The method can be applied to most a,co-alkanediamines with 
isolation of final products in reasonable yields.
In utilising these 8 -alkylaminotheophyllines, possessing an increasing methylene chain, 
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The accurate and regular monitoring of serum theophylline levels is an important goal 
in clinical chemistry. The effective use of the drug is limited by its narrow therapeutic 
range and broad inter-patient variability attributed to its elimination kinetics which is 
influenced by such factors as age, smoking and liver function (see section 1.4.1).
Methods available for the quantitative measurement of serum theophylline levels 
include chromatographic techniques such as gas chromatography and HPLC and a 
variety of non-isotopic immunoassay techniques including EIA and FIA, these are 
detailed in section 1.5. Subsequently, the need for a rapid easy to use homogeneous 
immunoassay for theophylline has led to focus in the area of immunosensors.
Interest in immunosensors has increased rapidly in the past few years due to their 
many potential advantages including small size, speed of response and specificity 
(Christesen e ta l,  1994). In particular immunosensors incorporating optical detection 
systems have been effectively utilised for monitoring a wide range of analytes 
including enzymes, hormones, viruses and blood components.
One such optical detection system which has shown great promise is the fluorescence 
capillary fill device (FCFD) an immunoassay system utilising a planar optical 
waveguide (Badley et al, 1987) for the fluorescent measurement of Rubella antibody 
(Parry et al., 1990) and PSA (Fletcher et al., 1993).
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Sensitivities within the picomolar range have been recorded incorporating a variety of 
fluorophores (FITC, Rhodamine and Allophyocyanin).
The utilisation of a planar optical waveguide negates the need for a separation step 
via the use of an evanescent wave and is effective in the quantitative determination of 
antibody-antigen reactions (Badley et a l, 1987). The FCFD, thus offers the user high 
specificity and sensitivity with a rapid result time which ultimately can be used at the 
site of patient care.
In summarising the importance of monitoring serum theophylline levels and the need 
for a rapid easy-to-use homogeneous immunoassay, the FCFD was subsequently 
utilised for the development of an immunoassay for theophylline. In the previous 
section the assessment of the FCFD was discussed by synthesising fluorescent 
analogues of theophylline for use in a competitive immunoassay. These analogues 
were assessed for immunoreactivity by devising binding experiments using FCFD 
devices covalently immobilised with the anti-theophylline antibody. Subsequent 
reaction kinetics as well as a standard curve for theophylline were assessed with 
methodology and results outlined in the next two sections.
5.2. Materials and Methods
5.2.1 Reagents
All reagents were purchased from Aldrich-Sigma Chemicals (Poole, Dorset) unless 
otherwise stated.
Theophylline monoclonal antibody (rat anti-mouse IgA) was kindly donated by 
Serono Diagnostics, USA division.
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All FCFD plates were manufactured at Serono Diagnostics, Woking.
5.2.2 Buffer solutions
Buffer solutions were as follows:
(i) Antibody buffer 0.1 M HEPES / 0.2 M NaCI;
(ii) wash buffer PBSTA pH 7.31;
(iii) Assay buffer Tris HC1 pH 8.8 and BSA (1 mg ml-1) in Tris buffer pH 8.8.
5.3 The Fluorescence Capillary Fill Device (FCFD)
The FCFD consists of two sheets of glass separated by a 100 pm gap with the lower 
surface containing the covalently immobilised antibody The FCFD uses small sample 
volumes (25 pi) which as the device fills by capillary action negates the need for 
sample metering.
On completion of the immune reaction, a complex of the antibody and the 
fluorescently labelled analyte is formed on the lower surface of the device. Bound and 
free fluorescence are then discriminated by use of the evanescent properties of the 
device, thus eliminating the need for a wash or separation step. The basic structure of 
the FCFD is shown in Figure 5.
Immobilised 
capture antibody opaque coating
^  0.1mm
Y Y Y Y Y Y Y Y emitted light
excitation light
Figure 5. The FCFD (fluorescence capillary fill device)
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5.3 .1 Fabrication o f FCFD devices
The FCFD devices were fabricated according to the method of Badley et a l , 1987 
(Figure 5.1).
Pre-fabrication of devices involved prior washing of glass plates with water then 
acetone, followed by activation of lower base plate with y-
aminopropyltrimethoxysilane. Activation allowed covalent immobilisation of the anti­
theophylline antibody to the lower plate with subsequent assembly of the device 
involving annealing of the top and lower plate under pressure.
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pi a i r  c oac i ngv
lop plate
(i) d e a n  (ii) c o n ju g a te  (m ) drying
'~ ly
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’ drying
>m I
(iii) surface p rep a ra tio n  





(vi) screen p rin ted  
g lue lines and 
spacers
ell assem bly  
(i) sandw ich  assem bly (ii) scrib ing  an d  breaking
final cell to  be 
packaged for s to rag e
Figure 5.1. Schematic diagram of the FCFD fabrication process
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5.3.2 Immobilisation of Antibody
Anti-theophylline IgA mouse monoclonal antibody (4.41 mg ml-1) was serially diluted 
to concentrations of 200 pg ml*1, 100 pg ml*1, 50 pg ml*1 and 25 pg ml*1 in 0.1 M 
HEPES / 0.2 M NaCl buffer. Coupling of the anti-theophylline antibody (15 pi) to the 
lower plate surface (activated) was through use carbonyldimidazole coupling 
chemistry.
Subsequent fabrication of the plates is outlined in section 5.3.1.
5.4 Conjugation of FITC to 8 -alkvlaminotheophvllines
8 -alkylaminotheophyllines were synthesised in an analytically pure form as their 
hydrobromide salts as outlined in section 4.6.
Conjugation to FITC was performed under basic controlled conditions at pH 9.0 +
0.1 using FITC isomer I. Isolation of the fluoresceinthiourea analogues involved 
purification through column chromatography to afford the desired derivatives (n=5, 8 , 




n = 5, 8 , 9, CH2OCH2CH2OCH2CH2 
Figure 5.2. General structure of the fluoresceinthiourea derivatives synthesised
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All fluoresceinthiourea derivatives were subsequently dissolved as stock solutions 
either in Tris HC1 buffer pH 8 .8  or Tris buffer containing BSA (1 mg ml-1). Sequential 
dilutions were performed by addition of either Tris buffer or BSA solution.
5.5 Assessment of assay performance
All assays using the FCFD were performed in duplicate following incubation at room 
temperature for 2 0  min.
Measurement of signal within the FCFD was through use of a fluorimeter equipped 
with appropriate filters for the FITC chromophore, with subsequent signal being 
inversely proportional to analyte concentration.
5.5.1 Evaluation ofimmunoreactivitv
The immunoreactivity was assessed through construction of a dose-response curve 
using the nonamethylene fluoresceinthiourea derivative which was serially diluted at 
appropriate concentrations in the assay buffer.
Following incubation, a plot of signal against analogue concentration (Figure 5.3) was 
constructed by measuring the signal from devices containing an increasing 
concentration (1 x 10'12-0.5 x 10-6 M)of the labelled analogue.
5.5.2 Assessment of antibody loading
Devices were fabricated using four antibody loading concentrations between 200 pg 
ml-1 and 25 pg ml-1.
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The effect of antibody loading in relation to the total binding of the fluorescently 
labelled analogue was investigated by incubating devices, at appropriate dilutions of 
analogue with increasing concentration of antibody immobilised on surface. Following 
incubation, devices were measured and the signal recorded.
The influence of antibody concentration on the signal observed as a measure of total 
binding to solid phase is depicted in Figure 5.4 as a plot of signal against analogue 
concentration.
5.5.3 Reaction kinetics
Incubation time was determined by studying the kinetics of theophylline-FITC binding 
to anti-theophylline solid phase. Three concentration pools of unlabelled theophylline 
(50 pg ml'1, 25 pg ml*1 and 7.5 pg ml'1) were used to assess the competitive binding 
reaction occurring within the devices. An appropriate concentration of the 
pentamethylene theophylline analogue (1 pM) was chosen, from the specific binding 
isotherm which was due solely to specific signal, for assessment of binding kinetics. 
Incubation times of 5, 10, 15, 20, 25 and 30 min were evaluated at 30 sec intervals. 
From the graph of signal against time (Figure 5.5), the optimal incubation time was 
chosen (e.g. time to reach equilibrium). Incubation times were thus set at 20 min.
To assess the kinetics of binding due solely to the FITC analogue, devices were 
incubated with a known concentration of the analogue and signal measured at 30 sec 
intervals for a time of 30 min. Figure 5.6 depicts the kinetics of binding of the FITC 
analogue without interference from theophylline.
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5.5.4 Measurement of total binding
FCFD devices coated with 200 pg ml*1 of antibody were used in the construction of 
binding isotherms for each of the fluoresceinthiourea analogues synthesised. In 
assessing total binding increasing concentration of analogue (0-5 pM) was introduced 
into devices. After incubation, total binding isotherms for each analogue was 
constructed by plotting signal observed against analogue concentration (pM).
A plot of signal against concentration for each of the analogues (n=5, 8 , 9, 
alkylethoxy) gave a typical dose response curve, see Figures 5.7-5.10.
5.5.5 Measurement of Specific Binding
Following construction of total binding isotherms, the specific binding of each 
analogue to solid phase was assessed using a competition binding assay between the 
labelled theophylline derivatives and unlabelled theophylline present as inhibitor.
Devices were incubated with various concentrations of the analogues, serially diluted 
from stock solution (0-5 pM), together with a 1000 fold molar excess of theophylline 
concentration.
Following incubation, the degree of non-specific binding (NSB) was assessed with 
specific binding calculated by subtraction of NSB from Total Binding
Specific binding = Total binding - Non specific binding
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Specific binding of each analogue to immobilised solid phase is outlined in Figures 
5.7-5.10, with linear regression analysis providing a measure of the binding affinities 
(KJ  of each fluorescent analogue for the anti-theophylline antibody (Table 5).
The analogue having the highest affinity for the anti-theophylline antibody was 
subsequently chosen as the labelled analyte for use in the theophylline competitive 
assay.
5.5.6 Theophylline standard curve
After preliminary optimisation of the assay conditions:
(a) for the antibody loading concentration 
giving reasonable signal
(b) for antigen concentration giving reasonable response 
to antibody
(c) for the kinetics of the assay and thus the time for 
assay to reach equilibrium
(d) for assessment of specific binding, with the analogue 
chosen as having the highest affinity for the anti­
theophylline antibody
a standard curve for theophylline was constructed.
The assay involved use of devices coated with antibody concentration of 2 0 0  pg ml*1 
with the chosen analogue, the pentamethylene derivative at a concentration of 1 pM. 
This concentration was chosen from analysis of the specific binding isotherms and 
observing a concentration where signal is due only to analogue and background 
effects are minimised, Figures 5.12.
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Theophylline standards were dilutions of stock between the clinically relevant range of 
theophylline (0-50 pg/ml) (0-277 pM) as well as the non-clinical and the highly toxic 
range (1 nM-10 mM). Thus standards curves using the pentamethylene analogue as 
the labelled analyte were assessed in both buffer (Tris HC1, pH 8 .8 ) and BSA solution.
Standard curve for theophylline in Tris buffer is depicted in Figure 5.12 together with 
the inhibition profile at high and low levels of theophylline concentration, Figure 5.13.
5.5.7 Specificity
The cross-reactivities of various analogues of theophylline including the structurally 
related methylxanthines (caffeine and theobromine) as well as several metabolites of 
theophylline were assessed at physiological concentrations (50 pg ml-1) and are 
summarised graphically in Figure 5.12.
5.5.8 Assessment of precision
Three pools of the selected concentration of the labelled analyte (pentamethylene 
derivative) were assayed as 1 0  replicates in one assay (within-run precision) and for a 
period of 1 0  different days (between run).
Thus within-assay coefficients of variation (CVs) were 6.5, 6.0 and 5.2 % at mean 
theophylline concentration of 5, 10, and 25 pg ml' 1 respectively. Between assay are 
slighter higher at 8.0, 7.5 and 5.0 % at these levels.
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5 6 Results
Figure 5.3 shows a typical dose-response curve of log concentration against signal 
and as can be seen the curve is not quite sigmoidal indicating that signal could be 










Concentration of analogue (M)
Figure 5.3. A dose-response curve for the pentamethylene analogue in the presence of 
Tris HC1 buffer pH8 .8 .
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However, increasing the analogue concentration above 1 pM required lowering of the 
gain of the FCFD analyser with an increase in scatter at high concentrations.
As can be observed from Figure 5.3, at low analogue concentrations from 10*12 to 1 0 ' 
9 M, there is little change from base line values. Increasing the analogue concentration 
from 10*9 to 10*7 M appears to follow a steady increase in signal which rises rapidly 
from 10' 7 to lfr6 M and beyond. A plateau of the signal was not observed although 
lowering of the gain could be one solution. However, the problem of non-specific 
interactions appears to be more prevalent at high analogue concentrations, which are 
not apparent at low concentrations where background effects appear to be lower.
In assessing the effect of antibody loading, devices immobilised with increasing 
concentrations of antibody solution were used as titres for optimisation of the base 
plate covering. A range of concentration of the FITC-analogue (0-2 x 10^M) was 
introduced into the devices containing a sequential decrease in antibody 
concentration.
Devices coated with 200 pg ml"1 and 1 0 0  pg ml' 1 of antibody solution gave good 
dose-response curves with saturation of signal being attained at concentrations of 1 p 
M and above, Figure 5.4. However it was surprising to observe that devices coated 
with 50 pg ml' 1 antibody solution also gave good signal to concentration ratio. In fact, 
from Figure 5.4, the dose-response curve for this concentration is comparable to the 
devices containing higher coating concentrations of antibody solution.
However, devices containing the lowest concentration of antibody solution gave 
comparably lower signals with increase in analogue concentration, implying the 
limiting effects of the antibody solution.
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Subsequently, the performance of the FCFD assay including assessment of the 
reaction kinetics, the construction of binding isotherms, as well the standard curve and 
precision of the assay were performed in devices immobilised with 2 0 0  pg m l1 of anti­
theophylline antibody. This in effect ensured that the antibody coating concentration 
was not the limiting factor in the assay, particularly in establishing a standard curve 
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Figure 5.4. Evaulation of antibody loading
The kinetic performance of the assay using a standard concentration of the labelled 
analogue (pentamethylene derivative) in the presence of unlabelled theophylline is 
depicted graphically in Figures 5.5. As is apparent from Figure 5.5, the initial rate of 
reaction in the presence of low concentrations of theophylline (7.5 pg ml'1) is 
extremely rapid with equilibration of the reaction around 5 minutes with the signal 
appearing to plateau after 15-20 min into the assay. At high analyte concentrations 
(25 pg m l1 and 50 pg ml'1) the signal observed is not only lower but equilibration of 
the reaction appears to occur at 10  min into the reaction, after which time a plateau of 











Figure 5.5. A comparison of the kinetics of binding in the presence of three standard 
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Figure 5 .6 . Kinetics of binding due to the pentamethylene analogue at 1 pM 
concentration.
136
In comparison devices containing labelled theophylline without the presence of 
inhibitor seem to equilibrate extremely rapidly, within the first 2-3 min of the reaction, 
Figure 5.6. After this initial increase the signal seems to plateau and remains steady up 
to 2 0  min into the assay.
From these observations it is apparent that the reaction kinetics of the competition 
assay is complicated, subsequently, with low concentrations of analyte the assay is 
rapid with little change in the signal observed. As this concentration is increased from 
25 pg m l1 to 50 pg ml' 1 the rate at which equilibrium seems to occur increases with a 
lowering of the signal observed. This increase in the time for equilibration to occur is 
attributed to the competition process occurring between labelled theophylline and 
unlabelled theophylline for a limited number of antibody binding sites within the 
devices. Overall an incubation time of 20 min seems to ensure that the competitive 
binding reaction between labelled theophylline and theophylline in sample has reached 
equilibrium and standard curve can be constructed with ease.
Binding isotherms were constructed by assessing both the total and the non-specific 
binding of each analogue to the anti-theophylline antibody in Tris buffer. Subtraction 
of total from the non-specific signal gave the corresponding specific binding isotherms 
of each of the analogues assessed. The concentration was optimised between 0 and 5 
pM were maximum signal was obtained for an increase in analogue concentration.
From the isotherms constructed each analogue gave a typical saturation plot of signal 
against concentration, Figures 5.7-5.10. Overall saturation of signal appears to occur 
between 1-2 pM for each analogue, with the pentamethylene spacer giving the highest 
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Figure 5.7. The binding isotherms of the pentamethylene analogue (n=5) in Tris HC1 
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Figure 5.8. The binding isotherms of the octamethylene analogue (n=8 ) in Tris HCl 
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Figure 5.9. The binding isotherms of the nonamethylene analogue (n=9) in Tris HC1 
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Figure 5.11. A comparison of the specific binding isotherms of the fluorescein 
thiourea derivatives synthesised
In each case the total binding gave the highest signal to concentration ratio while the 
non-specific binding curves gave a much lower almost linear plot. Subsequently, for 
each analogue concentrations below 1 pM gave specific signal without interference 
from non-specific background effects.
A comparison of the specific binding of each analogue against concentration is 
depicted in Figure 5.11. As can be observed the pentamethylene spacer gave the 
highest signal with increase in analogue concentration, with both the octa and 
nonamethylene derivatives giving comparable results below 0.5 pM While the lowest 
response was attributed to the alkylethoxy spacer
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These results agree fairly well to the rationale of the similarity in structure of each 
analogue synthesised. As would be predicted, binding isotherms would be fairly 
similar with the affinity of each analogue calculated through a Lineweaver-Burke plot, 
Table 5.
Me.
y  (  LINKER PQ) FITC
Me
*
Table 5. The Binding Affinities of the Fluorescein-thiourea derivatives
Linker moiety (Y) Binding Affinities Ka L mol*1
(CH2) 5 3.09+ 1.5 x 10 6
(c iy * 1.40 ± 0.66 x 10 6
(CH,), 3.23 ±1.82x10 6
CHjOCHjCHjOCHjCH, 1.04 ± 0.37 x 10 «
Analysis of binding affinity data infers a low affinity (pM) of each analogue for the 
anti-theophylline antibody. The highest affinity Ka = 3.08 x 106 L mol' 1 was attributed 
to the pentamethylene analogue, although each analogue gave comparable affinity 
constants, see Table 5.
From the calculation of the binding affinity, the pentamethylene spacer was selected as 
the derivative for use in assessing the full performance of the FCFD theophylline 
assay.
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Subsequently, a standard curve for theophylline was constructed with the basis of the 
assay the competitive binding reaction between the labelled theophylline derivative 
and unlabelled theophylline standards for the limited number of antibody binding sites 
within the lower base plates of the devices.
Assays were performed in both Tris buffer (pH 8 .8 ) and BSA solution, which 
provided a comparable protein matrix. The standard curve for theophylline is depicted 
in Figure 5.12, as a plot of concentration against signal. As can be observed an 
increase in theophylline concentration results in a decrease in signal, which is 
attributed to the competition process occurring within the devices. Increasing the 
concentration of theophylline standard to 100 pM and above results in a typical 
inhibition profile. Further, expansion of the concentration range of the theophylline 
standards resulted a typical inhibition profile as depicted in Figure 5.13.
From Figure 5.13, it is apparent that at low concentrations of theophylline (10*8M) 
high signals are observed which appear to scatter until 1 pM (lO^M) where upon 
there is a linear decrease in signal with increasing theophylline concentration. This 
linear decrease results in a lowering of the signal measured up until 30 pM, where 
signal appears to plateau. This inhibition profile subsequently, covers the clinical range 
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Figure 5.13. A competitive inhibition profile for theophylline in the presence of 
labelled analyte
143
Further, as a comparison theophylline inhibition profiles have also been performed in 
BSA solution covering this large concentration range, Figure 5 14 The graph depicts 
two profiles for the inhibition curve, one at 20 min incubation time and the other at 30 
min incubation. The profile is closely related to Figure 5.13, although in the presence 
of BSA there appears to be less scatter at high concentrations and can be attributed to 
bulk interaction in sample. The assay clearly shows that at 20 min an inhibition profile 
of theophylline concentration in BSA solution can be constructed depicting the safe 
and toxic levels of theophylline in sample. Increasing incubation times gives a slightly 
better profile and a smoother curve.
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Figure 5.14. A competitive inhibition profile of theophylline in the presence of 
labelled analyte in BSA solution
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The specificity of the assay was determined by evaluating the cross reactivity of the 
theophylline antibody in the presence of structurally related xanthines and metabolites 
of theophylline, Figure 5.15. The cross reactivity of these analogues was assessed by 
performing inhibition studies in the presence of anti-theophylline antibody at 
physiological concentrations of inhibitor (50 pg ml-1).
As can be observed from Figure 5.15, the structurally related xanthines caffeine and 
theobromine, as well as 1,3-dimethyluric acid, gave no appreciable difference in signal 
over the required concentration range and therefore did not cross react with the anti­
theophylline antibody. Further, this effect is particularly apparent for 1-methylxanthine 
and 3-methylxanthine where very little signal change is observed within this 
concentration range in comparison to theophylline. Thus, no significant cross 
reactivity was observed for these metabolites at physiological concentrations with the 
assay being highly specific to theophylline.
As a final assessment of assay reproducibility precision studies were performed using 
ten replicates of labelled theophylline analogue in the presence of three standard 
concentrations of theophylline. The CVs for the within run precision were fairly low 
with an average of 5%, with low concentration of the analyte giving a slightly higher 
CV and implying more scatter with errors in signal measurement. In comparison at 
high concentration of analyte (25 pg ml*1) the CV appears lower which may be due in 
effect to the competition process occurring within the devices and subsequently a 
stabilisation of the signal.
The day to day precision appeared to be higher with results on alternative days giving 
more scatter in the data observed than in the day to day running of the assay. Again, 
devices with high analyte concentration gave a lower CV in comparison to lower 
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Figure 5.15. Inhibition studies of structurally related xanthines for assessment of 
cross-reactivity.
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5.7 Discussion
The development of a novel immunoassay for theophylline using the FCFD requires 
careful optimisation of the assay conditions. Initial requirements of the assay were:
(i) a rapid assay time (less than 2 0  min);
(ii) specificity, with no interaction with exogenous and endogenous derivatives of 
theophylline including the structurally related xanthines caffeine and theobromine, as 
well as theophylline metabolites such as 3-methyluric acid and 3-methylxanthine;
(iii) good precision giving consistent results during multiple assay runs as well as 
providing a standard curve within the clinical range of theophylline.
Subsequently, in developing a competitive immunoassay for theophylline utilising the 
FCFD a series of theophylline analogues incorporating an alkyl and an alkylethoxy 
linker conjugated to FITC were synthesised as outlined in section 4.6.
A fluorescence based assay was developed due to the successful utilisation of 
fluorophores in the FCFD assay including the use of APC (allophyocyanin) in a PSA 
assay (Fletcher et a l , 1993, O’Neill et ah, 1995) and FITC (fluorescein 
isothiocyanate) in a rubella assay (Parry et al.y 1990). Subsequently, for measurement 
of the small haptens, in particular theophylline, the FCFD was chosen as a qualitative 
test for theophylline.
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However, theophylline itself is problematic in that (i) it is a very small hapten having a 
Mr of 180.1 and thus needs to be conjugated to large protein complex in order to 
obtain a specific monoclonal (ii) is very hydrophobic owing to the presence of the two 
N-Me groups which can hydrogen bond (section 1.1) to neighbouring theophyllines.
Reaction conditions of most immunoassays are favoured at neutral to reasonably high 
pH (i.e. pH 7.4-9.0) implying that theophylline as well as the labelled theophylline 
analogues needed to be soluble in the assay buffer favoured. Ultimately the aim of the 
assay was to achieve a standard curve in plasma serum and whole blood using patient 
samples, however serum albumin was the only protein matrix assessed in the standard 
curve. Thus correlation with an existing method couldn't be performed until an 
accurate and sensitive assay could be optimised.
Subsequently, in evaluating an assay for theophylline utilising the FCFD, binding 
isotherms were set up for each fluorescent analogue synthesised, structure of 
analogues are depicted in Figure 5.2.
This was not only to assess the immunoreactivity of each analogue but also to 
ascertain the binding affinities of each analogue for the anti-theophylline monoclonal 
antibody immobilised within the devices.
As outlined in the section 5.5, all analogues were immunoreactive against the 
monoclonal antibody and gave typical binding isotherms (e.g. increase in signal for 
increase in analogue concentration).
Saturation of the immobilised antibody appears to occur at a concentration of 1 (iM 
both in terms of total and specific signal observed.
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Above tthis concentration only the pentamethylene and the alkylethoxy analogue 
(Figures 5.7 and 5.10 respectively) appear to show signs of plateauing particularly for 
the specific signal observed. For the octamethylene and nonamethylene analogues 
(Figures 5.8 and 5.9 respectively) the total and specific signals observed appear to rise 
rapidly above 2.5 pM with no plateau being observed for analogue concentration up 
to 5 pM.
This increase (enhancement) in the signal fluorescence observed is a real effect and 
can only be attributed to the increase in analogue concentration which causes some 
physical effect in the FCFD. From the stochiometric equation it is apparent that 
saturation of the antibody binding sites, immobilised within the FCFD, occurs at an 
analogue concentration of 1 |oM. Above this concentration there appears to be an 
excess o f analogue within the device and, so as observed background effects are high. 
However, this rapid increase in signal fluorescence, particularly for the long chain 
alkylamino derivatives (n = 8 , 9) appears to indicate some form of interaction of 
neighbouring xanthene fluorescent moieties away from the immobilised antibody site 
leading to the possibility of stacking of these planar molecules and, hence, an increase 
in signal fluorescence observed. This observation is particularly true for the total 
signal measured where there is the greatest enhancement of the signal observed.
The specific signal observed (see Figures 5.7-5.10) apears to show a smaller 
enhancement in fluorescence signal which is attributed to the fact that specific signal is 
calculated from both the total and non specific signals measured within the FCFD 
devices.
Subsequently, the non specific signal was also assessed and found to be detrimental 
above concentrations of 2 pM (see Figures 5.7-5.10) where there is a distinct lack of 
selectively between the specific signal obtained and background effects.
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Therefore, in calculating the binding affinities of the fluorescent analogues, it was 
found that all the analogues had similar affinities for the theophylline antibody within 
the pM range.
Inhibition profiles utilising the pentamethylene analogue gave reasonable competitive 
binding curves through a broad concentration range in the presence of Tris buffer (pH 
8 .8 ), Figure 5.13 and BSA solution, Figure 5.14.
Thus, the FCFD provides an assay for theophylline in the range of clinical interest (1- 
50 pg ml' 1 = 5.56 - 278 x lO^M) without interference from other exogenous or 
endogenous xanthines at their normal physiological concentration, Figure 5.15. 
However, the only problem encountered in the assay seemed to be the lack of 
discrimination of signal from label bound to solid phase in relation to background at 
high concentrations. This may in fact be attributed to too little antibody present within 
the devices, even at high concentrations of antibody (200 pg ml-1) present. Although 
only 15 pi is immobilised onto solid phase, a larger volume may be required for 
further utilisation of the FCFD.
Further, in assessing the kinetics and the precision of the assay, it was found that the 
competitive reaction required incubation times of less than 2 0  min which ensured 
equilibration of the reaction had occurred. Also, the reasonable precision of the assay, 
particularly between every run ensured that the assay was robust and that results were 
reproducible.
However, further assessment of the assay needs to be fully investigated in order to 
develop a suitable assay for theophylline, in particular:
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(a) assaying of theophylline in a suitable protein matrix such as plasma serum with a 
view to develooping in assay in whole blood. Problems may be encountered due to 
the "stickiness" of the blood as well as the problems associated with the binding of 
plasma serum to theophylline which appears to be between 40-60% (Brors et al., 
1983, Buss etal., 1983);
(b) the sensitivity of the assay has to be determined together with the lowest limit of 
detection;
(c) a change in the immobilised antibody which is an IgA fraction and exists as a large 
complex. The use of an IgG fraction raised against theophylline or one of the 
analogues synthesised would ensure a higher affinity of the label for the antibody. 
Ultimately an affinity constant in the nanomolar range would be useful ensuring 
reasonable competition between theophylline and the labels. These options have to be 
fully investigated.
(e) A final but the most crucial aspect of the assay, a correlation with an existing 
method would be a useful comparison. Existing assays would provide an insight into 
the effectiveness of the FCFD for measuring clinical samples spiked with theophylline.
5.8 Conclusion
Overall, an assay for theophylline covering the clinical range has been achieved with a 
reasonable reaction time which is both highly specific and precise. The assay 
developed, although not commercialised, has the potenial to distinguish both safe and 
toxic levels of theophylline in assay buffer.
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Ultimately for a quantitative assay the FCFD system has to be fully optimised (section 
5.7) with a view to a commercial device incorporating all the components of the 
assay, the antibody as well as the fluorescent label in a rapid easy-to-use 
homogeneous assay.
Realistically, the device although simple to use requires a decrease in its reaction time 
as well as minaturisation of the technology in order to be of use in the clinical 
environment. In particular such technology can be envisaged for use in an 




I.R. spectra were recorded on the Perkin-Elmer 782 spectrophotometer as potassium 
bromide discs unless otherwise stated.
1HNMR spectra were recorded using Jeol JNM GX270 and Jeol JNM EX400 
spectrometers at 270 MHz and 400 MHz, respectively. Chemical shifts (8 ) were 
measured in ppm relative to tetramethylsilane (TMS) which was used as internal 
standard. Values of the number of protons for each signal are given between the 
brackets. Multiplicities are indicated as follows s (singlet); d (doublet); dd (double 
doublet); t (triplet); dt (double triplet); q (quartet); m (multiplet), br (broad).
Mass spectra were obtained using VG7070E analytical mass spectrophotometer, 
University of Bath, and reported in the form m/z (intensity relative to base = 100) for 
selected ions. Spectra were obtained using electron impact (E.I.), chemical ionisation 
(C.I.) or fast atom bombardment (FAB) ionisation techniques.
Elemental analysis was carried out using the EMA system 1106, microanalysis unit, 
University of Bath.
Melting points (m.p.s) were measured using a Gallenkemp melting point apparatus 
and are uncorrected.
All reactions were monitored by T.L.C on pre-coated silica plates manufactured by 
Merck; (Merck t.l.c aluminium sheets) silica 60 F254 Art no 5635.
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Products were visualised in a variety of ways; ultraviolet (U.V.) light; iodine vapour; 
spraying with phosphomolybidic acid in methanol followed by heating; ninhydrin in 
ethanol. TLC system of dichloromethane : methanol was used, unless otherwise 
stated, with all spots being detected by fluorescence quench at 254 nm.
Chromatographic separations were carried out using Sorbsil C60 (0.040 - 0.063) 
silica gel in the noted solvent system using forced air.
All solvents were evaporated under reduced pressure.
When required, ethanol was dried over magnesium turnings and iodine, collected after 
distillation.
Light petroleum refers to the fraction with boiling point 60-80°C.




Hydroxyacetic acid (8.5 g, 112 mmol) was added to 1,3-dimethyl-5,6 -diamino- 
pyrimidine-2,4-dione (8.3 g, 49 mmol) and the two compounds were thoroughly 
mixed until a brown paste was seen. The mixture was then heated at 100°C for 1 h, 
after which time the solution was diluted with aqueous NaOH (1 M, 110 ml) and was 
boiled under reflux for a further 2.5h.
The resulting solution was then acidified to pH 4 with 1 0 % aqueous H2S04, cooled to 
ambient temperature and stored at 0°C for 24h. Recrystallisation of the solid from 
water afforded a yellow crystalline product which was collected by filtering under 
reduced pressure, washed with water and ethanol and was dried to yield (15) (0.27 g, 
2.6%) as a yellow solid, m.p. 244°C (lit. (Bredereck and Fohlisch., 1962) m.p. 243- 
244°C); TLC (silica gel 10 C H ^  : 1 MeOH) Rf = 0.38; I.R. umax 3450 cm*1, 
3200 cm-1, 1670 cm-1; lH NMR 5 (D20 ) 3.25 (3 H, s, N-CH3), 3.40 (3 H, s, N-CH3), 
4.75 (2 H, s, CHj); m/z 210 (M+), 180 (100%).
1.3-Dimethvlpvrimidine-2.4.6-trione (16)
Propanedioic acid (22 g, 211 mmol) was added to a solution of 1,3-dimethylurea 
(15.9 g, 180 mmol) in acetic acid (35 ml) and heated with stirring to a temperature of 
70°C. After 1 h heating, acetic anhydride (72 ml) was added dropwise to the mixture 
and the temperature was allowed to rise to 90°C. The reaction was stirred at this 
temperature for a further 6  h.
On completion of the reaction, the mixture was cooled to ambient temperature with 
evaporation of the solvent affording a yellow crystalline mass which was collected by 
filtration, washed with ethanol (18 ml) and recrystallised from ethanol to afford (16) 
(20.74 g, 74%) as fine yellow needles. m.p. 120-121°C (lit. (Goldner et ah, 1966)
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m.p. 124-126°C); TLC (silica gel 10 CH2C12 : 1 MeOH) Rf = 0.78; I.R. umax 
1640cm-1; lU NMR 6  (D20) 3.23 ( 6  H, s, (N-CH3)2), 4.80 (2 H, s, 5-H); m/z 156 
(M+), 42 (100%).
1.3-Dimethvl-6-chloropyrimidine-2.4-dione (17)
Phosphorus oxychloride (120 ml, 780 mmol) was added dropwise to a stirred 
suspension of l,3-dimethyIpyrimidine-2,4,6-trione (15.6 g, 100 mmol) in water (5 ml). 
The mixture was boiled under reflux for 40 min, after which time the excess 
phosphorus oxychloride was removed by distillation under reduced pressure to reveal 
a brown gum. Ice was added to this gum which dissolved in the aqueous solution. The 
aqueous solution was then extracted twice with CH2C12, the combined organic 
extracts were collected then dried. The solvent was evaporated yielding (17) (11.27 g, 
65%) as a dark yellow solid, m.p. 109°C (lit. (Goldner et al., 1966) m.p. 109-110°C); 
TLC (silica gel 10 CH2C12 : 1 MeOH) Rf = 0.85; I.R. umax 1719 cm*1, 720 cm-1; W  
NMR 6  (CDC13) 3.40 (3 H, s, N-CH3), 3.50 (3 H, s, N-CH3), 6.00 (1 H, s, 5-H); m/z 
174 (M+), 82 (100%).
1 .3-Dimethvl-6-(2-hvdroxvethvlamino)pvrimidine-2.4-dione (181
A mixture of l,3-dimethyl-6-chloropyrimidine-2,4-dione (3.7 g, 21 mmol), 2-amino- 
ethanol (2.00 g, 33 mmol) and anhydrous sodium carbonate (4.45 g, 42 mmol) was 
boiled under reflux with stirring for 4 h, until formation of single product as shown by 
TLC (silica gel 10 : 1 MeOH).
After cooling to ambient temperature, the mixture was filtered. The solvent was 
evaporated from the clear filtrate revealing a yellow solid which on recrystallisation 
with ethanol afforded (18) (3.01g, 72%) as yellow needles, m.p. 170-171°C (lit. 
(Golner et al., 1966) m.p. 180-181°C); TLC (silica gel 10 CH2C12 : 1 MeOH) Rf =
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0.3; I.R. umax 3340-3240 cur1, 1650 cm-1; NMR 6  (D20) 3.33 (3 H, s, N-CH3),
3.55 (3 H, s, N-CH3), 3.81 (2 H, t, J 4 Hz, CH2-N), 3.93 (2 H, t, J 4 Hz, CH2-0); m/z 
199 (M+), 156(100%).
1J-Dimethvl-6-(2-hvdroxvethvlaminoV5-nitrosopyrimidine-2.4-dione (19)
Isoamyl nitrite (2.9 g, 24 mmol) was slowly added to suspension of l,3-dimethyl-6- 
(2-hydroxyethylamino)pyrimidine-2,4-dione (2.5 g, 12.6 mmol) in ethanol (78 ml). 
The mixture was stirred at ambient temperature for 10 min, after which time 10 drops 
of hydrochloric acid were added. On stirring for a further 30 min, the suspension 
changed from colourless to pink and finally to a purple colour. The reaction was 
continued until TLC (silica gel 10 CH2C12 : 1 MeOH) showed formation of product. 
After completion of reaction the product was collected by filtration and air dried. The 
resultant purple solid was recrystallised from ethanol to afford (19) (2.81 g, 63%) as 
fine purple needles, m.p. 230°C (lit. (Goldner et al., 1966) m.p. 230°C); TLC (silica 
gel 10 CH2C12 : 1 MeOH) Rf = 0.33; I.R. umax 3430 cm*1, 1679 cm*1; !H NMR 5 
(D20 ) 3.33 (3 H, s, N-CH3), 3.55 (3 H, s, N-CH3), 3.81 (2 H, t, J 4 Hz, CH^N), 3.93 
(2 H, t, J 4 Hz, CH2-0).
1.3-Dimethvl-3.7-dihvdro-8-hvdroxvmethyl-nH)-purine-2.6-dione (151 
Butanol (25 ml) was added to l,3-dimethyl-6-(2-hydroxyethylamino)-5-nitroso- 
pyrimidine-2,4-dione (1.00 g, 4.4 mmol) and the mixture boiled under reflux with 
stirring until decolourisation of the reaction mixture, and formation of single spot on 
TLC (silica gel 10 CH2CI2: 1 MeOH). The resulting clear solution was then cooled to 
ambient temperature and the solvent removed by evaporation under reduced pressure 
to reveal a cream coloured solid which was recrystallised from ethanol to afford (15) 
(0.50 g, 54%) as fine needles, m.p. 243°C (lit. (Goldner et al.y 1966) m.p. 243-244°
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C); TLC (silica gel 10 CH2C12: 1 MeOH) Rf = 0.39; LR. umax 3450 cm1, 3200 cm-1, 
1650 cm-1; lU NMR 6  (D20) 3.19 (3 H, s, N-CH3), 3.34 (3 H, s, N-CH3), 4.69 (2H, 
s, CH2-0); m/z 210 (M+), 180 (100%); Anal Calcd for C8H10N4O3: C, 45.71; H, 4.80; 
N, 26.66. Found C, 45.75; H, 4.88; N, 26.76.
1.3-Dimethvl-3.7-dihvdro-8-carboxv-(THVpurine-2.6-dione (20)
To a stirred solution of 1,3 -dimethyl-3,7-dihydro-8-hydroxymethyl-( 1 H)-purine-2,6- 
dione (0.3 g, 1.4 mmol) in water (0.7 ml), 2 M aqueous NaOH (1 ml) was added at 0° 
C. To this solution, 5 portions of potasium permanganate (0.32 g in 5.5 ml of water) 
were added dropwise and the resultant purple mixture stirred at ambient temperature 
for 3 h.
After 3 h, the resultant brown precipitate was removed by filtering under reduced 
pressure to reveal a clear filtrate which was acidified to pH 1 with concentrated 
hydrochloric acid and stored at 0°C for 24 h.
The yellow solid was collected by filtration, washed and recrystallised from water to 
yield (20) (0.17 g, 53%) as yellow needles, m.p. 269-272°C (lit. (Bredereck and 
Fohlisch, 1966) m.p. 273°C); TLC (silica gel 10 CH2C12 : 1 MeOH) Rf = 0.54; I.R. u 
max 3440 cnr1, 3180 cm’1, 1650 cnr1; lU NMR 5 (CF3C02D) 3.63 (3 H, s, N-CH3),
3.84 (3 H, s, N-CH3); m/z 224 (M+), 180 (100%); Anal calcd for C8H8N40 4: C, 
42.86; H, 3.60; N, 24.99. Found C, 42.98; H, 3.55; N, 25.17.
1 ■3-Dimethvl-6-('3-hvdroxvpropvlamino)pvrimidine-2.4-dione (21)
A mixture of l,3-dimethyl-6-chloropyrimidine-2,4-dione (5.00 g, 29 mmol), 3-amino- 
propanol (2.8 g, 37 mmol) and sodium carbonate (4.45 g, 42 mmol) in butanol (120 
ml) was boiled under reflux with stirring until formation of single product on TLC 
(silica gel 1 0  CH2C12: 1 MeOH).
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After cooling to ambient temperature, the mixture was filtered, the precipitate was 
removed and the remaining clear filtrate was evaporated to reveal a white solid which 
was recrystallised from ethanol to afford (21) (4.89 g, 80%) as white needles, m.p. 
150°C; TLC (silica gel 10 CHjC^ : IMeOH) Rf = 0.49; I.R umax 3460-3420cm-1, 
1630cm*1; lU NMR 5 (D20 ) 1.81 (2 H, q, J 7 Hz, CH2), 3.13 (3 H, s, N-CH3), 3.20 
(2 H, t, J 7 Hz, CH2-N), 3.25 (3 H, s, N-CH3), 3.64 (2 H,t, J 6  Hz, CH2-0), 4.86 
(1 H, s, 5 H); m/z 214 (M+), 31 (100%); Anal, calcd. for C9H15N30 3.1H20: C, 46.70;
H, 7.41; N, 18.16. Found C, 46.40; H, 7.46; N, 18.20.
I.3-Dimethvl-6-(3-hvdroxvpropvlaminoV5-nitrosopvrimidine-2.4-dione (22)
Isoamyl nitrite (2.09 g, 18 mmol) was slowly added to a suspension of the 1,3- 
dimethyl-6-(3-hydroxypropylamino)pyrimidine-2,4-dione (1.8 g, 7.4 mmol) in ethanol 
(57 ml). The mixture was stirred at ambient temperature for 10 min, after which time 
10 drops of hydrochloric acid was added. On stirring for a further 30 min, the 
suspension changed colour from clear to pink. The reaction was continued until TLC 
(silica gel 10 CH2C12: 1 MeOH) showed formation of the nitroso prduct.
After reaction had gone to completion, the purple product was collected by filtering 
under reduced pressure to afford a pink solid which was recrystallised from ethanol to 
give (22) (0.39 g, 2 0 %) as fine pale pink needles. m.p. 278°C; TLC (silica gel 1 0  
CH2C12 : 1 MeOH) Rf = 0.56; I.R umax 1640 cm 1; lH NMR 5 (D20) 1.95 (2 H, q, 
J 6  Hz, CHj), 2.99 (2 H, t, J 6  Hz, CH2-N), 3.33 (3 H, s, N-CH3), 3.56 (3 H, s, 
N-CH3), 3.69 (2 H, t, J 6  Hz, CH2-0); m/z 225 (M+), 181 (100%); Anal Calcd for 
C, 44.63; H, 5.83; N, 23.13. Found C, 44.80; H, 5.76; N, 23.20.
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1.3-Dimethvl-3.7-dihvdro-8-(2-hvdroxvethvO-( lHVpurine-2.6-dione (23)
A mixture of l,3-dimethyl-6-(3-hydroxypropylamino)-5-nitrosopyrimidine-2,4-dione 
(0.30 g, 1.2 mmol) in butanol (50 ml) was boiled under reflux with stirring for 1 h 
until the purple nitroso solution decolourised. The reaction was monitored by TLC 
(silica gel 10 CHjClj : 1 MeOH) for formation of single product.
After cooling to ambient temperature, the resulting clear solution was evaporated to 
reveal a cream coloured solid which, on recrystallisation with ethanol, afforded (23) 
(0.28 g, 82%) as fine white needles. m.p. 278°C; TLC (silica gel 1 0  CH2C12 : 1 
MeOH) Rf = 0.69; I.R umax 3360 cnr1’ 1650 cm-1; NMR 6  (D20) 2.94 (2 H, t, J 6  
Hz, CH2), 3.17 (3 H, s, N-CH3), 3.34 (3 H, s, N-CH3), 3.89 (2 H, t, J 6  Hz, CH20); 
m/z 225 (M+), 185 ( 1 0 0 %). Anal. Calcd. for (C9H12N40 3): C, 48.21; H, 5.40; N, 
24.99. Found C, 47.9; H, 5.26; N, 24.90.
1 .3-Dimethvl-6-(2-methoxvethvlamino)pvrimidine-2.4-dione (24)
A mixture of l,3-dimethyl-6-chloropyrimidine-2,4-dione (2.00 g, 11 mmol), 2- 
methoxyethylamine (1.12 g, 15 mmol) and sodium carbonate (2.33 g, 22 mmol) in 
butanol (65 ml) was boiled under reflux with stirring for 4 h until formation of single 
product on TLC (silica gel 10 CH2C12: 1 MeOH).
After cooling to ambient temperature the mixture was filtered, the precipitate was 
removed and the remaining clear filtrate was evaporated to reveal an off-white solid 
which was recrystallised from tetrahydrofuran to afford (24) (2.12 g, 91%) as cream 
needles, m.p. 190°C; TLC (silica gel 10 CHjC^ : 1 MeOH) Rf = 0.55; I.R.omax 3250 
cm-1 1700 cm-1, 1640-1600 cnr1, 1550 cm-1; 1HNMR 5 [(CD3)2SO] 3.07 (3 H, s, 
OCH3), 3.22 (2 H, q, J 6  Hz, Ctf2-NH), 3.25 (3 H, s, N-CH3), 3.46 (2 H, t, J 6  Hz, 
Ctf2-OCH3), 3.57 (3 H, s, N-CH3), 4.70 (1 H, s, 5-H), 6.76 (1 H. br, NH); m/z 210
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(M+), 180 (100%). Anal Calcd for (C9Ul3N30 3): C, 51.18; H, 6.20; N, 19.89. Found 
C, 51.2; H, 6.25; N, 19.86.
1.3-Dimethvl-6-(2-methoxvethvlarninoV5-nitrosopvrimidine-2.4-dione (25)
To a suspension of l,3-dimethyl-6-(2-methoxyethylamino)pyrimidine-2,4-dione 
(1.5 g, 7.03 mmol) in water (7 ml), sodium nitrite ().74 g, 10.7 mmol) was added 
portionwise. Over a 1 h period, acetic acid (0.74 ml) was added dropwise to the 
suspension, after which time a colour change occurred from clear to purple. The 
mixture was then stirred at ambient temperature until TLC (silica gel 1 0  CH2C12 : 1 
MeOH) showed formation of single product.
After completion of the reaction the purple precipitate was collected by filtering under 
reduced pressure. It was washed with water and recrystallised from ethanol to afford 
(25) (1.00 g, 58%) as purple needles, m.p 232-234°C; TLC (silica gel 1 0  CH2C12 : 1 
MeOH) Rf = 0.59; I.R. umax 3440 cm-1, 3180 cm-1, 1720 cm*1, 1640 cnr1, 1570 cm-1, 
1500 cm-1; lU NMR 5 (D20 ) 3.34 (3 H, s, N-CH3), 3.46 (3 H, s, OCH3), 3.56 (3 H, s, 
N-CH3), 3 .69 (2 H, t, J 6  H z, Ctf2-OCH3), 4.00 (2 H, t, J 6  Hz, Ctf2-NH); m/z 226 
(M+), 210 (100%).Anal Calcd for ( C jH ^ O J :  C, 44.63; H, 5.83; N, 23.13. Found 
C, 44.67; H, 5.80; N, 23.26.
1.3 -Dimethvl-3.7-dihvdro-8-methoxvmethvl-( lHVpurine-2.6-dione (26)
A mixture of l,3-dimethyl-6-(2-methoxyethylamino)-5-nitrosopyrimidine-2,4-dione 
(0.39 g, 1.60 mmol) in butanol (70 ml) was boiled under reflux with stirring for 3 h or 
until the purple nitroso solution decolourised. The reaction was monitored by TLC for 
formation of single product.
After cooling to ambient temperature the resulting solution was evaporated to reveal a 
cream solid which, on recrystallisation from ethanol, afforded (26) (0.27 g, 75%) as a
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cream powder, m. p. 165°C; TLC (silica gel 10 CH2C12 : 1 MeOH) Rf = 0 .6 ; I.R. u 
max 3400 cm'1, 3200-3100 cm-1, 1700 cm*1, 1650 cm*1, 1600 cm-1, 1510 cm*1; 
NMR 6  [(CD3)2SO] 3.23 (3 H, s, N-CH3), 3.31 (3 H, s, OCH3), 3.43 (3 H, s, 
N-CH3), 4.45 (2 H, s, CHj-O); m/z 224 (M+), 181 (100%); Anal Calcd. for 
(C9H 12N4 0 3 ): C, 48.21; H, 5.39; N, 24.99. Found C, 48.19; H, 5.38; N, 25.01.
1.3-dimethvl-3.7-dihvdro-8-nitropurine-2.6-dione (28)
A mixture of theophylline (20 g, 111 mmol) and glacial acetic acid (40 ml) was 
warmed to a temperature of 87°C. To this solution concentrated nitric acid (19.6 g, 
311 mmol) was added dropwise over a period of 1.5 h, with temperature of reaction 
kept below 105°C.
After reaction completion, the resulting yellow mixture was cooled, the solid collected 
and washed several times with water, dried to afford 1,3-dimethyl-3,7-dihydro-8- 
nitropurine-2,6-dione (16) (17 g, 6 6 %) as a powdery yellow solid .m.p. 280°C (lit. 
(Duesel, 1958) m.p. 282°C); TLC (silica gel 9 CH2C12 : 1 MeOH) Rf = 0.59; I.R u 
max 3500-3400 cm*1, 3250 cm*1, 2980 cm*1, 2600-2500 cm*1, 1700 cm*1, 1670-1640 
cm*1, 1530 cm*1, 1350 cm*1; lH N M R S  [(CD3)2SO] 3.25 (3 H, s, N-CH3), 3.43 (3 H, 
s, N-CH3), 8.41 (1 H, s, NH) Anal. Calcd. for (C7H7N50 4): C, 37.12; H, 3.13; N, 
31.10. Found C, 37.25; H, 3.35; N, 31.19.
Ll-Dimethvlethvl N-(2-(2-hvdroxvethoxytethoxv)carbamate (29)
Di-tert-butyl dicarbonate (4.15 g, 19 mmol) in dichloromethane (50 ml) was added 
dropwise to a solution of 2-(2-aminoethoxy)ethanol (2.00 g, 19 mmol) in dichloro­
methane (50 ml). The resulting solution was stirred at ambient temperature for 24 h. 
The solvent was removed by evaporation to reveal (17) (3.89 g, 99%) as a pale 
yellow o il; TLC (silica gel 20 CH2C12 : 1 MeOH) Rf = 0.30; I.R(film) umax 3500-
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3200 cm-1, 1700 cm-1; !H NMR 6  (CDC13) 1.45 (9 H, s, (CH3)3), 2.46 (1 H, s, N-H),
3.32 (2 H, q, J 6  Hz, CH^N), 3.58 (4 H, m, CH2-0-CH2), 3.75 (2 H, t, J 6  Hz, 
CH2-OH), 5.31 (1 H, s, OH); m/z 206, 106 (100%).
1.1-Dimethvlethvl N-f2-(2-(2-cvanoethoxv)ethoxv)ethv0carbamate (30)
Acrylonitrile (1.19 g, 23 mmol) was added dropwise to a stirred solution of 1,1-di- 
methylethyl N-(2-(2-hydroxyethoxy)ethoxy)carbamate (3.00 g, 15 mmol) containing 
10 drops of benzyltrimethylammonium hydroxide. The resulting solution was then 
stirred at ambient temperature for 24 h.
The brown solution was diluted with dichloromethane, washed four times with water, 
the combined organic extracts were dried with evaporation of the solvent yielding () 
(2.62 g, 6 8 %) as an orange-brown o il; TLC (silica gel 2 0  CH2C12 : 1 MeOH) Rf =
0.70; I.R.(film) umax 3380 cnr1, 2260 cm*1, 1740 cm-1; lH NMR 5 (CDC13) 1.45 (9 
H, s, (CH3)3), 2.64 (2 H, m, C^-CN), 3.54 (2 H, q, J 6  Hz, CH2-N), 3.73 ( 8  H, m, 2 
x CH2-0-CH2), 5.31 (1 H, s, N-H); m/z 246, 106 (100%).
Phenvlmethvl N-(2-(2-hvdroxvethoxy)ethyDcarbamate (31)
Phenylmethyl chloroformate (9.74 g, 57 mmol) in dichloromethane (15 ml) was added 
dropwise to a solution of 2-(2-aminoethoxy)ethanol (6.00 g, 57 mmol) and 
triethylamine (6.35 g, 63 mmol) in dichloromethane (25 ml). The resulting solution 
was stirred at ambient temperature for 24 h.
The solution was quenched with water (50 ml) and the organic layer was extracted, 
washed twice with 10% aqueous and water. The combined organic extracts
were collected and dried. Evaporation of the solvent afforded (19) (8.5 g, 62%) as a 
pale yellow oil; TLC (silica gel 20 C f^C ^: 1 MeOH) Rf = 0.5; I.R.(film) omax 3440- 
3300 cm-1, 1720 cm-1, 1560 cm-1; NMR 5 (CDC13) 3.20 (1 H, s, N-H), 3.35 (2 H,
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t, J 6  Hz, CH2-N), 3.48 (4 H, m, (CH2)20), 3.68 (2 H, m, CH2-0), 5.82 (1 H, s, OH),
7.32 (5 H, s, Aryl-H); m/z 240 (M+), 91 (100%).
Phenvlmethvl N-(2-(2-(2-cvanoethoxv>)ethoxv>)ethvncarbamate (32)
Acrylonitrile (0.99 g, 19 mmol) was added dropwise to a stirred solution of phenyl- 
methyl N-(2-(2-hydroxyethoxy)ethyl)carbamate (3.00 g, 13 mmol) containing 10 
drops of benzyltrimethylammonium hydroxide. The resulting brown solution was 
stirred at ambient temperature for 24 h.
The mixture was diluted with dichloromethane and was washed four times with water. 
The organic extracts were collected and dried and the solvent was removed to yield 
(20) (3.57 g, 98%) a brown oil; TLC (silica gel 2 0  CH2C12 : 1 MeOH) Rf=0.59; 
I.R(film) umax 3500-3400 cnr1, 2250 cm-1, 1730 cm 1; lH NMR 5 (CDC13) 3.01 (2 
H, m, CH2-CN), 3.80 ( 2  H, m, CH2-N), 3.96 ( 8  H, m, 2 x CH2-0-CH2), 5.45 (1  H, 
br, N-H), 7.62 (5 H, s, Aryl-H).
Phenvlmethvl N-(2-(2-(2-aminoethoxvlethoxvlethylcarbamate (35)
Phenylmethyl chloroformate (6.0 g, 35 mmol) in dichloromethane (20 ml) was added 
dropwise to a stirred solution of 3,6 -dioxaoctane-l,8 -diamine (52.1 g, 352 mmol), 
triethylamine (7.08g, 70 mmol) in dichloromethane (100 ml). The homogeneous 
mixture was left to stir at ambient temperature for 24 h.
After overnight stirring, the reaction mixture was washed once with water and the 
organic extract was acidified with 2M hydrochloric acid, collected then dried with 
evaporation of the solvent affording (36) (3.65 g, 50%) as a pale oil which crystallised 
on standing. The remaining aqueous extract was made basic with 2M NaOH extracted 
thrice with EtOAc, the organic extracts were then collected, dried with evaporation of 
the solvent affording (35) (0.22 g, 13.3%) as a pale o il; TLC (silica gel 10 CHjClj : 1
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MeOH) Rf = 0.3; I.R. omax 3250 cm'1, 1720 cm*1, 1640 cm*1; NMR 5 2.64 (2H, 
m, CHj-NHJ, 3.18 (2H, m, CHj-NH), 3.42 (4H, m, (CH2-0)2), 3.52 (4H, m, 
CH2CH2-NH), 5.03 (2H, br, A ryl-O y, 7.36 (5H, br, Aryl); m/z 283 (M+), 91 
( 100%).
2 -(2 -(2 -phthalimidoethoxvlethoxvlethanol (381
2-(2-(2-chloroethoxy)ethoxy)ethoxy (1.5 g, 8.91 mmol) was added to a mixture of 
potassium phthalimide (1.5 g, 8.10 mmol) in dimethylformamide (2 ml) and left to stir 
at 120°C for 5 h.
After completion of the reaction, the resulting precipitate was removed by filtration, 
with evaporation of the clear filtrate revealing a yellow-brown oil which was purified 
by column chromatography in the system (7 EtOAc : 7 Hexane : 1 MeOH) to afford 
(38) as a pale yellow oil (0.45 g, 20%); TLC (silica gel 7 EtOAc : 7 Hexane : 1 
MeOH) Rf = 0.31; I.R.umax 3480-3400 cm*1, 2880 cm*1, 1765 cm*1, 1710 cm*1, 
1680 cm*1, 1470 cm*1, 1390 cm*1, 1200 cm*1; 1HNMR 8  (CDC13) 2.97 (1  H, s, OH), 
3.5-4.01 (12 H, m, NCH2 + OCH2) 7.65 (4 H, m, Aryl).
2-(2-(2-Phthalimidoethoxvtethoxv)acetic acid (39)
To a stirred solution of the 2-(2-(2-phthalimidoethoxy)ethoxy)ethanol (1.91g, 6 .8  
mmol) in acetone (133 ml) Jones reagent (K^C^O? in H2S04) (7.6 ml) was added 
dropwise. The mixture was stirred at ambient temperature until disappearance of 
starting material.
After 5 h stirring the reaction was complete, the resulting precipitate was removed by 
filtration and the clear filtrate evaporated under reduced pressure to afford a pale 
yellow oil. The oil was then dissolved in CH2C12, washed twice with water (10 ml), 
once with 2 M hydrochloric acid (15 ml), the organic extracts were collected then
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dried, the solvent removed by evaporation under reduced pressure to afford a pale oil 
which after trituration with ether gave (39) (1.68g, 84%) as a white crystalline solid. 
m.p.270°C; TLC (silica gel 10 CH2C12 : 1 MeOH) Rf = 0.31; I.R. umax 3700-3340 
cm-1, 1770 cm-1, 1710 cm-1; 8  (CDC13) 3.71 (4 H, br, ( C H ^ ) ,  3.77 (2 H,
m, CH2), 3.93 (2 H, t, Ctf2-NH), 4.10 (2 H, m, CH2C02H), 5.70 (1 H, br, C02H), 
7.74-7.87 (4 H, m, Aryl-H4); m/z 294.1 (M+), 27.9 (100%). Anal calcd for 
(C14H15N 06): C, 57.34; H, 5.16; N, 4.78. Found C, 57.40; H, 5.21; N, 4.75.
L3-dimethvl-6-amino-5-(2-(2-(2-phthalimidoethoxv)ethoxv)acetvlamino>)pvrimidine-
2.4-dione (40)
To a solution of 5,6-diamino-l,3-dimethyluracil (0.34 g, 2 mmol) in 
dimethylformamide ( 8  ml), dicyclohexylcarbodiimide (0.41 g, 2 mmol) and 
phthalimido acid (0.59 g, 2 mmol) was added portionwise. The solution was allowed 
to stir at ambient temperature for 24 h with a further addition of dimethylformamide 
(4 ml).
The resulting precipitate was removed by filtration, the solvent evaporated under 
reduced pressure to afford an orange oil which was dissolved in dichloromethane, 
washed twice with water, the organic extracts collected, dried to reveal a pale yellow 
solid (1.05 g). The product was purified by column chromatography in the eluting 
system (9 CH2C12 : 1 MeOH), collected with evaporation of the solvent revealing a 
pale yellow solid which when trituated with EtOAc resulted in (40) (0.11 g, 12%) as a 
creamy colourless solid. m.p. 230°C; TLC (silica gel 9 CH2C12 : 1 MeOH) Rf = 0.72;
I.R.O max 3400 cm-1, 3360 cm*1, 1720 cm*1, 1650cm-1; lH NMR 5 [(CD3)2SO] 3.05 
(3 H, s, N-CH3), 3.26 (3 H, s, N-CH3), 3.61 (2 H, m, phth-CH2), 3.72 (2 H, q, CH2- 
O), 3.99 (4H, m, (CH^O)^, 6.61 (1 H, br, 5-NH), 7.86 (4 H, m, Aryl); m/z 445
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(M+); Anal Calcd for (C2oH23N50 7 ): C, 54.05; H, 4.99; N, 15.76. Found C, 54.10; H, 
5.21; N, 15.75.
Phenvlmethvl N-f6-0.1 -dimethvlethoxvcarbonvlamino)hexvl~|carbamate (42) 
Phenylmethyl chloroformate (0.61 g, 3.56 mmol) in dichloromethane ( 6  ml) was 
added dropwise, over a 30 min period, to a stirred solution of 1,1-dimethylethyl N-(6 - 
aminohexyl)carbamate hydrochloride (0.90 g, 3.56 mmol) and triethylamine (0.72 g, 
7.12 mmol) in dichloromethane (12 ml). The mixture was left to stir at ambient 
temperature for 24 h.
The resulting precipitate was removed by filtration, the clear filtrate was washed twice 
with water and once with 2M hydrochloric acid. The organic extracts were collected 
and dried, with removal of solvent, affording (42) (0.96 g, 77%) as a white crystalline 
solid, m.p. 190°C ; TLC (silica gel 10 CH2C12 : 1 MeOH) Rf = 0.62; I.R omax 3340 
cm-1, 1680 cm-1, 1550 cm-1; 'H NMR 5 (CDC13) 1.44 (17 H, m, (CH3) 3 + (CH2)4),
1.85 (1 H, br, N-H), 3.11 (2 H, q, J 6  Hz, Ci/2NH), 3.17 (2 H, m, C7/2NH), 4.85 (1
H, br, N-H), 5.09 (2 H, s, Aiyl-Ciy, 7.35 (5 H, s, Aryl); m/z 350 (M+); Anal Calcd 
for C19H3oN2 0 4 ; C, 65.12; H, 8.63; N, 7.99. Found C, 65.41; H, 8.61; N, 8.17.
Phenvlmethvl N-f 6 -aminohexvOcarbamate hvdrochloride(43>)
Hydrogen chloride was bubbled through a solution of phenylmethyl N-[6 -(l,l-di- 
methylethoxycarbonylamino)hexyl]carbamate (0.96 g, 2.7 mmol) in CHjC^ (100 ml) 
until precipitation of the desired product. The solvent was evaporated to afford (43) 
(0.68 g, 99%) as a white crystalline salt. m.p. 177°C (lit. (Atwell and Denny, 1977) 
m.p. 177-178°C); TLC (silica gel 10 C H ^  : 1 MeOH) Rf = 0.1; I.R omax 3470 cnr
I, 3340-3280 cm*1, 2750 cnr1, 2620 cm-1, 2500 cnr1, 1700 cm-1, 1630 cm-1, 1570 cm* 
!H NMR 5 (CDC13) 1.18 (4 H, m, 2 x CH2), 1. (4 H, m, 2 x CHj), 2.93 (2 H, t, J 6
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Hz, Ctf2NH3+), 3.08 (2 H, m, J 6  Hz, Gtf2NH), 3.61 (3 H, N+H3), 5.07 (2 H, s, Aryl- 
C ^ ) , 7.39 (5 H, s, Aryl); m/z 287 (M+); Anal Calcd for (C^ 22^ 0 2 .HC1); C, 
58.63; H, 8.08; N, 9.77. Found C, 58.65; H, 8.03; N, 9.74.
1.3 -Dimethvl-6 -f 6 -( phenvlmethoxvcarbonvlaminox)hexvlaminolpvrimidine-2.4-dione
m
A mixture of l,3-dimethyl-6-chloropyrimidine-2,4-dione (0.49 g, 2.85 mmol), 
phenylmethyl N-(6 aminohexyl)carbamate (840 mg, 3.7 mmol) and sodium carbonate 
(0.60 g, 5.7 mmol) in dioxane ( 8  ml) was boiled under reflux with stirring for 4 h until 
TLC (silica gel 10 CH2C12 :.l MeOH) showed formation of single product.
After cooling the mixture to ambient temperature chloroform was added. The solution 
was washed twice with water, once with saturated brine then dried. Evaporation of 
the solvent revealed a yellow semi-oily solid which on further standing solidified to a 
yellow solid which was recrystallised from ethanol to afford (44) (0.60 g, 54%) as a 
yellow crystalline solid, m.p. 128°C; TLC (silica gel 10 CH2C12 : 1 MeOH) Rf = 0.55;
I.R.umax 3360 cnr1, 3280 cm*1, 1700 cm-1, 1630 cm-1; 'H NMR 8  [(CD3)2SO] 0.90 
(4 H, m, 2 x CH2), 1.23 (4 H, m, 2 x CH2), 3.15 (2 H, t, J 6  Hz, NHCH2), 3.17 (2 H, 
t, J 6  Hz, NHCH2), 3.06 (3 H, s, N-CH3), 3.23 (3 H, s, N-CH3), 4.21 (1 H, dt, 
pyrimidine-5H + NH), 4.69 (2 H, PhCH2), 6.79 (5 H, m, Ph-H5), 7.70 (1H, br, NH); 
m/z 388 (M+) and 91 (100%); Anal Calcd for (C2oH28N4 0 4 ): C, 61.82; H, 7.27; N, 
14.43. Found C, 61.85; H, 7.36; N, 14.3.
1.3-dimethvl-6-[6fphenvlmethoxvcarbonvlamino)hexvlamino~|-5-nitrosopvrimidine-
2.4-dione (45̂ 1
Isoamyl nitrite (0.41 g, 3.54 mmol) was slowly added to a warmed solution of 1,3- 
dimethyl-6-[6-(phenylmethoxycarbonlyamino)hexylamino]pyrimidine-2,4-dione
168
(0.55 g, 1.42 mmol) in ethanol (25 ml). The mixture was stirred at ambient 
temperature for 1 0  min after which time 1 0  drops hydrochloric acid was added, the 
reaction was stirred at this temperature until TLC (silica gel 10 CH2C12: 1 MeOH) 
showed formation of nitroso product.
After overnight stirring at ambient temperature the resulting yellow solution was 
evaporated under reduced pressure to afford (45) a red oil (0.43 g, 73%). This 
product was subsequently used without further purification in the next step.
1.3-dimethvl-3.7-dihvdro-8-phenvlmethoxvcarbonvlpentaethvl-2.6-dione (46)
A solution of l,3-dimethyl-6-[6(phenylmethoxycarbonylamino)hexylamino]-5-nitroso- 
pyrimidine-2,4-dione (0.43 g, 1.03 mmol) in butanol (3 ml) was boiled under reflux 
with stirring until decolonisation of solution had occurred.
After cooling the solution to ambient temperature, the solvent was removed to afford 
a pale grey solid which was washed with ether, collected and recystallised fom butanol 
to reveal (46) (0.40 g, 97%) as a grey crystalline solid. m.p. 182-184°C; TLC (silica 
gel 1 0  CH2C12 : 1 MeOH) Rf = 0.65; I.R.umax 3300 cm-1, 1700 cm-1, 1680 cm-1, 
1660 cm-1, 1550 cm-1, 1500 cm*1; JH NMR 6  [(CD3)2SO] 1.55 (2 H, quintet, J 7.0 Hz, 
CH2), 1.67 (2 H, sextet, J 7.0 Hz, C iy , 1.90 (2H, quintet, J 7.3 Hz, CH2), 1.92 (2 H, 
t, J 7.3 Hz, purine-CHj), 3.23 (2 H, q, J 6.4 Hz, CH^NH), 3.45 (3 H, s, N-CH3), 
3.59 (3 H, s, N-CH3), 5.23 (2 H, br, Aryl-CH2), 7.54 (1 H, br, Aryl-NH), 7.58 (5 H, 
br, Aryl); m/z 400 (M+), 292 (M-PhCH2OH) and 91 (100%); Anal Calcd. for 




6 -Chloro-1,3-dimethylpyrimidine-2,4-dione (3.61 g, 41 mmol) was boiled under 
reflux with hexane-1,6-diamine (6.0 g, 52 mmol) and sodium carbonate (4.38 g, 
41 mmol) in dioxane (90 ml) for 3.5 h. The mixture was diluted with chloroform, 
washed twice with water and dried. Evaporation of the solvent gave (47) as a crude 
product (5.27g). This material was stirred with phenylmethyl chloroformate (3.76 g, 
22 mmol) and triethylamine (4.19 g, 41 mmol) in dichloromethane (180 ml) for 24 h. 
After overnight stirring, the resulting precipitate was removed by filtration, the filtrate 
washed twice with water, once with 2M aqueous HC1 and dried. Evaporation of the 
solvent afforded the crude product a pale cream solid which was chromatographed on 
silica in the system chloroform : EtOAc ( 4 : 1 )  with elution of product with EtOAc 
yielding the Cbz-aminoalkylaminopyrimidine (53) (4.25 g, 52%) as a white crystalline 
solid, m.p. 128-129°C; TLC (silica gel 10 CH2C12 : 1 MeOH) Rf = 0.59; I.Rumax 
3360cm*1, 3280cm*1, 1700cm*1, 1630cm*1, 1600cm*1, 1550cm*1; 1HNMR 5 (CDC13)
1.36 (4 H, m, 2 x CH^), 1.52 (2 H, quintet, J 6.5 Hz, CH2), 1.64 (2 H, quintet, J 6.9 
Hz, C iy , 3.05 (2 H, dt, J 5.3 Hz and 6.0 Hz, N H C iy, 3.08 (2 H, dt, J 6.4 Hz and
6 .8  Hz, NHCH2), 3.31 (3 H, s, N-CH3), 3.40 (3 H, s, N-CH3), 4.82 (1 H, br, N-H), 
4.83 (1 H, s, pyrimidine-5H), 4.88 (1 H, br, NH), 5.08 (2 H, s, PhC fy, 7.34 (5 H, m, 
Ph-H5); m/z 388 (M+) and 91 (100%); Anal Calcd for (C2 0 H28N4O4 ): C, 61.82; H, 
7.27; N, 14.43. Found C, 61.5; H, 7.34; N, 14.4.
1.3 -Dimethvl-6 -[ 9-( phenvlmethoxvcarbonvlaminolnonvlamino] pvrimidine-2.4-dione
(54)
A mixture of l,3-dimethyl-6-chloropyrimidine-2,4-dione (1.91 g, 11 mmol), nonane-
1,9-diamine (5.00 g, 32 mmol) and sodium carbonate (2.79 g, 16 mmol) in dioxane
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(60 ml) was boiled under reflux with stirring for 3 h or until formation of single 
product on TLC (silica gel 1 0  CH2C12: 1 MeOH).
After cooling to ambient temperature, chloroform was added to the mixture and the 
solution washed once with water, collected and dried. Evaporation of solvent gave the 
crude amine l,3-dimethyl-6-(9-aminononylamino)pyrimidine-2,4-dione (48) (3.16 g) 
as a pale yellow solid. This crude material (3.16 g, 11 mmol) was then stirred with 
phenylmethyl chloroformate (1.91 g, 2.11 mmol) and triethylamine (2.16 g, 21 mmol) 
in dichloromethane (150 ml). The reaction was left to stir at ambient temperature for 
24 h.
The resulting precipitate was removed by filtration, the filtrate washed twice with 
water, once with 2M aqueous HC1, collected and dried with evaporation of the 
solvent a yellow solid (3.56 g,) which was purified by flash column chromatography in 
the system (4 CHCI3 : 1 EtOAc) and flushed with EtOAc to afford (54) (2.02 g, 43%) 
as a white crystalline solid, m.p. 105°C; TLC (silica gel 10 CH2C12 : 1 MeOH) Rf =
0.55; I.R. omax 3420 cm*1, 1700 cm*1, 1680 cm*1, 1630 cm*1, 1600 cm*1, 1550-1530 
cm*1; lH NMR 8  (CDC13) 1.30 (4 H, br, 2 x CHJ, 1.50 (2 H, t, J 7.3 Hz, CH2), 1.66 
( 8  H, m, CH2CH2CH2CH2), 3.09 (2 H, q, J 7.3 Hz, CH2-NH), 3.18 (2 H, q, J 6.3 Hz, 
CH2-NH), 3.31 (3 H, s, N-CH3), 3.39 (3 H, s, N-CH3), 4.35 (1 H, br, NH), 4.79 (1 H, 
br, Aryl-NH), 4.86 (1 H, s, 5H), 5.09 (2 H, s, Aryl-CH2), 7.35 (5 H, s, Aryl); m/z 431 
(M+), 336 (M-PhCH2OH) 91 (100%). Anal. Calcd. for C20H28N4O4: C, 61.84; H, 
7.27; N, 14.42. Found C, 61.9; H, 7.35; N, 14.39.
1.3-Dimethvl-6-|' 10-(phenvlmethoxvcarbonvlamino)decylamino1pvrimidine-2.4-dione 
£55}
A mixture of l,3-dimethyl-6-chloropyrimidine-2,4-dione (1.35 g, 7.73 mmol), decane-
1,10-diamine (1.60 g, 9.28 mmol) and sodium carbonate (1.97 g, 190 mmol) in dioxan
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(15 ml) was boiled under reflux with stirring for 3 h or until formation of single 
product on TLC (silica gel 1 0  CH2C12: 1 MeOH).
After cooling to ambient temperature, the solution was diluted with chloroform 
washed once with water then dried. Evaporation of solvent gave the crude amine (49) 
(1.24g). This material (0.80 g, 2.58 mmol) was stirred with phenylmethyl chloro- 
formate (0.44 g, 2.58 mmol) and triethylamine (0.52 g, 5.51 mmol) in dichloro­
methane (120 ml). The homogeneous solution was then stirred at ambient temperature 
until formation of single product on TLC (silica gel 10CH2C12: 1 MeOH).
After overnight stirring the resulting precipitate was removed by filtration and the 
solution was washed twice with water, once with 2M aqueous HC1, dried with 
evaporation of the solvent affording (55) as a crude product which was 
chromatographed on silica as for product (54) to reveal (55) (0.62 g, 54%) as a white 
crystalline solid; m.p. 100-102°C; TLC (silica gel 10 CH2C12 : 1 MeOH) Rf = 0.56;
I.R. omax 3360 cm-1, 3280cm-1, 1700 cnr1, 1640 cm-1; [HNMR 5 (CDC13) 1.29 (12
H, m, 6  x CHj), 1.49 (2 H, m, CH2), 1.65 (2 H, quintet, J 6 .8  Hz, CH2), 3.08 (2 H, 
dt, J 5.1Hz and 7.1 Hz, CH2), 3.18 (2 H, q, J 6 .6 Hz, N -C iy , 3.31 (3 H, s, N-CH3), 
3.39 (3H, s, N-CH3), 4.40 (1 H, br, NH), 4.81 (1 H, s, pyrimidine-5H), 5.09 (2 H, s, 
PhCH2), 7.35 (5 H, m, Ph-H5); m/z 444 (M+), 336 (M-PhCH2OH), and 91 (100%); 
Anal Calcd for ( C ^ J ^ ^ O ^ :  C, 64.82; H, 8.17; N, 12.61. Found C, 65.1; H, 8.14; 
N, 12.65.
I.3 -Dimethvl-6 -f 2- (2-f 2'-( phenvlmethoxvcarbonvlamino^ethoxv] ethoxvl ethvlamino V 
pvrimidine-2.4-dione (56)
A mixture of l,3-dimethyl-6-chloropyrimidine-2,4-dione (2.82 g, 16 mmol), 3,6- 
dioxooctane-1,8-diamine (6 g, 40 mmol) and sodium carbonate (3.43 g, 32 mmol) in
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dioxan (65 ml) was boiled under reflux with stirring for 3 h or until formation of 
single product on TLC (silica gel 10 CHjClj: 1 MeOH).
After cooling to ambient temperature, chloroform was added to the mixture and the 
solution washed once with water, collected, dried with evaporation of solvent 
affording the crude amine (50) (3.03g). The crude l,3-dimethyl-6-(2-{2-[2- 
aminoethoxy]ethoxy}ethylamino)pyrimidine-2,4-dione (3.03 g, 11 mmol) was then 
treated with phenylmethyl chloroformate (1.90 g, 11 mmol) and triethylamine (2.14 g, 
21 mmol) in dichloromethane (150 ml). The reaction was left to stir at ambient 
temperature for 24 h.
The organic extract was washed twice with water, once with 2M hydrochloric acid, 
collected and dried. The solvent was evaporated to yield (56) as a yellow/brown oil 
(3.56 g) which was purified by flash column chromatography in EtOAc then 5 EtOAc 
: 1 MeOH affording [42] as an oil (2.04 g, 44%); TLC (silica gel 10 CHjC^ : 1 
MeOH) Rf = 0.65; I.R. omax 3400-3280 cm-1, 1740-1670cm-1; lU NMR 5 (CDC13) 
3.24 (2 H, q, J 6  Hz, NHCHj), 3.31 (3 H, s, N-CH3), 3.36 (3 H, s, N-CH3), 3.40 (2
H, q, J 5.3 Hz, NHCH2), 3.58 (2 H, t, J 6  Hz, NHCH2CH2), 3.62 (4 H, s, 
0CH2CH20), 3.68 (2 H, t, J 6  Hz, NHCH2CH2), 4.83 (1 H, s, pyrimidine-5H), 5.00 
(1 H, br, NH), 5.09 (2 H, s, Aryl-CH2), 5.29 (1 H, br, NH), 7.35 (5 H, s, Aryl-H5); 
m/z 421 (M+), 91 (1 0 0 %). Anal. Calcd for (C20H28N4O6):C, 57.12; H, 6.72; N, 13.33. 
Found C, 56.95; H, 6.78; N, 13.39.
I.3-Dimethvl-6-f9-aminononvlamino>)pvrimidine-2.4-dione (51) 
6-Chloro-l,3-dimethylpyrimidine-2,4-dione ( 1 .0 0  g, 5.7 mmol) was boiled under 
reflux with nonane-1,9-diamine (1.81 g, 11.4 mmol) and sodium carbonate (1.21 g,
1.4 mmol) in ethanol (40 ml) for 3 h. The mixture was filtered and the solvent was 
evaporated under reduced pressure to afford a pale yellow solid which was
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recrystallised in aqueous ethanol to yield 6-(9-anunononylamino)-l,3-dimethyl- 
pyrimidine-2,4-dione (54) (1.09 g, 65%) as a white solid m.p. 210-212°C; TLC (silica 
gel 10 CH2C12 : 1 MeOH) Rf = 0.12; I.R .umax 3500cm-1, 1660cm-1; !HNMR 5 
[(CD3)2SO] 1.29 (14 H, m, 7 x C iy , 2.54 (2 H, m, CH2NH2), 3.03 (2 H, m, 
NHCH2), 3.03 (3 H, s, N-CH3), 3.26 (3 H, s, N-CH3), 4.65 (1 H, br, NH), 6.72 (1 H, 
s, pyrimidine 5 H); m/z 297 (M+), 159 (100%).
1.3-Dimethvl-6-( 10-aminodecvlamino>)pvrimidine-2.4-dione (52) 
6-Chloro-l,3-dimethylpyrimidine-2,4-dione (2 .0 0  g, 11.5 mmol) was boiled under 
reflux with decane-1,10-diamine (3.96 g, 23 mmol) and sodium carbonate (2.44 g, 
23 mmol) in ethanol (100 ml) for 3 h or until the formation of single product on TLC 
(silica gel 10 CH2C1 : 1 MeOH). After cooling to ambient temperature the mixture 
was filtered and the solvent was evaporated under reduced pressure to afford a white 
waxy-solid which was recrystallised in aqueous ethanol to yield 6 -(1 0 -amino- 
decylamino)-l,3-dimethylpyrimidine-2,4-dione (55) (2.30 g, 64%) as white solid; 
m.p.72-74°C; TLC (silica gel 10 CHjC^ ; 1 MeOH) Rf = 0.15; I.R. umax 3400 cm-1, 
1660 cm 1; !HNMR 5 (CF3C02D) 1.41 (16H, m, (CH2)8), 1.82 (2H, m, CH2-NH2), 
3.28 (2H, s, CHj-NH), 3.60 (3H, s, N-CH3), 3.69 (3H, s, N-CH3).
L3-dimethvl-6-[6-(phenvlmethoxycarbonvlaminoIhexvlamino]-5-nitrosopvrimidine-
2.4-dione (57)
Isoamyl nitrite (1.11 g, 9.51 mmol) was slowly added to a warmed solution of 1,3-di- 
methyl-6-[6-(phenylmethoxycarbonylamino)hexylamino]pyrimidine-2,4-dione (1.6 8  g,
4.32 mmol) in ethanol (33 ml). The mixture was stirred at ambient temperature for 10 
min, after which time 1 0  drops of hydrochloric acid was added, the reaction was
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monitored until TLC (silica gel 10 CH2C1 2: 1 MeOH) showed formation of nitroso 
product.
After overnight stirring, the resulting yellow solution was evaporated under reduced 
pressure to afford (57) a purple oil (1.07 g, 59%). This product was used without 
further purification in the next step.
1.3-Dimethvl-6-(9-(rphenvlmethoxvcarbonvlaminolnonvlaminoV5-nitrosopyrimidine-
2.4-dione (581
Isoamyl nitrite (0.94 g, 8.03 mmol) was slowly added to a suspension l,3-dimethyl-6- 
(9-(phenylmethoxycarbonylamino)nonylamino)pyrimidine-2,4-dione (1.57 g, 
3.65 mmol) in ethanol (27 ml). The mixture was stirred at ambient temperature for 1 0  
min, after which time two drops of hydrochloric acid was added and the mixture 
continued to stir for a further 30 min.
After reaction had gone to completion, the solvent was removed by evaporation to 




Isoamyl nitrite (0.30 g, 2.53 mmol) was added to a suspension of l,3-dimethyl-6-(10- 
(phenylmethoxycarbonylamino)decylamino)pyrimidine-2,4-dione (0.45 g, 1.01 mmol) 
in ethanol (20 ml). The mixture was stirred at ambient temperature for 10 min after 
which time a drop of HC1 was added and the mixture continued stirring for a further 
30 min by which time the solution changed from a clear to a pink colour.
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After reaction had gone to completion, the solvent was removed under reduced 
pressure to afford a reddish-purple oil (0.69 g) which was used without further 
purification for the next step.
1.3 -Dimethvl-6 -f 2- (2- \ 2l-(phenvlmethoxvcarbonvlamino')ethoxv~|ethoxvl ethvlaminoV
5-nitrosopvrimidine-2.4-dione (60)
Isoamyl nitrite (0.80 g, 6.84 mmol) was slowly added to a suspension of 1,3-dimethyI-
6-(2-{2-[2'-(phenylmethoxycarbonylamino)ethoxy]ethoxy}ethylamino)pyrimidine-2,4- 
dione (1.75 g, 4.16 mmol) in ethanol (32 ml). The mixture was stirred at ambient 
temperature for 10 min after which time two drops of 3 M aqueous HC1 was added. 
The mixture was continued to stir for a further 30 min by which time the solution 
changed from a clear to a pink colour.
After 2 h stirring, the solvent was removed by evaporation to afford (60) (1.82 g, 




A solution of l,3-dimethyl-6-[6-(phenylmethoxycarbonylamino)hexylamino]-5- 
nitrosopyrimidine-2,4-dione (1.07 g, 2.56 mmol) in butanol (41 ml) was boiled under 
reflux with stirring until decolonisation of solution had occurred.
After 0.5 h stirring the solution was cooled to ambient temperature with evaporation 
of solvent affording a pale solid which was recystallised fom butanol to reveal (61) 
(0 .8 8  g, 8 6 %) as a pale buff solid m.p. 182-184°C; TLC (silica gel 1 0  CH2C12 : 1 
MeOH) Rf = 0.54; I.R.umax 3300 cm-1, 1700 cm-1, 1685 cm-1, 1660 cm-1; lUNMR 5 
[(CD3)2SO] 1.31 (2 H, m, C ^ C H ^ ^ C ^ C H j) , 1.43 (2 H, m, NCH2CJ72), 1.66
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(2 H, m, purineCH2Ctf2), 2.69 (2 H, t, J 7.4Hz, purine-CH2), 2.98 (2 H, q, J 7 Hz, 
NCH2) 3.21 (3 H, s, N-CH3), 3.37 (3 H, s, N-CH3), 4.99 (2 H, s, Aryl-CH2), 7.30 
(1 H, t, J 7 Hz, N//CH2), 7.34 (5H, m, Aryl), 13.2 (1H, br, purine-NH); m/z 400 
(M+), 292 (M-PhCH2OH) and 91 (100%); Anal Calcd. for (C20H25N5O4 ): C, 60.14;
H, 6.31; N, 17.53. Found C, 60.09; H, 6.34; N, 17.50.
I.3-Dimethvl-3.7-dihvdro-8-(8-(phenvlmethoxvcarbonvlamino)octv0purine-2.6-dione 
(62)
A solution of the nitroso product (44) (0.84 g, 1.83 mmol) in butanol (30 ml) was 
boiled under reflux until decolourisation of the solution had occurred or until TLC 
(silica gel 10 CH2C12 : 1 MeOH) had shown formation of cyclised product.
After 0.5h stirring the solution was cooled to ambient temperature, with evaporation 
of the solvent affording a brown solid which was recrystallised from butanol to reveal
(62) as a cream solid (0.30 g, 37%) m.p. 145°C; TLC (silica gel 1 0  CHjClj : 1 
MeOH) Rf = 0.66; I.R omax 3320 cm*1, 1740 cm*1, 1680 cm*1, 1640cm*; LH NMR 5 
[(CD3)2SO] 1.24 ( 8  H, m, 4  x CHJ, 1.38 (2 H, t, J 6  Hz, CH2), 1.65 (2 H, t, J 6  Hz, 
CH2), 2.65 (2 H, t, J 6.2 Hz, CH2NH), 2.95 (2 H, q, J 6.2 Hz, CH2NH), 3.21 (3 H, s, 
N-CH3), 3.41 (3 H, s, N-CH3), 4.99 (2 H, s, Aryl-CH2), 7.22 (1 H, br, Aryl-NH),
7.33 (5 H, m, Aryl), 13.15 (1 H, s, NH); m/z 442 (M+), 334 (M-PhCH2OH), 91 
(100%); Anal. Calcd. for (C23H31N50 4): C, 62.57; H, 7.08; N, 15.86. Found C, 62.99; 




A solution of l,3-dimethyl-6-(10-phenylmethoxycarbonylamino)decylamino)-5- 
nitrosopyrimidine-2,4-dione (0.69 g, 1.46 mmol) in butanol (15 ml) was boiled under 
reflux with stirring until the decolourisation of solution had occurred and TLC (silica 
gel 10 CH2C12: 1 MeOH) showed consumption of nitroso product.
After 40 min stirring, the solvent was removed by evaporation to afford a brown solid 
which was recrystallised from butanol to reveal (63) (0.30 g, 45%) as a brown 
crystalline mass. m.p. 95°C; TLC (silica gel 10 CH2C12 : 1 MeOH) Rf = 0.60; I.R. u 
max 3300cm-1, 1730cm-1, 1700cm-1, 1650cm-1, 1550cm-1, 1500cm-1; lH NMR 5 
[(CD3)2SO] 1.24 ( 1 0  H, m, 5 x C iy , 1.38 (2 H, t, J 6  Hz, CH2), 1.67 (4 H, t, 2 x 
CH2), 2.66 (2 H, q, J 7.6 Hz, CH2-NH), 2.97 (2 H, q, J 6.4 Hz, purine-CH2), 3.22 
(3 H, s, N-CH3), 3.41 (3 H, s, N-CH3), 4.99 (2 H, s, Aryl-CH2), 7.22 (1 H, t, N-H), 
7.34 (5H, m, Aryl); m/z 455 (M+), 347 (M-PhCH2OH) and 194 (100%); Anal Calcd 
for (C2 4H33N5O4 ): C, 63.26; H, 7.31; N, 15.38. Found C, 63.6; H, 7.28; N, 15.4.
1.3-dimethvl-3.7-dihvdro-8-N-/2-(2-['2-fN-phenvlmethoxvcarbonvlaminolethoxv]-
ethoxvlethvlamino)purine-2.6-dionef641
A solution of the nitroso product (49) (1.82 g, 4.05 mmol) in butanol (67 ml) was 
boiled under reflux until decolourisation of the solution or TLC (silica gel 10 CH2C12 : 
1 MeOH) had shown formation of cyclised product.
After 0.5 h stirring the solution was cooled to ambient temperature, the solvent was 
evaporated to afford (64) (1.19 g, 6 8 %) as a yellow oil. TLC (silica gel 1 0  CH2C12 : 1 
MeOH) Rf = 0.48; I.R (film) omax 3420 cm-1, 3250 cm-1, 3200 cm-1, 1740 cm-1, 1680 
cm-1, 1600 cm-1, 1500 cm-1; NMR 6  [(CD3)2SO] 3.15 (2 H, q, J 5.9 Hz, N C iy , 
3.23 (3 H, s, N-CH3), 3.40 (2 H, m, N O ^ O y ,  3.42 (3 H, s, N-CH3), 3.55 (2 H, m)
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and 3.59 (2 H, m) (O O ^O ^O ), 4.53 (2 H, s, purine-CH2), 5.00 (2 H, s, Aryl-CH2),
7.33 (6 H, m, Aiyl-H5 + NH), 13.57 (1 H, br, purine-NH); m/z 431 (M+), 91 (100%). 




dione (0.23 g, 0.58 mmol) hydogen bromide in acetic acid (0.8 ml) was added. The 
mixture stirred at ambient temperature for 15 min. After completion of the reaction, 
the mixture was triturated with ether, collected by filtration, washed with a further 
five portions of ether, dried (P20 5/Na0H) to give the hydrobromide (65) (0.20 g, 
100%) as a light purple solid; m.p. 250°C; TLC (silica gel 10 CH2C12 ; 1 MeOH) R f= 
0.1; I.R. umax 3500-3400 cm'1, 3240 cnr1, 2980 cnr1, 2860 cm*1, 1740 cm-1, 1680 
cm-1; !H NMR 5 [(CD3)2SO] 1.31 (2 H, quintet, J 6.7 Hz, CH2), 1.56 (2 H, quintet, J
7.3 Hz, CHj), 1.70 (2 H, q, J 7.3 Hz, CH2), 2.70 (2 H, t, J 7.7 Hz, purine-CH2), 2.75 
(2 H, q, J 7.7 Hz, CHj-NHj), 3.22 (3 H, s, N-CH3), 3.41 (3 H, s, N-CH3), 7.74 (1 H, 
br, N+H3); m/z 346 (M+), 180 (100%); Anal Calcd for C12H20N5O2Br: C, 41.63; H, 
5.82; N, 20.23. Found C, 41.57; H, 5.77; N, 20.22.
8-(8-AminooctvlV2.4-dimethvlpurine-1.3-dione hvdrobromide (66)
To l,3-Dimethyl-3,7-dihydro-8-(8-(phenylmethoxycarbonylamino)octyl)purine-2,6- 
dione (0.3 g, 0.68 mmol) hydrogen bromide in acetic acid (1.0 ml) was added. The 
mixture was stirred at ambient temperature for 15 min. After completion of the 
reaction, the mixture was triturated with ether, collected by filtration and washed 
with a further five portions of ether, dried to give 8-(8-aminooctyl)-2,4- 
dimethylpurine-l,3-dione hydrobromide (66) (0.26 g, 100%); m.p. 239°C; TLC(silica
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gel 10 CHjClj : 1 MeOH) Rf = 0.15; I.R. umax 3440 cm-1, 3200 cm-1, 2940 cm-1, 
2860 cm-1, 1760 cnr1, 1680 cm-1, 1570 cm-1; lH NMR 6 [(CD3)2SO] 1.27 (8 H, br, 
(CH2)4), 1.52 (2 H, q, CH2), 1.67 (2 H, q, J 6.7 Hz, C iy , 2.68 (2 H, t, J 7.6 Hz, 
purine-CHj), 2.76 (2 H, sextet, J 6.4 Hz, CH2-N+H3), 3.22 (3 H, s, N-CH3), 3.41 (3
H, s, N-CH3), 7.72 (1 H, br, N+H3); m/z 388 (M+), 180 (100%). Anal calcd for 
C15H26N50 2Br: C, 46.42; H, 6.75; N, 18.04. Found C, 46.41; H, 6.67; N, 18.10.
8-(9-AminononyB-2.4-dimethvlpurine-1.3-dione hvdrobromide (671 
To l,3-Dimethyl-3,7-dihydro-8-(9-(phenylmethoxycarbonylamino)nonyl)purine-2,6- 
dione (0.30 g, 0.657 mmol) hydrogen bromide in acetic acid (1.0 ml) was added and 
the mixture stirred at ambient temperature for 15 min. After completion of the 
reaction, the mixture was triturated with ether, collected by filtration and washed 
with a further five portions of ether, dried to give 8-(9-aminonyl)-2,4-dimethylpurine-
I,3-dione hydrobromide (67) (0.23 g, 87%) as a purple-grey crystalline solid; m.p. 
218-219°C; TLC(silica gel 10 CH2C12 : 1 MeOH) Rf = 0.1; I.R. umax 3160 cm 1, 
1720 cm-1, 1680 cm-1; 'H NMR 5 [(CD3)2SO] 1.25 (10 H, br,
CHjCHjCtfjC/^CtfjCtfjCtfjCHjCHj), 1.51 (2 H, m, purine-CH2), 1.67 (2 H, m, 
NHCI^CHj), 2.68 (2 H, t, J 7.5 Hz, purine-CH2), 2.75 (2 H, m, NCHJ, 3.22 (3 H, s, 
N-CH3), 3.41 (3 H, s, N-CH3), 7.71 (3 H, s, N+H3); m/z 403 (M^, 180 (100%). Anal 
calcd for C16H28N50 2Br: C, 57.71; H, 4.41; N, 12.24. Found C, 57.84; H, 4.47; N, 
12.22 .
8- {2-[2-( 2-Aminoethoxvlethoxv] ethvl) -2.4-dimethvlpurine-1.3 -dione hvdrobromide 
(68}
To l,3-dimethyl-3,7-dihydro-8-N-(2-{2-[2-(N-phenylmethoxycarbonylamino)-
ethoxy]ethoxy}ethylamino)purine-2,6-dione (0.30 g, 0.70 mmol) hydrogen bromide in
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acetic acid (1.0 ml) was added and the mixture stirred at ambient temperature for 15 
min. After completion of the reaction, the mixture was triturated with ether, collected 
by filtration and washed with a further five portions of ethyl acetate (distilled and 
dried), dried to give the hydrobromide salt (68) (0.26 g, 100%) as a yellow solid, m.p. 
220°C; TLC (silica gel 10 CH2C12 : 1 MeOH) Rf = 0.1; W  NMR 6 [(CD3)2SO] 2.97 
(2 H, sextet, J 6 Hz, CH2N), 3.23 (3 H, s, N-CH3), 3.43 (3 H, s, N-CH3), 3.62 (6 H, 
m, OCH2CH2OCH2CH2N), 4.55 (2 H, s, purine-CH2), 7.83 (3 H, br, N+H3); m/z 378 
(M+), 180 (100%). Anal Calcd for C12H20N5O4Br: C, 38.11; H, 5.33; N, 18.52. 
Found C, 38.15; H, 5.27; N, 18.46
5- (N-f 5-(2.4-Dimethvl-1.3 -dioxopurin-8-vDpentvl'lthioureido) -3,.6'-dihroxvspiroriso- 
benzofiiran-1 |'3H].9,-[9H]xanthenl-3-one (691
3'-6'-Dihydroxy-5-isothiocyanatospiro(isobenzofiiran-l[3H],9'-[9H]xanthen-3-one 
(fluoresecein-5-isothiocyanate) (0.34 g, 0.87 mmol) was suspended in water (12 ml) 
and brought to pH 9.0 by dropwise addition of 1 M aqueous K2C03. To this stirred 
solution the 8-(5-Aminopentyl)-2,4-dimethylpurine-l,3-dione hydrobromide (0.30 g, 
0.87 mmol) in 2:1 H20/dioxan (10 ml) was added over a 30 min period. The reaction 
was stirred at ambient temperature until the disappearence of starting amine with the 
pH being carefully maintained at 9.0 by dropwise addition of 1 M aqueous K2C03 
throughout the course of the reaction.
After 3 h stirring at ambient temperature, the solution was acidified to pH 6.0 by 
dropwise addition of 2 M aqueous HC1 with a precipitate being seen. The mixture 
was then taken up in water (200 ml) and freeze dried for 24 h to reveal an orange 
fluffy solid which was purified by flash column chromatography in the solvent system 
EtOAc followed by 10 EtOAc : 1 MeOH to afford (69) as an orange-yellow solid 
(0.28 g, 50%); m.p. 197°C; TLC (silica gel 10 EtOAc : 1 MeOH) Rf = 0.55; I.R. u
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max 3480 cm*1, 3140 cm'1, 1710 cm-1, 1660 cm-1, 1640 cm*1; JH NMR 5 [(CD3)2SO]
1.37 (2 H, m, CHj), 1.62 (2 H, q, J 6.6Hz, purine-CH2), 1.76 (2 H, q, CH2), 2.73 (2 
H, t, J 7.7 Hz, CH2-NH), 3.24 (3 H, s, N-CH3), 3.40 (3 H, s, N-CH3), 3.53 (2 H, m, 
CH2-NH), 6.56 (2 H, dd, 2' and 7’-H2), 6.61 (2 H, d, xanthene 1', 8'-H2), 6.70 (2 H, d, 
J 5.1 Hz, xanthene 4' and 5 '-^ ), 7.20 (1 H, d, J 8.2 Hz, Ar-3H), 7.73 (1 H, m, Ar- 
4H), 8.12 (1 H, br, N-H), 8.25 (1 H, br, Ar-6H), 9.93 (1 H, br, CH2-NH), 10.14 (2 H, 
s, 2 x OH), 13.21 (1 H, br, purine-NH); m/z 655 (M+). Anal Calcd for 




(fluoresecein-5-isothiocyanate) (0.20 g, 0.52 mmol) was suspended in water (12 ml) 
and brought to pH 9.0 by dropwise addition of 1 M aqueous K^CO^ To this stirred 
solution, the 8-(8-Aminooctyl)-2,4-dimethylpurine-l,3-dione hydrobromide (0.2 g, 
0.52 mmol) in 2:1 H20/dioxan (6 ml) was added over a 30 min period. The reaction 
was stirred at ambient temperature until the disappearence of starting amine with the 
pH being carefully at 9.0 by dropwise addition of 1 M aqueous K2C03 throughout the 
course of the reaction.
After 3 h stirring at ambient temperature, the solution was acidified to pH 6.0 by 
dropwise addition of 2 M aqueous HC1 with a precipitate being seen. The mixture was 
taken up in water (200 ml) and freeze dried for 24 h to reveal an orange fluffy solid 
which was purified by flash column chromatography in the solvent system EtOAc 
followed by 10 EtOAc : 1 MeOH to afford (70) (0.26 g, 72%)as an orange yellow 
solid. m.p. 182°C, TLC (silica gel 5 EtOAc : 1 MeOH) Rf = 0.65, I.R.umax 3500- 
3100 cm*1, 2960 cnr1, 2880 cm-1, 1710 cm-1, 1660 cm-1, 1610 cnr1; !H NMR 8
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[(CD3)SO] 1.30 (8 H, br, 4 x CH2), 1.55 (2 H, m, NHCH2CH2), 1.66 (2 H, m, 
purine-CHjCHj), 2.67 (2 H, t, J 7.3 Hz, purine-CH2), 3.22 (3 H, s, N-CH3), 3.41 (3
H, s, N-CH3), 3.49 (2 H, m, CHj-NH), 6.53 (2 H, dd, 2' and T - iy , 6.58 (2 H, d, 
xanthene 1', 8 '-^ ), 6.68 (2 H, d, J 2.2 Hz, xanthene 4', 5'-H2), 7.19 (1 H, d, J 8.4 Hz, 
Ar-3H), 7.70 (1 H, m, Ar-4H), 8.27 (1 H, br, Ar-6H), 10.13 (2 H, s, 2 x OH); m/z
696.8 (M+). Anal Calcd for (C36H36N60 7S): C, 62.05; H, 5.21; N, 12.01. Found C, 
62.11; H, 5.27; N, 12.02.
5 -CN-( 9-(2.4-Dimethvl-1.3 -dioxopurin-8-vnnonvlthioureidoV 3 6l-dihvdroxvspiro(iso- 
benzofuran-1 [3H].9'-r9Fr|xanthenV3-one (711
3'-6'-Dihydroxy-5-isothiocyanatospiro(isobenzofuran-l[3H],9,-[9H]xanthen-3-one 
(fluoresecein-5-isothiocyanate) (0.14 g, 37 pmol) was suspended in water (10 ml) and 
brought to pH 9.0 by dropwise addition of 1 M aqueous K2C03. To this stirred 
solution, the 8-(9-Aminononyl)-2,4-dimethylpurine-l,3-dione hydrobromide (0.15 g, 
0.37 mmol) in 2:1 H20/dioxan (5 ml) was added over a 30 min period. The reaction 
was stirred at ambient temperature until the disappearence of starting amine with the 
pH being carefully maintained at 9.0 by dropwise addition of 1 M aqueous K2C03 
throughout the course of the reaction.
After 3 h stirring at ambient temperature, the reaction was complete. The solution was 
acidified to pH 6.0 by dropwise addition of 2 M aqueous HC1. Water (30 ml) was 
added and the mixture was freeze-dried for 24 h to reveal an orange fluffy solid 
(0.47 g) which was purified by flash column chromatography in the system EtOAc 
followed by 10 EtOAc : 1 MeOH to afford (71) (0.18 g, 68%) as an orange yellow 
solid. m.p.l78°C; I.R omax 3400-3000 cm*1, 2940cm*1, 2860 cm*1, 1740 cm*1, 
1700 cm*1, 1650 cm*1, 1610 cm*1; !H NMR 5 [(CD3)2SO)] 1.29 (10 H, br, 5 x C iy ,
I.56 (2 H, m, N H C H ^iy , 1.68 (2 H, m, purine-CH2CH2), 2.67 (2 H, t, J 7.5 Hz,
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purine-CH2), 3.22 (3 H, s, N-CH3), 3.41 (3 H, s, N-CH3), 3.48 (3 H, s, N-CH3), 3.48 
(2 H, m, NHCH2), 6.56 (2 H, dd, J 8.8 and 2.2 Hz, xanthene 2', 7-H2), 6.59 (2 H, d, 
J 8.8 Hz, xanthene 1', 8'-NH2), 6.67 (2 H, d, J 2.2, xanthene 4', 5*-^), 7.17 (1 H, d, J 
8.4 Hz, Ar-3H), 7.70 (1 H, m, Ar-4H), 8.06 (1H, br, NH), 8.22 (1 H, brs, Ar-6H), 
9.86 (1 H, br, CH2NH), 10.13 (2 H, s, 2 x OH), and 13.15 (1 H, purine NH); m/z 
710.3 (M+); Anal cald for (C37H38N60 7S): C, 62.52; H, 5.39; N, 11.82. Found C, 
65.45; H, 5.41; N, 11.75.
5 -fN- (2-f 2-( 2.4-dimethvl-1.3 -dioxopurin-8-ylmethoxy)ethoxv] ethyl) thioureidoV36- 
dihvdroxyspiro(isobenzofuran-l [3H1.9t-f9H)xanthen)-3-one (72) 
3’-6'-Dihydroxy-5-isothiocyanatospiro(isobenzofiiran-l[3H],9'-[9H]xanthen-3-one 
(fluoresecein-5-isothiocyanate) (0.21 g, 0.53 mmol) was suspended in water (12 ml) 
and brought to pH 9.0 by dropwise addition of 1 M aqueous I^CO^ To this stirred 
solution 8-{2-[2-(2-Aminoethoxy)ethoxy]ethyl}-2,4-dimethylpurine-1,3-dione hydro­
bromide (0.2 g, 0.53 mmol) in 2:1 H20/dioxan (6 ml) was added over a 30 min 
period. The reaction was stirred at ambient temperature until the disappearence of 
starting amine with the pH being carefully maintained at 9.0 by dropwise addition of 1 
M aqueous l^CC^ throughout the course of the reaction.
After 3 h stirring at ambient temperature the reaction was complete, the solution was 
acidified to pH 5.0 by dropwise addition of 2 M aqueous HC1. The mixture was taken 
up in water (200 ml), freeze-dried for 24 h to reveal an orange fluffy solid which was 
purified by flash column chromatography in the solvent system EtOAc followed by 10 
EtOAc : 1 MeOH to afford (56) (0.28 g, 77%) an orange yellow solid, m.p. 197°C; 
TLC (silica gel 10 EtOAc : 1 MeOH) Rf = 0.58; I.R. omax 3400-3200 cm-1, 
1740 cm*1, 1700 cm-1, 1650 cnr1, 1610 cm*1; lR  NMR 5 [(CD3)2SO] 3.22 (3 H, s, 
NCH3), 3.41 (3 H, s, N-CH3), 3.63 (8 H, m, OCH2CH2OCH2CH2), 4.54 (2 H, s,
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purine-CH2), 6.56 (2 H, dd, J 8.8 and 2.2 Hz, xanthene 2', 7'-H2), 6.59 (2 H, d, 
J 8.8 Hz, xanthene 1', 8'-H2), 6.66 ( 2H, d, J 2.2 Hz, xanthene 4', 5'-H2), 7.18 (1 H, d, 
J 8.4 Hz, Ar-3H), 7.73 (1 H, brd, J 8.5 Hz, Ar-4H), 8.1 (1 H, hr, CH2NH), 8.26 (1
H, br, Ar-6H), 10.05 (1 H, br, NH), 10.14 (2 H, s, 2 x OH), 13.6 (1 H, purine NH); 
m/z 687 (M+). Anal calcd for C33H30N6O9S: C, 57.71; H, 4.41; N, 12.24. Found C, 
57.61; H, 4.45; N, 12.22.
2.2-Dimethvl-8- (5 - [ 5 -( dimethvlaminolnaphthalene-1 -sulphonvlamino]pentvl) purine-
I.3-dione (731
To a solution of 8-(5-Aminopentyl)-2,4-dimethylpurine-l,3-dione hydrobromide (0.2 
g, 0.58 mmol) in 2:1 H20/dioxan (12 ml), 0.5 M aqueous Na^Og was added 
dropwise until pH was maintained at 9.5. To this mixture dansyl chloride (0.16 g, 0.58 
mmol) in dioxane (10 ml) was added and the solution stirred at ambient temperature 
within the pH range 9.5-10.0 until the disappearence of the starting hydrobromide. 
After 3 h stirring at ambient temperature, the pH was adjusted to 7.0 by the dropwise 
addition of 2 M aqueous HC1, water (25 ml) was added and the resulting solution 
freeze-dried for 24 h. To this solid ethyl acetate was added, the solution washed once 
with water, dried and the solvent evaporated to reveal (73) (0.16 g, 55%) as green- 
yellow solid. m.p. 183°C; TLC (silica gel 10 EtOAc : 1 MeOH) Rf = 0.55; *H NMR 5 
[(CD3)2SO] 1.14 (2 H, m, C H ^ C ^ C H jC H ,) , 1.29 (2 H, quintet, J 7 Hz, 
CH2Ctf2CH2CH2CH2), 1.46 (2 H, quintet, J 7 Hz, CH2CH2CH2Ctf2CH2), 2.76 (2 H, 
q, J 5.9 Hz, NHCHj), 2.81 (6 H, s, N(CH3)2), 3.22 (3 H, s, purine N-CH3), 3.39 (5 
H, br, purine N-CH3 + purine-CH2), 7.24 (1 H, d, J 7.3 Hz, Ar-H), 7.58 (1 H, t, 8.1 
Hz, Ar-H), 7.61 (1 H, t, J 7.7 Hz, Ar-H), 7.87 (1 H, t, J 5.9 Hz, N tfC iy , 8.08 (1 H, 




amino} -B'-b'-dihvdroxvspirorisobenzofliran-1 -[ 3H].9'-[9H]xanthen-3-one (74)
5 - { 4,6-Dichloro-1,3,5 -triazin-4-ylamino } -3', 6’-dihydrospiro(isobenzofuran-1 [3 H],9'- 
[9H]xanthen-3-one (0.31 g, 0.58 mmol) in water (12 ml) was brought to pH 8.0 by 
dropwise addition of 1 M aqueous K2C03. To this mixture a solution of the 8-(5- 
Aminopentyl)-2,4-dimethylpurine-l,3-dione hydrobromide (0.20 g, 0.58 mmol) in 2:1 
HjO/dioxan (6 ml) was added over a 10 min period and the mixture stirred at ambient 
temperature for 5h with the pH being controlled at pH 8.0 by further addition of 1 M 
aqueous KjCC^.
After completion of the reaction the pH was reduced to 5.0 by the dropwise addition 
of 2 M aqueous HC1, water was added and the resulting aqueous solution freeze-dried 
for 24 h. The resulting solid was then purified by flash column chromatography in 
EtOAc then flushed with 10 EtOAc: 1 MeOH, collected, with evaporation of the 
solvent affording () (0.18 g, 68%) as a yellow solid, m.p. 210°C; TLC (silica gel 10 
EtOAc : 1 MeOH) Rf = 0.43; lU NMR 6 [(CD3)2SO] 1.29 (2 H, m, 
C H jC H ^tfjC H jO y, 1.47 (2 H, m, NCH2CH2), 2.54 (2 H, m, NHCH2), 3.10 (2 H, 
m, CH2), 3.25 (3 H, s, purine N-CH3), 3.29 (5 H, br, purine N-CH3 + purine-CH2), 
6.41 (2 H, dd, xanthene 2' and 7'-H2), 6.48 (2 H, d, xanthene 1’ and 8'-H2), 6.48 (2 H, 
d, xanthene 4’ and 5 '-^ ), 7.14 (1 H, d, J 8.4 Hz, Ar-3H), 10.02 (2 H, s, 2 x OH).
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